[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1263
1. Bafandeh Y, Khoshbaten M, Eftekhar Sadat AT, Farhang S: Clinical predictors of colorectal polyps and carcinoma in a low prevalence region: results of a colonoscopy based study. World J Gastroenterol; 2008 Mar 14;14(10):1534-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical predictors of colorectal polyps and carcinoma in a low prevalence region: results of a colonoscopy based study.
  • AIM: To estimate the prevalence of colorectal cancer (CRC) in patients with long lasting colonic symptoms undergoing total colonoscopy; and to establish clinical features predicting its occurrence.
  • The prevalence of colorectal neoplasia was 15.3% (34 subjects) and 37.7% (181 subjects) had a completely normal colon.
  • Adenomatous polyps were detected in 56 (11.7%) patients, in 12.3% of men and 10.9% of women.
  • The mean age of the patients with a polyp was significantly higher than the others (49.53 +/- 14.16 vs 41.85 +/- 16.26, P = 0.001).
  • Most of the adenomatous polyps were left sided and tubular; only 22.5% of polyps were more than 10 mm.
  • The mean age of patients with cancer was significantly higher than the others (60.25 +/- 8.26 vs 42.13 +/- 16.08, P < 0.005) and higher than patients with polyps [60.25 (8.26) vs 49.53 (1.91) (P < 0.0005)].
  • None of the symptoms (diarrhea, abdominal pain, rectal bleeding, constipation, altering diarrhea and constipation, history of cancer, known irritable bowel disease, history of polyp and fissure or family history of cancer) were predictors for cancer or polyps, but the age of the patient and unexplained anemia independently predicted cancer.
  • CONCLUSION: Less advanced patterns and smaller sizes of adenomas in Iran is compatible with other data from Asia and the Middle East, but in contrast to western countries.
  • Prevalence of colonic neoplasia in our community seems to be lower than that in western population.
  • Colonic symptoms are not predictors for polyps or cancer but unexplained anemia and elder age can predict CRC.
  • [MeSH-major] Adenoma / diagnosis. Adenoma / epidemiology. Colonic Polyps / diagnosis. Colonic Polyps / epidemiology. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Colorectal Dis. 2000 Feb;15(1):29-34 [10766088.001]
  • [Cites] J Cancer Res Ther. 2005 Oct-Dec;1(4):204-7 [17998654.001]
  • [Cites] Am J Gastroenterol. 2000 Dec;95(12):3615-9 [11151901.001]
  • [Cites] East Mediterr Health J. 1999 Jul;5(4):766-77 [11338699.001]
  • [Cites] Public Health Nutr. 2002 Feb;5(1A):149-55 [12027278.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):565-86 [12134619.001]
  • [Cites] Dis Colon Rectum. 2002 Aug;45(8):1035-40 [12195187.001]
  • [Cites] J Korean Med Sci. 2002 Oct;17(5):604-10 [12378009.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Dec;31(4):971-99 [12489273.001]
  • [Cites] J Med Assoc Thai. 2004 Jan;87(1):41-6 [14971533.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):777-81 [14999789.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):481-5 [14994108.001]
  • [Cites] Am Surg. 2004 Mar;70(3):259-64 [15055851.001]
  • [Cites] ANZ J Surg. 2004 Jul;74(7):547-9 [15230787.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1215-22 [15247133.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1460-5 [15489649.001]
  • [Cites] Ann Surg. 1971 Dec;174(6):1002-8 [5132429.001]
  • [Cites] Am J Surg. 1976 Feb;131(2):185-91 [175719.001]
  • [Cites] Cancer. 1977 Jan;39(1):274-8 [832242.001]
  • [Cites] Cancer. 1977 May;39(5):2258-64 [870171.001]
  • [Cites] Pathol Annu. 1977;12 Pt 1:87-116 [917598.001]
  • [Cites] Cancer. 1988 Apr 1;61(7):1472-6 [3345499.001]
  • [Cites] Gastroenterology. 1991 Apr;100(4):1033-40 [2001800.001]
  • [Cites] Am J Gastroenterol. 1995 Mar;90(3):353-65 [7872270.001]
  • [Cites] Ann Intern Med. 1995 Dec 15;123(12):904-10 [7486484.001]
  • [Cites] Cancer. 1996 Sep 15;78(6):1187-94 [8826939.001]
  • [Cites] Int J Colorectal Dis. 1997;12(5):267-71 [9401839.001]
  • [Cites] Postgrad Med J. 2004 Nov;80(949):667-9 [15537853.001]
  • [Cites] Br J Surg. 2005 Apr;92(4):478-81 [15609377.001]
  • [Cites] BMC Cancer. 2005;5:52 [15913456.001]
  • [Cites] Asian Pac J Cancer Prev. 2005 Apr-Jun;6(2):130-4 [16101320.001]
  • [Cites] Aliment Pharmacol Ther. 2005 Nov 1;22(9):859-64 [16225496.001]
  • [Cites] Asian Pac J Cancer Prev. 2006 Jan-Mar;7(1):65-8 [16629518.001]
  • [Cites] Orv Hetil. 2006 Apr 23;147(16):741-6 [16711260.001]
  • [Cites] Asian Pac J Cancer Prev. 2006 Apr-Jun;7(2):309-12 [16839228.001]
  • [Cites] Cancer Lett. 2006 Aug 18;240(1):143-7 [16288832.001]
  • [Cites] J Epidemiol. 2006 Nov;16(6):240-8 [17085874.001]
  • [Cites] AJR Am J Roentgenol. 2007 Mar;188(3):619-21 [17312044.001]
  • [Cites] Dis Colon Rectum. 2007 Jul;50(7):990-5 [17525859.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):162-8 [10900274.001]
  • (PMID = 18330943.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2693747
  •  go-up   go-down


2. Osunkoya AO, Cohen C, Lawson D, Picken MM, Amin MB, Young AN: Claudin-7 and claudin-8: immunohistochemical markers for the differential diagnosis of chromophobe renal cell carcinoma and renal oncocytoma. Hum Pathol; 2009 Feb;40(2):206-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specificity was verified by negative control reactions without primary antibody and appropriate membranous staining patterns in positive control tissues (colon carcinoma and adjacent nonneoplastic kidney).
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Membrane Proteins / biosynthesis


3. Oset P, Jasińska A, Szcześniak P, Orszulak-Michalak D, Talar-Wojnarowska R, Małecka-Panas E: [Analysis of serum gastrin levels in patients with adenomatous polyps of the colon]. Pol Merkur Lekarski; 2009 May;26(155):458-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of serum gastrin levels in patients with adenomatous polyps of the colon].
  • Adenomatous polyps are known risk factor of colon cancer.
  • Gastrin is a peptide hormone involved in the growth of both normal and malignant intestinal tissue, which probably may promote progression through the adenoma-carcinoma sequence.
  • AIM OF OUR STUDY: To assess the association between serum gastrin levels and size, type and localization of colonic adenomas.
  • MATERIAL AND METHODS: The study included 60 patients with adenomatous polyps of the colon and 30 healthy volunteers.
  • RESULTS: We observed higher serum gastrin levels in patients with colonic adenomas compared to control group (59.65 pg/ml vs. 46.89 pg/ml; p < 0.05).
  • There was no association between gastrin levels and size, number, localisation and histologic type of polyps (p > 0.05).
  • CONCLUSION: Despite of elevated serum levels in patients with colonic adenomas we did not observe the association between gastrin levels and size, grade of dysplasia and histologic type of polyps.
  • The exact role of hipergastrinemia in process of colon carcinogenesis remains to be determined.
  • [MeSH-major] Adenomatous Polyps / blood. Gastrins / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19606697.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Gastrins
  •  go-up   go-down


Advertisement
4. Dubé C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D, U.S. Preventive Services Task Force: The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med; 2007 Mar 6;146(5):365-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DATA SYNTHESIS: Regular use of aspirin reduced the incidence of colonic adenomas in RCTs (relative risk [RR], 0.82 [95% CI, 0.7 to 0.95]), case-control studies (RR, 0.87 [CI, 0.77 to 0.98]), and cohort studies (RR, 0.72 [CI, 0.61 to 0.85]).
  • CONCLUSIONS: Aspirin appears to be effective at reducing the incidence of colonic adenoma and colorectal cancer, especially if used in high doses for more than 10 years.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Aspirin / therapeutic use. Colorectal Neoplasms / prevention & control. Primary Prevention
  • [MeSH-minor] Adenoma / prevention & control. Adult. Cardiovascular Diseases / chemically induced. Colonic Polyps / prevention & control. Female. Gastrointestinal Diseases / chemically induced. Humans. Incidence. Male. United States / epidemiology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] ACP J Club. 2007 Jul-Aug;147(1):15-6 [17608380.001]
  • [CommentIn] Gastroenterology. 2007 Aug;133(2):717-8 [17681190.001]
  • [CommentIn] Ann Intern Med. 2007 Nov 6;147(9):674; author reply 674-5 [17975195.001]
  • [SummaryForPatientsIn] Ann Intern Med. 2007 Mar 6;146(5):I35 [17339615.001]
  • (PMID = 17339622.001).
  • [ISSN] 1539-3704
  • [Journal-full-title] Annals of internal medicine
  • [ISO-abbreviation] Ann. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; R16CO5Y76E / Aspirin
  • [Number-of-references] 61
  •  go-up   go-down


5. Bernstein CN: Neoplasia in inflammatory bowel disease: surveillance and management strategies. Curr Gastroenterol Rep; 2006 Dec;8(6):513-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently the addition of dye spraying onto the colon to facilitate targeted biopsy has become increasingly associated with enhanced dysplasia surveillance; however, random biopsies are mostly still undertaken, even by those endoscopists who use chromoendoscopy.
  • However, for those with adenoma-like masses, ongoing surveillance after polypectomy could still be considered appropriate.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2004 Feb;126(2):451-9 [14762782.001]
  • [Cites] Gut. 2003 Jun;52 Suppl 4:iv12-6 [12746263.001]
  • [Cites] Dis Colon Rectum. 2006 Jul;49(7):950-7 [16729218.001]
  • [Cites] Gastroenterology. 2001 Mar;120(4):820-6 [11231935.001]
  • [Cites] Gut. 2001 Apr;48(4):526-35 [11247898.001]
  • [Cites] Gastroenterology. 2004 Sep;127(3):706-13 [15362025.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):934-44 [7926483.001]
  • [Cites] Gastrointest Endosc. 1996 Aug;44(2):168-76 [8858323.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1030-8 [16618396.001]
  • [Cites] Am J Gastroenterol. 1995 Dec;90(12):2106-14 [8540497.001]
  • [Cites] Gastroenterology. 1992 Nov;103(5):1611-20 [1426881.001]
  • [Cites] Cancer Immunol Immunother. 2006 May;55(5):528-37 [16034560.001]
  • [Cites] Scand J Gastroenterol. 2005 Sep;40(9):1076-80 [16211714.001]
  • [Cites] Gastroenterology. 2003 Apr;124(4):880-8 [12671882.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Dec;2(12):1088-95 [15625654.001]
  • [Cites] Gut. 2005 Nov;54(11):1573-8 [15994215.001]
  • [Cites] Lancet. 1994 Jan 8;343(8889):71-4 [7903776.001]
  • [Cites] Aliment Pharmacol Ther. 2000 Feb;14(2):145-53 [10651654.001]
  • [Cites] Exp Mol Pathol. 2006 Feb;80(1):1-10 [16277983.001]
  • [Cites] Gut. 2003 Aug;52(8):1127-32 [12865270.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):534-41 [15224277.001]
  • [Cites] Gastroenterology. 1998 Nov;115(5):1079-83 [9797361.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1288-94; discussion 1488-91 [10579969.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1311-9 [14598247.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):854-62 [11241255.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1039-46 [16618397.001]
  • [Cites] Am J Gastroenterol. 2003 Dec;98(12):2784-8 [14687833.001]
  • [Cites] Am J Gastroenterol. 2002 Apr;97(4):922-7 [12008669.001]
  • [Cites] Gastroenterology. 2006 Jun;130(7):1941-9 [16762617.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1295-300 [10579970.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1183-6 [7577018.001]
  • [Cites] Gut. 2004 Dec;53(12):1813-6 [15542520.001]
  • [Cites] Gastroenterology. 2004 Sep;127(3):950-6 [15362049.001]
  • (PMID = 17105691.001).
  • [ISSN] 1522-8037
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


6. Al-Daraji WI, Abdellaoui A, Salman WD: Osseous metaplasia in a tubular adenoma of the colon. J Clin Pathol; 2005 Feb;58(2):220-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osseous metaplasia in a tubular adenoma of the colon.
  • Flexible sigmoidoscopy revealed a 1.5 cm polyp 30 cm from the anus.
  • The polyp was removed during the sigmoidoscopy by electrocautery and sent for histological examination.
  • The polyp was a tubular adenoma with mild dysplasia.
  • The adenoma contained numerous foci of metaplastic bone.
  • This is the first case of osseous metaplasia in a tubular adenoma of the colon to be reported.
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology. Ossification, Heterotopic / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Colon / pathology. Female. Humans. Metaplasia / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1981 Aug;27(3):198-9 [7297837.001]
  • [Cites] Scand J Gastroenterol. 2000 May;35(5):556-8 [10868462.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1968 Nov;104(3):561-5 [5687904.001]
  • [Cites] J Can Assoc Radiol. 1962 Dec;13:135-9 [13960743.001]
  • [Cites] Hum Pathol. 1989 Jan;20(1):86-8 [2492256.001]
  • [Cites] Arch Pathol Lab Med. 1994 Jan;118(1):64-5 [8285834.001]
  • [Cites] Am J Pathol. 1955 Jan-Feb;31(1):73-91 [13218132.001]
  • [Cites] Ann Pathol. 1988;8(1):64-6 [3134902.001]
  • (PMID = 15677548.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770563
  •  go-up   go-down


7. Patel P, Widjaja D, Blum S, Glandt M, Akella J, Chilimuri S, Balar B: Significance of bowel wall thickening on computed tomography scan: higher risk of pathology among African Americans compared to Hispanics. J Natl Med Assoc; 2009 Apr;101(4):345-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of 94 patients with bowel wall thickening on CT scans, 7 (8%) had adenocarcinoma, 5 (5%) had large adenomas, 3 (3%) had infectious colitis, 2 (2%) ischemic colitis, 1 (1%) had inflammatory bowel disease, and 1 (1%) had a benign stricture.
  • [MeSH-major] African Americans / statistics & numerical data. Colon / pathology. Colonic Diseases / diagnosis. Hispanic Americans / statistics & numerical data. Tomography, X-Ray Computed
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma / radiography. Adenoma / diagnosis. Adenoma / pathology. Adenoma / radiography. Colitis / diagnosis. Colitis / pathology. Colitis / radiography. Colonoscopy. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Colorectal Neoplasms / radiography. Diagnosis, Differential. Female. Humans. Inflammatory Bowel Diseases / diagnosis. Inflammatory Bowel Diseases / pathology. Inflammatory Bowel Diseases / radiography. Male. Middle Aged. Retrospective Studies. Risk Factors


8. Bae RC, Jeon SW, Cho HJ, Jung MK, Kweon YO, Kim SK: Gastric dysplasia may be an independent risk factor of an advanced colorectal neoplasm. World J Gastroenterol; 2009 Dec 7;15(45):5722-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To evaluate the relationship between gastric dysplasia and Helicobacter pylori (H pylori) and the occurrence of colorectal adenoma, and to define the necessity for colonoscopy in patients with gastric dysplasia or H pylori infection.
  • No significant difference was found between the H pylori positive and negative subjects in terms of the prevalence of colorectal adenoma and advanced colorectal adenoma (P = 0.261).
  • Patients with gastric dysplasia showed no elevated risk of colorectal adenoma (OR = 0.910, 95% CI: 0.587-1.411, P = 0.738), but had a significantly higher risk of having advanced colorectal adenoma (OR = 3.382, 95% CI: 1.700-6.342, P = 0.000).
  • CONCLUSION: The study emphasizes the need for colon surveillance in patients with gastric dysplasia, regardless of H pylori infection.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dtsch Med Wochenschr. 1987 Dec 18;112(51-52):1967-72 [2826097.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Dis Colon Rectum. 1989 Aug;32(8):641-52 [2752850.001]
  • [Cites] Digestion. 1989;42(4):212-6 [2806754.001]
  • [Cites] N Engl J Med. 1989 Dec 7;321(23):1562-6 [2586553.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Am J Gastroenterol. 1992 Jan;87(1):37-42 [1728122.001]
  • [Cites] N Engl J Med. 1992 Mar 5;326(10):658-62 [1736104.001]
  • [Cites] Gastroenterology. 1992 Apr;102(4 Pt 1):1136-41 [1551522.001]
  • [Cites] Gut. 1992 Mar;33(3):289-92 [1568643.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3099-102 [1591722.001]
  • [Cites] Cancer. 1992 Sep 15;70(6 Suppl):1727-31 [1516027.001]
  • [Cites] Nature. 1992 Sep 17;359(6392):235-7 [1528264.001]
  • [Cites] Am J Pathol. 1992 Oct;141(4):797-804 [1357973.001]
  • [Cites] Dis Colon Rectum. 1992 Dec;35(12):1170-3 [1335405.001]
  • [Cites] Hum Mol Genet. 1992 Nov;1(8):559-63 [1338691.001]
  • [Cites] Int J Cancer. 1993 Jul 9;54(5):759-64 [8392033.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] Surg Oncol. 1992 Oct;1(5):357-61 [1341271.001]
  • [Cites] J Clin Pathol. 1993 Dec;46(12):1116-9 [8282836.001]
  • [Cites] J Natl Cancer Inst. 1995 May 17;87(10):762-3 [7563155.001]
  • [Cites] J Clin Gastroenterol. 1995 Oct;21(3):198-202 [8648052.001]
  • [Cites] N Engl J Med. 1996 Dec 5;335(23):1727-32 [8929264.001]
  • [Cites] J Clin Gastroenterol. 1997 Dec;25(4):605-7 [9451672.001]
  • [Cites] Cancer Detect Prev. 1999;23(3):204-14 [10336999.001]
  • [Cites] Digestion. 1999;60(3):210-5 [10343134.001]
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):1058-9 [15986436.001]
  • [Cites] Korean J Gastroenterol. 2006 Mar;47(3):191-7 [16554672.001]
  • [Cites] Dig Liver Dis. 2008 May;40(5):361-5 [18291734.001]
  • [Cites] Am J Gastroenterol. 2001 Jan;96(1):84-8 [11197293.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Dis Colon Rectum. 2004 Aug;47(8):1331-40 [15484347.001]
  • [Cites] Monogr Pathol. 1977;(18):149-75 [611411.001]
  • [Cites] Z Gesamte Inn Med. 1981 Sep 15;36(18):682-4 [7314752.001]
  • [Cites] J Clin Gastroenterol. 1982 Feb;4(1):23-7 [7077060.001]
  • [Cites] Mt Sinai J Med. 1983 Jan-Feb;50(1):8-18 [6601767.001]
  • [Cites] Endoscopy. 1983 May;15 Suppl 1:144-7 [6872972.001]
  • (PMID = 19960571.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2789227
  •  go-up   go-down


9. Khatibzadeh N, Ziaee SA, Rahbar N, Molanie S, Arefian L, Fanaie SA: The indirect role of site distribution in high-grade dysplasia in adenomatous colorectal polyps. J Cancer Res Ther; 2005 Oct-Dec;1(4):204-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The indirect role of site distribution in high-grade dysplasia in adenomatous colorectal polyps.
  • BACKGROUND: The appropriate application of Endoscopic modalities for polypectomy depends on the likelihood that the adenoma in question harbors invasive cancer.
  • While prior studies have evaluated polyp size and morphology in assessing the risk of malignancy, in recent decay some authorities have paid more attention to dysplasia.
  • All in all, the relative risk of cancer based on polyp distribution in correlation with dysplasia has not been statistically studied which is done in our study.
  • METHODS AND MATERIALS: Between June 2001 and March 2004, the distribution of 130 adenomatous polyps was compared with synchronous invasive or in situ cancer.
  • Factors such as Patient age, Patients gender, location of lesion, size of polyp, histological subtype of adenoma on biopsy, degree of dysplasia, synchronous cancer, color of polyp, and number of polyps were included in the data collection.
  • CONCLUSION: Lesions greater than 1 cm in diameter with high-grade dysplasia after splenic flexure should be managed as presumptive malignancies with segmental colon resection.
  • [MeSH-major] Adenomatous Polyps / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17998654.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


10. Egan JB, Thompson PA, Ashbeck EL, Conti DV, Duggan D, Hibler E, Jurutka PW, Leroy EC, Martínez ME, Mount D, Jacobs ET: Genetic polymorphisms in vitamin D receptor VDR/RXRA influence the likelihood of colon adenoma recurrence. Cancer Res; 2010 Feb 15;70(4):1496-504
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms in vitamin D receptor VDR/RXRA influence the likelihood of colon adenoma recurrence.
  • No gene-level associations were observed for VDR, nor was any single SNP in VDR related to any metachronous adenoma after correction for multiple comparisons.
  • Haplotypes within linkage blocks of RXRA support an approximately 30% reduction in odds of metachronous neoplasia arising in the proximal colon among carriers of specific haplotypes, which was strongest (OR(proximal), 0.67; 95% CI, 0.52-0.86) for carriers of a CGGGCA haplotype (rs1805352, rs3132297, rs3132296, rs3118529, rs3118536, and rs7861779).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mutat. 2006 Nov;27(11):1129-34 [16937379.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1706-16 [17087956.001]
  • [Cites] Genet Epidemiol. 2007 Jul;31(5):383-95 [17410554.001]
  • [Cites] J Clin Gastroenterol. 2007 Sep;41(8):731-46 [17700421.001]
  • [Cites] Nat Rev Drug Discov. 2007 Oct;6(10):793-810 [17906642.001]
  • [Cites] Gut. 2007 Nov;56(11):1557-63 [17604322.001]
  • [Cites] J Natl Cancer Inst. 2007 Nov 7;99(21):1594-602 [17971526.001]
  • [Cites] PLoS One. 2008;3(1):e1483 [18213391.001]
  • [Cites] Nutr Cancer. 2008;60(1):97-108 [18444141.001]
  • [Cites] Cell Mol Life Sci. 2008 May;65(10):1523-43 [18278436.001]
  • [Cites] Int J Cancer. 2008 Aug 1;123(3):586-93 [18470879.001]
  • [Cites] Carcinogenesis. 2008 May;29(5):944-8 [18375961.001]
  • [Cites] Nutr Rev. 2008 Oct;66(10 Suppl 2):S98-112 [18844852.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):2958-69 [18990737.001]
  • [Cites] Carcinogenesis. 2009 May;30(5):769-76 [19255064.001]
  • [Cites] Carcinogenesis. 2009 Jul;30(7):1170-80 [19403841.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1156-62 [10770980.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2304-12 [10786699.001]
  • [Cites] Endocrinology. 2000 Nov;141(11):3931-9 [11089522.001]
  • [Cites] J Cell Biol. 2001 Jul 23;154(2):369-87 [11470825.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Aug;10(8):869-74 [11489753.001]
  • [Cites] Cancer Causes Control. 2001 Sep;12(7):607-14 [11552708.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1267-74 [11751444.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25313-22 [12000762.001]
  • [Cites] Exp Hematol. 2003 Jun;31(6):488-94 [12829024.001]
  • [Cites] Nat Rev Cancer. 2003 Aug;3(8):601-14 [12894248.001]
  • [Cites] J Biol Chem. 2003 Aug 8;278(32):29954-62 [12771132.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7799-806 [14633706.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1765-71 [14652238.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):789-96 [14685227.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1502-8 [15342452.001]
  • [Cites] Int J Epidemiol. 1980 Sep;9(3):227-31 [7440046.001]
  • [Cites] Lancet. 1989 Nov 18;2(8673):1176-8 [2572900.001]
  • [Cites] Endocrinology. 1994 Apr;134(4):1710-7 [8137734.001]
  • [Cites] Cell. 1995 Dec 15;83(6):835-9 [8521507.001]
  • [Cites] Cancer Res. 1996 Feb 1;56(3):623-32 [8564982.001]
  • [Cites] J Endocrinol. 1997 Sep;154 Suppl:S57-73 [9379138.001]
  • [Cites] J Bone Miner Res. 1998 Mar;13(3):325-49 [9525333.001]
  • [Cites] Hum Genet. 1998 Oct;103(4):462-9 [9856491.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 1;97(11):846-53 [15928305.001]
  • [Cites] Hum Genomics. 2005 Jun;2(2):144-51 [16004730.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2061-3 [16172209.001]
  • [Cites] Nat Genet. 2005 Nov;37(11):1217-23 [16244653.001]
  • [Cites] Endocr Rev. 2005 Dec;26(7):898-915 [16126938.001]
  • [Cites] N Engl J Med. 2006 Feb 16;354(7):684-96 [16481636.001]
  • [Cites] Am J Hum Genet. 2006 Apr;78(4):629-44 [16532393.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 5;98(7):451-9 [16595781.001]
  • [Cites] Anticancer Res. 2009 Sep;29(9):3511-36 [19667145.001]
  • [Cites] Am J Hum Genet. 2007 Dec;81(6):1158-68 [17966093.001]
  • [Cites] EMBO Rep. 2006 Oct;7(10):1030-4 [16936639.001]
  • (PMID = 20145122.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K07 CA106269; United States / NCI NIH HHS / CA / CA023074-22S1; United States / NCI NIH HHS / CA / P50 CA095060-01; United States / NCI NIH HHS / CA / P30 CA023074; United States / NCI NIH HHS / CA / K07CA106269; United States / NCI NIH HHS / CA / CA95060; United States / NCI NIH HHS / CA / CA77145; United States / NCI NIH HHS / CA / P01 CA041108; United States / NCI NIH HHS / CA / CA23074; United States / NCI NIH HHS / CA / CA095060-01; United States / NCI NIH HHS / CA / P50 CA095060; United States / NCI NIH HHS / CA / R01 CA123065; United States / NCI NIH HHS / CA / K07 CA106269-01A1; United States / NCI NIH HHS / CA / P30 CA023074-22S1; United States / NCI NIH HHS / CA / P01 CA041108-13; United States / NCI NIH HHS / CA / P01CA41108; United States / NCI NIH HHS / CA / CA041108-13; United States / NCI NIH HHS / CA / CA106269-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Calcitriol; 0 / Retinoid X Receptor alpha
  • [Other-IDs] NLM/ NIHMS262521; NLM/ PMC3019606
  •  go-up   go-down


11. Lee HH, Son YJ, Lee WH, Park YW, Chae SW, Cho WJ, Kim YM, Choi HJ, Choi DH, Jung SW, Min YJ, Park SE, Lee BJ, Cha HJ, Park JW: Tristetraprolin regulates expression of VEGF and tumorigenesis in human colon cancer. Int J Cancer; 2010 Apr 15;126(8):1817-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tristetraprolin regulates expression of VEGF and tumorigenesis in human colon cancer.
  • Here, we report that TTP suppress the growth of human colon cancer cells both in vivo and in vitro by regulating of the expression of vascular endothelial growth factor (VEGF).
  • TTP protein expression in human colonic tissues was markedly decreased in colonic adenocarcinoma compared with in normal mucosa and adenoma.
  • VEGF expression was higher in colonic adenocarcinoma than in normal mucosa and adenoma.
  • Specific inhibition of TTP expression by RNA-interference increased the expression of VEGF in cultured human colon cancer cells, and TTP overexpression markedly decreased it.
  • These findings demonstrate that TTP acts as a negative regulator of VEGF gene expression in colon cancer cells, suggesting that it can be used as novel therapeutic agent to treat colon cancer.
  • [MeSH-major] Adenocarcinoma / metabolism. Colonic Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Tristetraprolin / metabolism. Vascular Endothelial Growth Factor A / biosynthesis
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adult. Aged. Aged, 80 and over. Animals. Blotting, Western. Cell Line, Tumor. Electrophoresis, Polyacrylamide Gel. Electrophoretic Mobility Shift Assay. Female. Gene Expression. Humans. Immunohistochemistry. Intestinal Mucosa / metabolism. Male. Mice. Mice, Nude. Middle Aged. Neoplasm Staging. RNA Stability / genetics. RNA, Messenger / genetics. RNA, Small Interfering. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Xenograft Model Antitumor Assays

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697322.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Tristetraprolin; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


12. Tan KL, Wilson S, O'Neill C, Gordon D, Napier S: Something not quite right: Gardner syndrome diagnosed by multiple cutaneous lesions and genetic testing. Surgeon; 2005 Dec;3(6):412-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gardner syndrome is a variant of familial adenomatous polyposis characterized by intestinal adenomatous polyps, which can progress to adenocarcinoma, and a variety of extraintestinal manifestations, including skin cysts, osteomas, soft tissue fibrous tumours and a characteristic ocular lesion.
  • Gardner syndrome was considered only after excision of subcutaneous fibrous tumours from the mastoid region and paraspinal area and was confirmed by genetic testing in spite of the patient's refusal to undergo colonic endoscopic examination.
  • Subsequent resection revealed approximately 70 adenomatous colonic polyps in the colon and rectum but no invasive tumour, highlighting the benefits of genetic testing in treatment planning.

  • Genetic Alliance. consumer health - Gardner Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353862.001).
  • [ISSN] 1479-666X
  • [Journal-full-title] The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland
  • [ISO-abbreviation] Surgeon
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


13. Law DJ, Labut EM, Merchant JL: Intestinal overexpression of ZNF148 suppresses ApcMin/+ neoplasia. Mamm Genome; 2006 Oct;17(10):999-1004
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We sought to determine whether intestinal ZNF148 overexpression would abrogate adenoma development in the ApcMin/+ mouse, i.e., whether ZNF148 is a tumor suppressor.
  • The presence of the ZNF148TgVZ allele in ApcMin/+ mice correlated with reduced gastrointestinal bleeding at 5 weeks, a 50% reduction in adenoma burden at 20-22 weeks, and prolonged survival (median survival of 33.5 days vs. 21.5 days), relative to nontransgenic littermates.
  • They also suggest that ZNF148 is a therapeutic target to inhibit colon cancer development.
  • [MeSH-major] Adenomatous Polyposis Coli Protein / metabolism. DNA-Binding Proteins / metabolism. DNA-Binding Proteins / physiology. Intestines / metabolism. Transcription Factors / metabolism. Transcription Factors / physiology
  • [MeSH-minor] Adenoma / metabolism. Adenoma / mortality. Alleles. Animals. Apoptosis / physiology. Crosses, Genetic. Gastrointestinal Diseases / genetics. Gastrointestinal Diseases / mortality. Gastrointestinal Diseases / prevention & control. Hemorrhage / genetics. Hemorrhage / mortality. Hemorrhage / prevention & control. Intestinal Neoplasms / metabolism. Intestinal Neoplasms / mortality. Mice. Mice, Inbred C57BL. Mice, Transgenic. Pedigree. Survival Analysis. Tumor Burden / genetics. Tumor Suppressor Proteins / metabolism. Tumor Suppressor Proteins / physiology

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mamm Genome. 1998 Feb;9(2):165-7 [9457682.001]
  • [Cites] Nucleic Acids Res. 2006 Mar 03;34(5):1342-50 [16517939.001]
  • [Cites] Science. 1992 May 1;256(5057):668-70 [1350108.001]
  • [Cites] Int J Gastrointest Cancer. 2002;31(1-3):79-88 [12622418.001]
  • [Cites] Mol Cell Biol. 1996 Dec;16(12):6644-53 [8943318.001]
  • [Cites] J Biol Chem. 2001 Nov 23;276(47):43713-22 [11559712.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(14 ):4670-83 [11416144.001]
  • [Cites] J Biol Chem. 2000 Sep 29;275(39):30725-33 [10899165.001]
  • [Cites] Oncogene. 2005 Mar 31;24(14):2354-66 [15735748.001]
  • [Cites] J Biol Chem. 2002 Sep 6;277(36):33275-83 [12065599.001]
  • [Cites] Nat Genet. 2003 Feb;33(2):172-6 [12524542.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Food Chem Toxicol. 2002 Aug;40(8):1171-8 [12067580.001]
  • [Cites] Am J Physiol. 1998 Mar;274(3 Pt 1):G544-51 [9530156.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4368-74 [12907606.001]
  • [Cites] J Biol Chem. 1998 Aug 7;273(32):19955-64 [9685330.001]
  • [Cites] J Natl Cancer Inst. 1990 Apr 18;82(8):650-61 [2157027.001]
  • [Cites] J Appl Microbiol. 2002;93(3):390-7 [12174036.001]
  • (PMID = 17019648.001).
  • [ISSN] 0938-8990
  • [Journal-full-title] Mammalian genome : official journal of the International Mammalian Genome Society
  • [ISO-abbreviation] Mamm. Genome
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5P30CA46592; United States / NIDDK NIH HHS / DK / R01 DK055732-08; United States / NIDDK NIH HHS / DK / DK065004; United States / NIDDK NIH HHS / DK / P30 DK034933; United States / NIDDK NIH HHS / DK / 2P30DK34933-20; United States / NIDDK NIH HHS / DK / R01 DK055732; United States / NIDDK NIH HHS / DK / DK55732; United States / NIDDK NIH HHS / DK / P30 DK034933-219001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / DNA-Binding Proteins; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / ZNF148 protein, human
  •  go-up   go-down


14. Marshall JR: Prevention of colorectal cancer: diet, chemoprevention, and lifestyle. Gastroenterol Clin North Am; 2008 Mar;37(1):73-82, vi
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This article focuses on preventing the initiation and promotion of neoplastic growth in colon cancer, particularly with dietary measures.
  • Short-term trials that alter intermediate biomarkers that are more sensitive than the adenoma to interventions may be necessary.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Dec;5(12):947-53 [8959315.001]
  • [Cites] Am J Epidemiol. 1988 Sep;128(3):490-503 [2843038.001]
  • [Cites] CA Cancer J Clin. 1997 May-Jun;47(3):154-60 [9152173.001]
  • [Cites] J Natl Cancer Inst. 1997 Jul 2;89(13):948-55 [9214674.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 7;90(1):57-62 [9428784.001]
  • [Cites] N Engl J Med. 1999 Jan 21;340(3):169-76 [9895396.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 2;91(11):950-3 [10359547.001]
  • [Cites] Am J Epidemiol. 1999 Jul 1;150(1):88-96 [10400558.001]
  • [Cites] JAMA. 2006 Feb 8;295(6):643-54 [16467233.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] Am J Clin Nutr. 2007 May;85(5):1353-60 [17490973.001]
  • [Cites] J Nutr. 2000 Feb;130(2):129-32 [10720158.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1149-55 [10770979.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1156-62 [10770980.001]
  • [Cites] Can J Gastroenterol. 2000 Apr;14(4):299-307 [10799083.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 1;92(21):1740-52 [11058617.001]
  • [Cites] N Engl J Med. 2000 Nov 30;343(22):1603-7 [11096167.001]
  • [Cites] J Natl Cancer Inst. 1990 Nov 21;82(22):1746-52 [2231769.001]
  • [Cites] N Engl J Med. 1990 Dec 13;323(24):1664-72 [2172820.001]
  • [Cites] J Am Diet Assoc. 1992 Aug;92(8):969-77 [1640041.001]
  • [Cites] J Natl Cancer Inst. 1992 Oct 7;84(19):1491-500 [1433333.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Mar-Apr;2(2):159-76 [8467251.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 2;85(11):875-84 [8492316.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 2;86(3):183-91 [8283490.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 2;86(3):192-9 [8283491.001]
  • [Cites] N Engl J Med. 1994 Jul 21;331(3):141-7 [8008027.001]
  • [Cites] J Natl Cancer Inst. 1994 Jul 20;86(14):1053-7 [7802771.001]
  • [Cites] J Natl Cancer Inst. 1995 Feb 15;87(4):265-73 [7707417.001]
  • [Cites] Epidemiol Rev. 1994;16(2):273-97 [7713180.001]
  • [Cites] Am J Clin Nutr. 1995 May;61(5):1083-90 [7733033.001]
  • [Cites] Am J Epidemiol. 1996 May 15;143(10):1069-78 [8629614.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 May;5(5):375-83 [9162304.001]
  • [Cites] Gastroenterology. 1996 Dec;111(6):1411-7 [8942718.001]
  • [Cites] N Engl J Med. 1987 Jan 1;316(1):22-8 [3785347.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):11-21 [11900248.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):630-9 [12101110.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):891-9 [12621133.001]
  • [Cites] Cancer. 1971 Jul;28(1):3-13 [5165022.001]
  • [Cites] Cancer. 1974 Sep;34(3):suppl:801-6 [4853174.001]
  • [Cites] Br Med J. 1976 Dec 25;2(6051):1525-36 [1009386.001]
  • [Cites] J Natl Cancer Inst. 1978 Sep;61(3):709-14 [278848.001]
  • [Cites] Cancer Detect Prev. 1982;5(3):331-4 [7151066.001]
  • [Cites] Prev Med. 1987 Jul;16(4):451-9 [2819846.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] JAMA. 1996 Dec 25;276(24):1957-63 [8971064.001]
  • (PMID = 18313540.001).
  • [ISSN] 0889-8553
  • [Journal-full-title] Gastroenterology clinics of North America
  • [ISO-abbreviation] Gastroenterol. Clin. North Am.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA037447-22; United States / NCI NIH HHS / CA / U10 CA037447-22
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 55
  • [Other-IDs] NLM/ NIHMS44598; NLM/ PMC2637789
  •  go-up   go-down


15. Zheng HC, Tsuneyama K, Takahashi H, Miwa S, Sugiyama T, Popivanova BK, Fujii C, Nomoto K, Mukaida N, Takano Y: Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression. J Cancer Res Clin Oncol; 2008 Apr;134(4):481-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant Pim-3 expression is involved in gastric adenoma-adenocarcinoma sequence and cancer progression.
  • PURPOSE: Pim-3, a member of the proto-oncogene Pim family with serine/threonine kinase activity was aberrantly expressed in cancerous lesions of endoderm-derived organs such as liver, pancreas, and colon.
  • METHODS: Pim-3 expression was immunohistochemically examined on the tissue microarrays containing primary (n = 285) and metastastic (n = 37) sites of gastric carcinomas, in comparison with adenoma (n = 48) and non-cancerous mucosa (n = 84).
  • RESULTS: Pim-3 expression was enhanced in adenoma (64.6%) and metastasis sites of gastric carcinoma (73.0%), to a lesser degree in primary sites of gastric carcinoma (39.3%) when compared to non-cancerous mucosa (13.1%, p < 0.0001).
  • CONCLUSIONS: Aberrant Pim-3 expression was involved in gastric adenoma-adenocarcinoma sequence and subsequent invasion and metastasis process in gastric cancer.
  • [MeSH-major] Adenocarcinoma / chemistry. Adenoma / chemistry. Protein-Serine-Threonine Kinases / analysis. Proto-Oncogene Proteins / analysis. Stomach Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1560-3 [14571786.001]
  • [Cites] J Surg Oncol. 2007 Aug 1;96(2):95-101 [17443727.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):209-18 [15540201.001]
  • [Cites] Int J Cancer. 2005 Nov 10;117(3):376-80 [15900596.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1141-9 [15167936.001]
  • [Cites] Carcinogenesis. 2002 Jan;23(1):201-5 [11756242.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):241-52 [15799824.001]
  • [Cites] Lung Cancer. 2006 Feb;51(2):181-91 [16324768.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):169-80 [8534865.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5A):3579-83 [17094486.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Jun;31(2):499-516 [12134615.001]
  • [Cites] Mol Cell Biol. 2003 Jun;23(11):3897-908 [12748291.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4536-44 [14982870.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):242-8 [15543611.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Dec;132(12):817-23 [16807756.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] Cancer Sci. 2007 Mar;98(3):321-8 [17270021.001]
  • [Cites] Pathol Int. 2003 Oct;53(10 ):659-66 [14516315.001]
  • [Cites] Eur J Cancer. 1999 Apr;35(4):647-51 [10492641.001]
  • [Cites] Brain Pathol. 2003 Oct;13(4):507-18 [14655756.001]
  • [Cites] Am J Gastroenterol. 2001 Jan;96(1):16-26 [11197247.001]
  • [Cites] J Biol Chem. 1998 Jun 26;273(26):16535-43 [9632723.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):432-40 [18091387.001]
  • [Cites] EMBO J. 1999 Jun 15;18(12):3359-69 [10369676.001]
  • [Cites] Cell Oncol. 2005;27(4):215-23 [16308470.001]
  • [Cites] J Clin Invest. 2005 Oct;115(10):2618-24 [16200194.001]
  • [Cites] J Clin Pathol. 2007 Mar;60(3):273-7 [16714395.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6741-7 [16818649.001]
  • [Cites] Croat Med J. 2007 Apr;48(2):207-17 [17436385.001]
  • [Cites] Br J Cancer. 2006 Nov 20;95(10):1371-8 [17088917.001]
  • [Cites] Hepatogastroenterology. 2006 Jul-Aug;53(70):484-90 [16995446.001]
  • (PMID = 17876606.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Proto-Oncogene Proteins; 0 / Vascular Endothelial Growth Factor A; EC 2.7.11.1 / PIM3 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


16. Jurek D, Fleckl E, Marian B: Bile acid induced gene expression in LT97 colonic adenoma cells. Food Chem Toxicol; 2005 Jan;43(1):87-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bile acid induced gene expression in LT97 colonic adenoma cells.
  • LT97 human colonic adenoma cells reflecting early premalignant genotype and growth characteristics have been posed to tumor promoting bile acids in order to identify marker genes that permit identification of tumor promoters in vitro.
  • Transient induction of c-fos was seen with the non-promoting taurodesoxycholate (TDOC) as well as DOC, however extended induction at 3 h was only achieved by DOC and CDC reaching 3-6-fold as compared to the control.
  • Stimulation of COX-2 expression was completely specific for the tumor promoting analogs DOC and CDC.
  • Expression of VEGF was stimulated 4-5-fold in the tumor promoter (DOC and CDC) groups and about 2-fold in the non-promoting controls TDOC and GCDC.
  • At later times the tumor promoter specific difference was lost.
  • Our results show that all three genes are modulated in a tumor promoter dependent way and that their upregulation in LT97 adenoma cells can be used for in vitro testing of colon tumor promoters and chemopreventive compounds.
  • [MeSH-major] Adenoma / metabolism. Bile Acids and Salts / pharmacology. Biomarkers, Tumor / metabolism. Colonic Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / drug effects

  • Hazardous Substances Data Bank. DEOXYCHOLIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15582199.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bile Acids and Salts; 0 / Biomarkers, Tumor; 0 / Isoenzymes; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins c-fos; 0 / Tumor Necrosis Factor-alpha; 0 / Vascular Endothelial Growth Factor A; 005990WHZZ / Deoxycholic Acid; 0GEI24LG0J / Chenodeoxycholic Acid; 516-50-7 / Taurodeoxycholic Acid; 63231-63-0 / RNA; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  •  go-up   go-down


17. Petko Z, Ghiassi M, Shuber A, Gorham J, Smalley W, Washington MK, Schultenover S, Gautam S, Markowitz SD, Grady WM: Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res; 2005 Feb 1;11(3):1203-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps.
  • Colon cancer is the third leading cause of cancer-related death in the United States, affecting approximately 147,000 people each year.
  • Most colon cancers arise from benign neoplasms and evolve into adenocarcinomas through a stepwise histologic progression sequence that starts from adenomas or hyperplastic polyps/serrated adenomas.
  • Genetic alterations and, more recently, epigenetic alterations have been associated with specific steps in this polyp-adenocarcinoma sequence and likely drive the histologic progression of colon cancer.
  • Consequently, we have assessed in colon adenomas and hyperplastic polyps the methylation status of MGMT, CDKN2A, and MLH1 to determine the timing and frequency of these events in the polyp-carcinoma progression sequence and subsequently to analyze the potential for these methylated genes to be molecular markers for adenomas and hyperplastic polyps.
  • We have found that methylated MGMT, CDKN2A, and MLH1 occur in 49%, 34%, and 7% of adenomas and in 5%, 10%, and 7% of hyperplastic polyps, respectively, and that they are more common in histologically advanced adenomas.
  • Furthermore, analysis of fecal DNA from persons who have undergone colonoscopic exams revealed methylated CDKN2A, MGMT, and MLH1 in fecal DNA from 31%, 48%, and 0% of individuals with adenomas and from 16%, 27%, and 10% of individuals with no detectable polyps, respectively.
  • These results show that aberrant methylated genes can be detected frequently in sporadic colon polyps and that they can be detected in fecal DNA.
  • Notably, improvements in the specificity and sensitivity of the fecal DNA-based assays will be needed to make them clinically useful diagnostic tests for polyps.
  • [MeSH-major] Biomarkers, Tumor / genetics. Colonic Polyps / genetics. Colorectal Neoplasms / genetics. DNA Methylation. DNA, Neoplasm / genetics
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adenoma / genetics. Adenoma / pathology. Carrier Proteins. Cell Line, Tumor. CpG Islands / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Feces / chemistry. Humans. Hyperplasia. Neoplasm Proteins / genetics. Nuclear Proteins. O(6)-Methylguanine-DNA Methyltransferase / genetics

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709190.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 95103; United States / NCI NIH HHS / CA / U01 CA 094986
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Neoplasm; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


18. Goldstein NS: Small colonic microsatellite unstable adenocarcinomas and high-grade epithelial dysplasias in sessile serrated adenoma polypectomy specimens: a study of eight cases. Am J Clin Pathol; 2006 Jan;125(1):132-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small colonic microsatellite unstable adenocarcinomas and high-grade epithelial dysplasias in sessile serrated adenoma polypectomy specimens: a study of eight cases.
  • Eight sessile serrated adenoma (SSA), right colon polypectomies with focal invasive adenocarcinoma or high-grade dysplasia were studied to identify features indicating a high risk of transformation and characterize the morphologic features of serrated dysplasia; 6 cases had invasive adenocarcinoma; 2 were high-grade dysplasia.
  • Mean polyp maximum dimension was 8.5 mm (range, 6-12 mm).
  • The majority of each polyp was nonmalignant SSA.
  • Small proximal SSAs can transform into adenocarcinoma without a component of adenomatous dysplasia.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma / pathology. Chromosomal Instability. Colonic Neoplasms / pathology. Microsatellite Repeats
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Aged. Aged, 80 and over. Carrier Proteins / analysis. Cell Transformation, Neoplastic / pathology. Colonic Polyps / pathology. Epithelium / pathology. Humans. Middle Aged. Nuclear Proteins / analysis

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16483002.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / MLH1 protein, human; 0 / Nuclear Proteins
  •  go-up   go-down


19. Zoghbi S, Drouin E, Claustre J, Bara J, Scoazec JY, Plaisancié P: Intestinal MUC2 and gastric M1/MUC5AC in preneoplastic lesions induced by 1,2-dimethylhydrazine in rat: a sequential analysis. Int J Oncol; 2007 Feb;30(2):489-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our study was performed to sequentially analyze the expression of the intestinal mucin MUC2 and of the gastric mucin MUC5AC as indicators during progression of preneoplastic biomarkers in rat colon.
  • Similar alterations in mucin expression were observed in human colonic pre-neoplastic lesions.
  • These findings suggest that a decrease in MUC2 expression and staining of MUC5AC in non-goblet-like cells predicts histological progression of preneoplastic lesions.
  • [MeSH-minor] Adenoma / metabolism. Animals. Carcinoma / metabolism. Cell Line, Tumor. Colon / metabolism. Humans. Male. Mucin 5AC. Mucin-2. Precancerous Conditions. Rats. Rats, Inbred F344. beta Catenin / metabolism

  • Hazardous Substances Data Bank. 1,2-DIMETHYLHYDRAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203232.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Carcinogens; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / Muc2 protein, rat; 0 / Muc5ac protein, rat; 0 / Mucin 5AC; 0 / Mucin-2; 0 / Mucins; 0 / beta Catenin; IX068S9745 / 1,2-Dimethylhydrazine
  •  go-up   go-down


20. Rutter CM, Savarino JE: An evidence-based microsimulation model for colorectal cancer: validation and application. Cancer Epidemiol Biomarkers Prev; 2010 Aug;19(8):1992-2002
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: CRC-SPIN simulates individual event histories associated with colorectal cancer, based on the adenoma-carcinoma sequence: adenoma initiation and growth, development of preclinical invasive colorectal cancer, development of clinically detectable colorectal cancer, death from colorectal cancer, and death from other causes.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2010 AACR.
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):162-8 [10900274.001]
  • [Cites] Eur Radiol. 2010 Jun;20(6):1404-13 [20033180.001]
  • [Cites] Am J Gastroenterol. 2000 Dec;95(12):3418-22 [11151871.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2001 Mar 9;50(9):162-6 [11393486.001]
  • [Cites] Gastrointest Endosc Clin N Am. 2002 Jan;12(1):1-9, v [11916153.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Feb;14(2):183-8 [11981343.001]
  • [Cites] Br J Surg. 2002 Jul;89(7):845-60 [12081733.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2191-200 [14657426.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):481-5 [14994108.001]
  • [Cites] Am J Gastroenterol. 2004 Aug;99(8):1544-50 [15307875.001]
  • [Cites] Cancer. 1975 Dec;36(6):2251-70 [1203876.001]
  • [Cites] J Natl Cancer Inst. 1990 Nov 21;82(22):1769-72 [2231773.001]
  • [Cites] Am J Gastroenterol. 1993 Apr;88(4):496-500 [8470627.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):24-8 [8978338.001]
  • [Cites] Int J Colorectal Dis. 1997;12(5):267-71 [9401839.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1116-28 [10506694.001]
  • [Cites] Am Surg. 2005 Dec;71(12):1024-6 [16447472.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):255-62 [16454827.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):343-50 [16454841.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):389-94 [16492934.001]
  • [Cites] Gut. 2006 Aug;55(8):1145-50 [16469791.001]
  • [Cites] Stat Med. 2007 Jan 15;26(1):98-109 [16372387.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2213-21 [17455218.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1570-95 [18384785.001]
  • [Cites] Am J Prev Med. 2008 Sep;35(3):194-202 [18619761.001]
  • [Cites] N Engl J Med. 2008 Sep 18;359(12):1218-24 [18799558.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 3;100(23):1672-94 [19033571.001]
  • [Cites] Ann Intern Med. 2009 Jan 6;150(1):1-8 [19075198.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):169-74 [10900275.001]
  • (PMID = 20647403.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA097427-08; United States / NCI NIH HHS / CA / U01 CA097427; United States / NCI NIH HHS / CA / U01 CA097427-08; United States / NCI NIH HHS / CA / U01 CA97427
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Validation Studies
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS208492; NLM/ PMC2919657
  •  go-up   go-down


21. Oikonomou E, Pintzas A: Cancer genetics of sporadic colorectal cancer: BRAF and PI3KCA mutations, their impact on signaling and novel targeted therapies. Anticancer Res; 2006 Mar-Apr;26(2A):1077-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These genes, that have been implicated in the adenoma-carcinoma transition, cause deregulation and constitutive activation of the MAP AKT/kinase pathways, rendering growth advantages to colon tumor cells.
  • This review focuses on the key genetic alterations underlying the cumulative effect of multiple mutations within the colon cancer cell.


22. Shaked G, Czeiger D: Distended urinary bladder and diverticulum-a rare cause of large-bowel obstruction. Am J Surg; 2009 Feb;197(2):e23-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The colonic obstruction was secondary to external compression of the rectosigmoid colon against the sacrum by a distended bladder and diverticulum.
  • Later the patient underwent surgery to remove an enlarged benign prostatic adenoma, which was the underlying cause of the bladder distention.


23. Su MY, Ho YP, Hsu CM, Chiu CT, Chen PC, Lien JM, Tung SY, Wu CS: How can colorectal neoplasms be treated during colonoscopy? World J Gastroenterol; 2005 May 14;11(18):2806-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: For many physicians who ordinarily treat patients with colonic diseases, colonoscopy is considered a prime study interest.
  • RESULTS: Histological diagnoses were 4596 neoplastic lesions (4 376 adenomas and 220 adenocarcinomas) and 906 non-neoplastic lesions (891 hyperplastic and 15 inflammatory polyps).
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Colonoscopy. Colorectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15884128.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4305922
  •  go-up   go-down


24. Neklason DW, Stevens J, Boucher KM, Kerber RA, Matsunami N, Barlow J, Mineau G, Leppert MF, Burt RW: American founder mutation for attenuated familial adenomatous polyposis. Clin Gastroenterol Hepatol; 2008 Jan;6(1):46-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] American founder mutation for attenuated familial adenomatous polyposis.
  • BACKGROUND & AIMS: Specific mutations in the adenomatous polyposis coli (APC) gene can lead to an attenuated form of familial adenomatous polyposis (AFAP).
  • Although AFAP mutation carriers have a 69% risk of colorectal cancer by age 80, clinical recognition remains a challenge in some cases because they present with few colonic adenomas and are difficult to distinguish clinically from patients with sporadic polyps.
  • The data show that 36.6% of the mutation-positive family members have fewer than 10 colonic adenomatous polyps, and 3 (6.8%) of these individuals were diagnosed with colorectal cancer.
  • CONCLUSIONS: In view of the apparent age of this mutation, a notable fraction of both multiple-adenoma patients and perhaps even colon cancer cases in the United States could be related to this founder mutation.
  • The colon cancer risk associated with the mutation makes genetic testing of considerable importance in patients with a personal or family history of either colonic polyps or cancer at a young age.

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • Genetic Alliance. consumer health - Familial Polyposis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Mol Genet. 2000 Sep 22;9(15):2215-21 [11001924.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1872-85 [16697750.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):198-213 [11438509.001]
  • [Cites] Dis Colon Rectum. 2002 Jan;45(1):127-34; discussion 134-6 [11786778.001]
  • [Cites] Nat Genet. 2002 Feb;30(2):227-32 [11818965.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2954-8 [11867715.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8161-6 [12034871.001]
  • [Cites] Hum Mol Genet. 2002 Nov 1;11(23):2961-7 [12393807.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):919-32 [12621137.001]
  • [Cites] Trends Biotechnol. 2003 Mar;21(3):113-6 [12628367.001]
  • [Cites] Fam Cancer. 2003;2(1):43-55 [14574166.001]
  • [Cites] Am J Hum Genet. 2003 Dec;73(6):1250-60 [14624392.001]
  • [Cites] JAMA. 2004 Feb 11;291(6):718-24 [14871915.001]
  • [Cites] Gastroenterology. 2004 Aug;127(2):444-51 [15300576.001]
  • [Cites] Hum Hered. 1971;21(6):523-42 [5149961.001]
  • [Cites] N Engl J Med. 1990 Mar 29;322(13):904-8 [2156161.001]
  • [Cites] J Med Genet. 1991 May;28(5):289-96 [1650842.001]
  • [Cites] N Engl J Med. 1992 Mar 5;326(10):658-62 [1736104.001]
  • [Cites] Cell. 1993 Dec 3;75(5):951-7 [8252630.001]
  • [Cites] Hum Genet. 1994 Mar;93(3):281-6 [8125478.001]
  • [Cites] Hum Mutat. 1994;3(2):121-5 [8199592.001]
  • [Cites] Hum Genet. 1995 Dec;96(6):705-10 [8522331.001]
  • [Cites] Cancer. 1995 Dec 15;76(12):2427-33 [8625067.001]
  • [Cites] Ann Intern Med. 1997 Apr 1;126(7):514-9 [9092316.001]
  • [Cites] Am J Hum Genet. 1998 Jun;62(6):1290-301 [9585611.001]
  • [Cites] Nat Genet. 1998 Dec;20(4):385-8 [9843214.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1857-60 [10213492.001]
  • [Cites] Am J Med Genet. 1999 Oct 8;86(4):321-4 [10494086.001]
  • [Cites] Hum Genet. 1999 Nov;105(5):388-98 [10598803.001]
  • [Cites] Am J Hum Genet. 2000 Sep;67(3):582-90 [10924409.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Apr 1;158(1):70-4 [15771908.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1696-716 [15887160.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):195-7 [11438508.001]
  • (PMID = 18063416.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / NCI-CN-67000; United States / NCI NIH HHS / CA / P01-CA073992; United States / NCI NIH HHS / CA / R01 CA040641-21; United States / NCI NIH HHS / CA / R01 CA040641; United States / NCI NIH HHS / CA / P01 CA073992-10; United States / NCI NIH HHS / CA / CA040641-21; United States / NCI NIH HHS / CN / N01 CN067000; United States / NCI NIH HHS / CA / R01-CA040641; United States / NCI NIH HHS / CA / P01 CA073992; United States / NCI NIH HHS / CA / CA073992-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS37623; NLM/ PMC2245898
  •  go-up   go-down


25. Lieberman D: Debate: small (6-9 mm) and diminutive (1-5 mm) polyps noted on CTC: how should they be managed? Gastrointest Endosc Clin N Am; 2010 Apr;20(2):239-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Debate: small (6-9 mm) and diminutive (1-5 mm) polyps noted on CTC: how should they be managed?
  • New diagnostic technologies can visualize colon polyps, but not remove them.
  • There is clear consensus that polyps 10 mm or larger need to be removed.
  • There is still controversy surrounding the appropriate reporting and management of small 1 to 5 mm and 6 to 9 mm polyps.
  • The author recommends that patients whose largest polyp is 6 mm or larger should be offered colonoscopy.
  • If the largest polyp is less than 6 mm in size, and imaged with high reliability, the author recommends reporting the finding, and individualizing the decision to pursue colonoscopy versus repeat imaging.
  • [MeSH-major] Colonic Polyps. Colonography, Computed Tomographic / methods. Colonoscopy / methods. Decision Making
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / epidemiology. Adenoma / etiology. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / epidemiology. Colorectal Neoplasms / etiology. Humans. Mass Screening / methods. Precancerous Conditions. Prevalence. Severity of Illness Index. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20451813.001).
  • [ISSN] 1558-1950
  • [Journal-full-title] Gastrointestinal endoscopy clinics of North America
  • [ISO-abbreviation] Gastrointest. Endosc. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


26. Shimomura T, Hiyama T, Tanaka S, Yoshihara M, Arihiro K, Chayama K: Synchronous and subsequent lesions of serrated adenomas and tubular adenomas of the colorectum. Pathobiology; 2010;77(5):273-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous and subsequent lesions of serrated adenomas and tubular adenomas of the colorectum.
  • The characteristics of synchronous and subsequent lesions of serrated adenomas (SAs) of the colorectum are still unclear.
  • This study aimed to clarify the characteristics of synchronous and subsequent lesions of SAs compared with tubular adenomas (TAs) of the colorectum.
  • The histology of the index polyp and synchronous and subsequent lesions tended to be identical.
  • Our data suggest that the colonic tumorigenesis potential of patients with SA may differ from that of patients with TA.
  • [MeSH-major] Adenoma / pathology. Colon / pathology. Colorectal Neoplasms / pathology. Rectum / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Polyps / pathology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21116119.001).
  • [ISSN] 1423-0291
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


27. Francois F, Park J, Bini EJ: Colon pathology detected after a positive screening flexible sigmoidoscopy: a prospective study in an ethnically diverse cohort. Am J Gastroenterol; 2006 Apr;101(4):823-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon pathology detected after a positive screening flexible sigmoidoscopy: a prospective study in an ethnically diverse cohort.
  • OBJECTIVES: Although the association between distal neoplasia on sigmoidoscopy and proximal colonic pathology on follow-up colonoscopy has been well-described, it is not known if these findings are consistent across ethnic groups.
  • Colonoscopy was recommended for all patients with a polyp on flexible sigmoidoscopy, regardless of size.
  • Advanced neoplasms were defined as adenomas > or = 10 mm in diameter or any adenoma, regardless of size, with villous histology, high-grade dysplasia, or cancer.
  • The prevalence of neoplasia in the distal colon was 12.6% in Caucasians, 11.2% in African Americans, 15.9% in Hispanics, and 24.7% in Asians (p = 0.002).
  • Of the 290 patients with neoplastic lesions on sigmoidoscopy, follow-up colonoscopy identified neoplasms in the proximal colon in 63.9% of Caucasians, 59.3% of African Americans, 66.7% of Hispanics, and 26.3% of Asians (p = 0.01).
  • Advanced neoplasms in the proximal colon were highest in African Americans (34.9%) and lowest in Asians (10.5%).
  • CONCLUSIONS: In our study population, Asians demonstrated a higher prevalence of distal colonic neoplasia and a lower prevalence of proximal colonic neoplasia compared to non-Asians.
  • Future studies should explore ethnic variation in colonic neoplasia prevalence and location since ethnic variation could lead to tailored colorectal cancer screening strategies.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Colonic Neoplasms / ethnology. Colonoscopy. Sigmoidoscopy
  • [MeSH-minor] African Continental Ancestry Group / statistics & numerical data. Aged. Asian Americans / statistics & numerical data. Colon / pathology. Colonic Polyps / diagnosis. Colonic Polyps / ethnology. Colonic Polyps / pathology. European Continental Ancestry Group / statistics & numerical data. Female. Hispanic Americans / statistics & numerical data. Humans. Male. Middle Aged. Prevalence

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16494591.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Costa-Nogueira C, Villar-Portela S, Cuevas E, Gil-Martín E, Fernández-Briera A: Synthesis and expression of CDw75 antigen in human colorectal cancer. BMC Cancer; 2009;9:431
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By immunohistochemistry we assessed the CDw75 expression in 25 colorectal adenomas, 43 tumours, 13 transitional and 28 healthy tissues of CRC patients.
  • CDw75 expression was positive in 20% of colorectal adenomas.
  • CONCLUSION: The major contribution of this study is the inclusion of data from transitional tissue and the analysis of CDw75 antigen expression in CRC and in colorectal adenomas, little known so far.
  • The expression of CDw75 in colorectal adenomas suggests that this antigen may be a tumour marker in CRC.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Antigens, CD / biosynthesis. Antigens, CD / metabolism. Biomarkers, Tumor / analysis. Colorectal Neoplasms / metabolism. Sialyltransferases / biosynthesis. Sialyltransferases / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2000 Mar;46(3):359-66 [10673297.001]
  • [Cites] Glycobiology. 2006 Feb;16(2):146-54 [16192407.001]
  • [Cites] Hybridoma. 2000 Aug;19(4):281-6 [11001400.001]
  • [Cites] J Pathol. 2001 Feb;193(2):169-74 [11180162.001]
  • [Cites] Eur J Biochem. 2001 Nov;268(22):5876-84 [11722575.001]
  • [Cites] J Biol Chem. 2002 Nov 29;277(48):45719-28 [12235148.001]
  • [Cites] Pathol Oncol Res. 2002;8(3):175-82 [12515997.001]
  • [Cites] Eur J Biochem. 2003 Mar;270(5):950-61 [12603328.001]
  • [Cites] Oncogene. 2003 Oct 16;22(46):7137-45 [14562042.001]
  • [Cites] World J Gastroenterol. 2004 Jun 1;10(11):1682-5 [15162552.001]
  • [Cites] Eur J Biochem. 2004 Sep;271(18):3623-34 [15355339.001]
  • [Cites] Nature. 1982 Nov 18;300(5889):274-6 [7144883.001]
  • [Cites] Anal Biochem. 1985 Oct;150(1):76-85 [3843705.001]
  • [Cites] J Biol Chem. 1987 Feb 5;262(4):1596-601 [3805045.001]
  • [Cites] Int J Cancer. 1989 Sep 15;44(3):434-9 [2476402.001]
  • [Cites] Dis Colon Rectum. 1990 Jun;33(6):498-501 [2351004.001]
  • [Cites] J Biol Chem. 1991 Aug 25;266(24):15984-91 [1714903.001]
  • [Cites] J Biol Chem. 1991 Nov 15;266(32):21674-80 [1657976.001]
  • [Cites] Am J Pathol. 1991 Dec;139(6):1435-48 [1661075.001]
  • [Cites] Cancer Res. 1992 Apr 1;52(7):1775-9 [1312899.001]
  • [Cites] Eur J Biochem. 1993 Jan 15;211(1-2):135-40 [7678804.001]
  • [Cites] Arch Biochem Biophys. 1993 Jun;303(2):255-9 [8512312.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1522-7 [8348485.001]
  • [Cites] Cancer Lett. 1993 Dec 20;75(3):143-9 [8313349.001]
  • [Cites] Clin Sci (Lond). 1995 Oct;89(4):397-404 [7493440.001]
  • [Cites] Glycoconj J. 1996 Feb;13(1):115-21 [8785482.001]
  • [Cites] FASEB J. 1997 Mar;11(4):248-55 [9068613.001]
  • [Cites] J Surg Oncol. 1998 Feb;67(2):85-9 [9486778.001]
  • [Cites] Int J Cancer. 1999 Apr 12;81(2):243-7 [10188726.001]
  • [Cites] Biochem J. 1961 Nov;81:384-92 [13860975.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4645-52 [15930282.001]
  • [Cites] Oncology. 2005;69(5):436-44 [16319516.001]
  • [Cites] Int J Cancer. 2000 Oct 1;88(1):58-65 [10962440.001]
  • (PMID = 20003255.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; EC 2.4.99.- / Sialyltransferases; EC 2.4.99.1 / ST6GAL1 protein, human
  • [Other-IDs] NLM/ PMC2803195
  •  go-up   go-down


29. Kobunai T, Watanabe T, Yamamoto Y, Eshima K: The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR. Biochem Biophys Res Commun; 2010 Apr 23;395(1):158-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR.
  • PURPOSE: Kirsten rat sarcoma (KRAS) gene mutations occur early in the progression of colorectal adenoma to carcinoma.
  • [MeSH-major] Carcinoma / genetics. Colonic Neoplasms / genetics. DNA Mutational Analysis / methods. Polymerase Chain Reaction. Proto-Oncogene Proteins / genetics. ras Proteins / genetics

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20361930.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


30. Lecomte T, Cellier C, Meatchi T, Barbier JP, Cugnenc PH, Jian R, Laurent-Puig P, Landi B: Chromoendoscopic colonoscopy for detecting preneoplastic lesions in hereditary nonpolyposis colorectal cancer syndrome. Clin Gastroenterol Hepatol; 2005 Sep;3(9):897-902
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: In hereditary nonpolyposis colorectal cancer (HNPCC) syndrome, flat and small adenomas are particularly prone to malignant transformation but might be missed by standard colonoscopy.
  • Conventional colonoscopy was performed first, followed by a second colonoscopy with chromoendoscopy with indigo carmine (.4%) dye sprayed onto the entire proximal colon.
  • Seven lesions, detected in 5 patients, were adenomas, 3 of which were located in the proximal colon.
  • Eleven additional adenomas were detected in the proximal colon of 8 patients, and 8 of these 11 lesions were flat.
  • The use of chromoendoscopy significantly increased the detection rate of adenomas in the proximal colon, from 3 of 33 patients to 10 of 33 patients (P = .045).
  • CONCLUSION: Relative to conventional colonoscopy, high-resolution colonoscopy with chromoendoscopy markedly improves the detection of adenomas in patients with HNPCC syndrome and might help to prevent colorectal carcinoma in these patients with a very high risk of colorectal cancer.
  • [MeSH-major] Adenoma / diagnosis. Colonoscopy. Colorectal Neoplasms, Hereditary Nonpolyposis / diagnosis. Precancerous Conditions / diagnosis
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adult. Aged. Carrier Proteins / genetics. Colon / pathology. Female. Genetic Predisposition to Disease. Germ-Line Mutation / genetics. Humans. Male. Middle Aged. MutS Homolog 2 Protein / genetics. Nuclear Proteins / genetics. Pilot Projects. Prospective Studies

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Hereditary Cancer.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16234028.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


31. East JE, Suzuki N, Arebi N, Bassett P, Saunders BP: Position changes improve visibility during colonoscope withdrawal: a randomized, blinded, crossover trial. Gastrointest Endosc; 2007 Feb;65(2):263-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTERVENTIONS: Videotaped, back-to-back examination of colon proximal to rectosigmoid junction in left lateral position only, then with position changes: left lateral for the cecum to the hepatic flexure, supine for the transverse colon, and right lateral for the splenic flexure and the descending colon, or vice versa.
  • Luminal distension was scored on a scale of 1 to 5 for each colonic area: 1, complete collapse; 5, widely distended to limit of view.
  • RESULTS: Scores for the 2 examinations from the blinded video reviewer were significantly higher in the transverse, the splenic flexure, and the descending colon, P = .02, .002, and <.001, respectively.
  • Without position changes, 6 of 14 of patients (43%) would have had a nondiagnostic distension score (1 or 2) in at least 1 colonic area, P = .03.
  • CONCLUSIONS: Position change, a cost-neutral intervention, during colonoscope withdrawal improved luminal distension between hepatic flexure and sigmoid-descending junction and has the potential to reduce adenoma and early cancer miss rates.
  • [MeSH-minor] Colon. Cross-Over Studies. Humans. Single-Blind Method. Videotape Recording


32. Vasen HF, de Vos Tot Nederveen Cappel WH: An evidence-based review on surveillance for Lynch syndrome. Dis Colon Rectum; 2006 Nov;49(11):1797-8; author reply 1799
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenoma / genetics. Colonoscopy. Colorectal Neoplasms / genetics. Genetic Predisposition to Disease. Heterozygote. Humans. Mutation. Population Surveillance

  • Genetic Alliance. consumer health - Lynch syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Dis Colon Rectum. 2006 Jan;49(1):80-93; discussion 94-5 [16284887.001]
  • (PMID = 17053868.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


33. Croce MV, Sálice VC, Lacunza E, Segal-Eiras A: Alpha 1-acid glycoprotein (AGP): a possible carrier of sialyl lewis X (slewis X) antigen in colorectal carcinoma. Histol Histopathol; 2005 01;20(1):91-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: tissue and serum samples from 88 patients with colorectal cancer, 22 adenomas and 23 normal were included.
  • [MeSH-minor] Adenoma / immunology. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / immunology. Colon / immunology. Colon / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15578427.001).
  • [ISSN] 0213-3911
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / 5-acetylneuraminyl-(2-3)-galactosyl-(1-4)-(fucopyranosyl-(1-3))-N-acetylglucosamine; 0 / Antibodies, Monoclonal; 0 / Oligosaccharides; 0 / Orosomucoid
  •  go-up   go-down


34. Xu J, Yang L, Guo Y, Zhao D, Wang L, Bai L: Perforation of sigmoid diverticulum following endoscopic polypectomy of an adenoma. BMJ Case Rep; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perforation of sigmoid diverticulum following endoscopic polypectomy of an adenoma.
  • Colonic polyps or carcinomas located within a colonic diverticulum are very rare phenomena.
  • There are a few reports in the literature describing adenocarcinoma arising within colonic diverticulum.
  • Endoscopic resection of the polyp poses a risk of perforation because of the lack of muscular coats in the diverticulum.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22461856.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029913
  •  go-up   go-down


35. Anderson C, Ellenhorn J, Hellan M, Pigazzi A: Pilot series of robot-assisted laparoscopic subtotal gastrectomy with extended lymphadenectomy for gastric cancer. Surg Endosc; 2007 Sep;21(9):1662-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six patients had adenocarcinoma and one patient had a high-grade dysplastic adenoma.
  • There was one intraoperative complication requiring a colon resection for a devascularized segment.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Ann Surg. 2004 Jan;239(1):14-21 [14685095.001]
  • [Cites] Lancet Oncol. 2006 Apr;7(4):309-15 [16574546.001]
  • [Cites] Lancet. 1996 Apr 13;347(9007):995-9 [8606613.001]
  • [Cites] Gastric Cancer. 1999 Nov;2(3):186-190 [11957094.001]
  • [Cites] Gastric Cancer. 2005;8(2):75-7 [15864713.001]
  • [Cites] Br J Surg. 2007 Feb;94(2):204-7 [17058319.001]
  • [Cites] Arch Surg. 2003 Jul;138(7):777-84 [12860761.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1522-30 [10188901.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2002 Jun;12(3):204-7 [12080272.001]
  • [Cites] J Surg Oncol. 2005 Jul 1;91(1):90-4 [15999352.001]
  • [Cites] Gastric Cancer. 1999 Dec;2(4):230-234 [11957104.001]
  • [Cites] Surgery. 1998 May;123(5):573-8 [9591011.001]
  • [Cites] Surg Clin North Am. 2003 Dec;83(6):1429-44 [14712877.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2069-77 [15082726.001]
  • [Cites] Surg Endosc. 2001 Sep;15(9):928-31 [11605108.001]
  • [Cites] World J Urol. 2006 Jun;24(2):152-60 [16758248.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2001 Apr;11(2):83-7 [11330389.001]
  • [Cites] Arch Surg. 2000 Jul;135(7):806-10 [10896374.001]
  • [Cites] Surgery. 2005 Mar;137(3):317-22 [15746786.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):232-7 [15650632.001]
  • [Cites] Surg Endosc. 2002 Aug;16(8):1187-91 [11984681.001]
  • [Cites] Surg Endosc. 2007 Jan;21(1):21-7 [17031743.001]
  • [Cites] Expert Rev Med Devices. 2006 May;3(3):335-43 [16681455.001]
  • [Cites] Surg Endosc. 2003 May;17(5):758-62 [12618942.001]
  • [Cites] Br J Surg. 2001 Jan;88(1):128-32 [11136325.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Dec;13(6):361-5 [14712095.001]
  • [Cites] Surg Endosc. 2000 Jan;14(1):27-31 [10653231.001]
  • (PMID = 17345142.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


36. Tanaka T: Colorectal carcinogenesis: Review of human and experimental animal studies. J Carcinog; 2009;8:5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The focus is on human and murine colorectal carcinogenesis and the histogenesis of this malignant disorder.
  • A summary of a model of colitis-associated colon tumorigenesis (an AOM/DSS model) will also be presented.
  • The earliest phases of colorectal oncogenesis occur in the normal mucosa, with a disorder of cell replication.
  • The large majority of colorectal malignancies develop from an adenomatous polyp (adenoma).
  • Carcinomas usually originate from pre-existing adenomas, but this does not imply that all polyps undergo malignant changes and does not exclude de novo oncogenesis.
  • Besides adenomas, there are other types of pre-neoplasia, which include hyperplastic polyps, serrated adenomas, flat adenomas and dysplasia that occurs in the inflamed colon in associated with inflammatory bowel disease.
  • Colorectal neoplasms and/or pre-neoplasms can be prevented by interfering with the various steps of oncogenesis, which begins with uncontrolled epithelial cell replication, continues with the formation of adenomas and eventually evolves into malignancy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drug Metab Rev. 1998 May;30(2):405-19 [9606610.001]
  • [Cites] Science. 1993 Jun 11;260(5114):1658-61 [8503013.001]
  • [Cites] Nature. 1993 Jul 22;364(6435):352-5 [8332195.001]
  • [Cites] Int J Cancer. 1993 Jan 21;53(2):260-3 [7678832.001]
  • [Cites] Cell. 1993 Nov 19;75(4):817-25 [8242752.001]
  • [Cites] Cell. 1993 Nov 19;75(4):805-16 [8242751.001]
  • [Cites] Mol Cell Biol. 1993 Jul;13(7):4242-50 [8321226.001]
  • [Cites] Biochemistry. 1991 May 14;30(19):4637-48 [2029511.001]
  • [Cites] Hum Mol Genet. 1992 Sep;1(6):387-90 [1338760.001]
  • [Cites] Gut. 1992 Apr;33(4):524-9 [1316306.001]
  • [Cites] Carcinogenesis. 1992 Sep;13(9):1509-12 [1394832.001]
  • [Cites] Nature. 1992 Sep 17;359(6392):235-7 [1528264.001]
  • [Cites] Cancer Res. 1991 Mar 1;51(5):1564-7 [1997197.001]
  • [Cites] Am J Clin Nutr. 1991 Jan;53(1 Suppl):226S-237S [1985392.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):7937-41 [2253235.001]
  • [Cites] N Engl J Med. 1990 Nov 1;323(18):1228-33 [2215606.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Prog Clin Biol Res. 1988;279:319-33 [2847199.001]
  • [Cites] Pathology. 1989 Apr;21(2):138-42 [2812873.001]
  • [Cites] Cancer. 1989 Sep 1;64(5):1138-46 [2758387.001]
  • [Cites] Cancer. 1989 Aug 15;64(4):950-5 [2743285.001]
  • [Cites] Cancer. 1988 Dec 1;62(11):2373-7 [3179952.001]
  • [Cites] Cancer Res. 1988 Jul 15;48(14):4121-6 [3383201.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):829-34 [3338040.001]
  • [Cites] Int Rev Cytol. 1984;90:309-73 [6389415.001]
  • [Cites] Cancer Lett. 1987 Oct 30;37(2):147-51 [3677050.001]
  • [Cites] Cancer Res. 1985 Jan;45(1):1-8 [3880665.001]
  • [Cites] Dis Colon Rectum. 1985 Nov;28(11):847-51 [4053897.001]
  • [Cites] Gastroenterology. 1990 Mar;98(3):694-702 [1688816.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Am J Surg Pathol. 1990 Jun;14(6):524-37 [2186644.001]
  • [Cites] Science. 1990 Jan 5;247(4938):49-56 [2294591.001]
  • [Cites] J Cancer Res Clin Oncol. 1984;108(1):129-34 [6430908.001]
  • [Cites] Cancer Invest. 1983;1(1):41-7 [6667399.001]
  • [Cites] J Clin Pathol. 1982 Aug;35(8):830-41 [7107955.001]
  • [Cites] Gastroenterology. 1981 Mar;80(3):578-84 [7450448.001]
  • [Cites] Cancer. 1977 Nov;40(5 Suppl):2436-45 [200341.001]
  • [Cites] Cancer Res. 1977 Nov;37(11):4182-9 [198131.001]
  • [Cites] Virchows Arch B Cell Pathol. 1978 Dec 21;29(3):211-23 [104430.001]
  • [Cites] Biochem Pharmacol. 1977 Oct 1;26(19):1763-8 [907715.001]
  • [Cites] Lab Invest. 1974 Apr;30(4):505-13 [4363166.001]
  • [Cites] J Natl Cancer Inst. 1973 Sep;51(3):1029-39 [4355212.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):594-604 [12154352.001]
  • [Cites] J Biol Chem. 2002 Jul 19;277(29):26281-5 [12011067.001]
  • [Cites] Lancet Oncol. 2002 Feb;3(2):83-8 [11905459.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):314-46 [11839647.001]
  • [Cites] Gut. 2001 Apr;48(4):526-35 [11247898.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3416-21 [11248093.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2640-5 [11226292.001]
  • [Cites] BMJ. 2000 Oct 7;321(7265):886-9 [11021873.001]
  • [Cites] Drugs Aging. 2000 May;16(5):329-34 [10917070.001]
  • [Cites] Mol Med Today. 2000 Dec;6(12):462-9 [11099951.001]
  • [Cites] Chirurg. 2000 Oct;71(10):1230-4; discussion 1234-5 [11077584.001]
  • [Cites] Nature. 2000 Nov 16;408(6810):307-10 [11099028.001]
  • [Cites] Am J Pathol. 2000 Sep;157(3):737-45 [10980113.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3333-7 [10910033.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3323-7 [10910031.001]
  • [Cites] Gut. 2000 Jul;47(1):43-9 [10861263.001]
  • [Cites] Mt Sinai J Med. 2000 May;67(3):227-40 [10828908.001]
  • [Cites] Dis Colon Rectum. 2000 Jun;43(6):782-7 [10859077.001]
  • [Cites] Science. 2000 May 12;288(5468):1053-8 [10807576.001]
  • [Cites] Oncol Rep. 2000 May-Jun;7(3):501-8 [10767359.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Mar;9(3):239-47 [10750661.001]
  • [Cites] Toxicol Lett. 2000 Mar 15;112-113:395-402 [10720758.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):469-76 [10688867.001]
  • [Cites] Oncogene. 2000 Jan 27;19(4):546-55 [10698524.001]
  • [Cites] Carcinogenesis. 2009 Feb;30(2):183-96 [19037092.001]
  • [Cites] Gastroenterology. 2009 Feb;136(2):542-50.e6 [19103203.001]
  • [Cites] CA Cancer J Clin. 2009 Jan-Feb;59(1):27-41 [19147867.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Dec;1(7):562-7 [19139006.001]
  • [Cites] Chem Biol Interact. 2009 Jan 27;177(2):128-36 [19028472.001]
  • [Cites] Gastroenterology. 2009 Mar;136(3):780-98 [19263594.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):264-71 [19003968.001]
  • [Cites] World J Gastroenterol. 2008 Nov 21;14(43):6632-5 [19034964.001]
  • [Cites] Br J Cancer. 1998 Feb;77(4):588-94 [9484816.001]
  • [Cites] Br J Cancer. 1998;77(3):466-71 [9472645.001]
  • [Cites] Dis Colon Rectum. 1997 Oct;40(10 Suppl):S80-5 [9378018.001]
  • [Cites] Am J Pathol. 1997 Mar;150(3):833-9 [9060821.001]
  • [Cites] Am J Gastroenterol. 1997 Feb;92(2):204-11 [9040192.001]
  • [Cites] Science. 1997 Feb 14;275(5302):967-9 [9020077.001]
  • [Cites] Cell. 1997 Feb 7;88(3):323-31 [9039259.001]
  • [Cites] Nat Genet. 1996 Nov;14(3):255-7 [8896552.001]
  • [Cites] Cell. 1996 Dec 13;87(6):1001-14 [8978605.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Oct 14;227(2):553-7 [8878551.001]
  • [Cites] Cell. 1996 Oct 18;87(2):175-85 [8861902.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Oncogene. 1996 Aug 15;13(4):787-95 [8761300.001]
  • [Cites] Nat Genet. 1996 Jul;13(3):343-6 [8673134.001]
  • [Cites] Am J Surg Pathol. 1994 Jun;18(6):559-68 [7513966.001]
  • [Cites] Nature. 1994 Jun 2;369(6479):411-4 [8196769.001]
  • [Cites] Science. 1994 Jun 3;264(5164):1463-7 [7811320.001]
  • [Cites] Cancer Lett. 1995 Jun 29;93(1):55-71 [7600544.001]
  • [Cites] Cell. 1995 Jan 27;80(2):293-9 [7834749.001]
  • [Cites] Science. 1995 Jun 2;268(5215):1336-8 [7761852.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5527-30 [7923190.001]
  • [Cites] Cell. 1994 Aug 12;78(3):409-24 [8062384.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8683-6 [8378348.001]
  • [Cites] Carcinogenesis. 2006 Jan;27(1):162-9 [16081511.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):25-34 [16049979.001]
  • [Cites] Oncogene. 1999 Apr 29;18(17):2747-54 [10348349.001]
  • [Cites] Oncogene. 1999 Apr 22;18(16):2599-606 [10353603.001]
  • [Cites] Hematol Oncol Clin North Am. 1998 Oct;12(5):963-73 [9888016.001]
  • [Cites] Biochemistry (Mosc). 1998 Jul;63(7):854-65 [9721338.001]
  • [Cites] Nature. 1998 Oct 22;395(6704):801-4 [9796814.001]
  • [Cites] N Engl J Med. 1998 Oct 29;339(18):1277-84 [9791143.001]
  • [Cites] Gastroenterology. 1997 Oct;113(4):1146-58 [9322509.001]
  • [Cites] J Pathol. 1998 Jul;185(3):246-55 [9771477.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 1998 Jun 29;353(1370):821-30 [9684279.001]
  • [Cites] Asian Pac J Cancer Prev. 2006 Jul-Sep;7(3):495-501 [17059355.001]
  • [Cites] Cancer Lett. 2006 Jul 8;238(1):69-75 [16046055.001]
  • [Cites] Surg Endosc. 2006 Feb;20(2):270-3 [16341566.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):714-9 [16407113.001]
  • [Cites] Curr Biol. 2002 Feb 19;12(4):253-65 [11864565.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8664-7 [11751382.001]
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8408-11 [11731419.001]
  • [Cites] Mol Cell. 2001 Mar;7(3):683-94 [11463392.001]
  • [Cites] Mol Cell. 2001 Mar;7(3):673-82 [11463391.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1523-32 [11410486.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1874-8 [11280741.001]
  • [Cites] Curr Gastroenterol Rep. 2005 Oct;7(5):389-95 [16168238.001]
  • [Cites] Chem Biol Interact. 2005 Jun 30;155(1-2):1-9 [15904905.001]
  • [Cites] Cancer Res. 1976 May;36(5):1585-92 [178424.001]
  • [Cites] Cancer Res. 1975 Nov;35(11 Pt 1):2962-8 [1182690.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] Histol Histopathol. 2005 Apr;20(2):483-92 [15736053.001]
  • [Cites] J Pathol. 2005 Jan;205(2):130-44 [15641015.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):229-38 [15459021.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):4997-5002 [9560217.001]
  • [Cites] Nat Genet. 1999 Oct;23(2):176-84 [10508513.001]
  • [Cites] Br J Cancer. 1975 Jul;32(1):60-77 [1174451.001]
  • [Cites] Cancer. 1975 Feb;35(2):413-8 [1111917.001]
  • [Cites] Cancer Sci. 2004 Sep;95(9):721-7 [15471557.001]
  • [Cites] Mutat Res. 2004 Nov 2;555(1-2):107-19 [15476855.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(17):7598-611 [15314168.001]
  • [Cites] J Mol Med (Berl). 2004 Jul;82(7):434-48 [15175863.001]
  • [Cites] Environ Mol Mutagen. 2004;44(1):26-35 [15199544.001]
  • [Cites] Cancer Sci. 2004 Jun;95(6):475-80 [15182426.001]
  • [Cites] Int J Colorectal Dis. 2004 Jul;19(4):308-15 [14605835.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Feb;4(1):29-42 [14965265.001]
  • [Cites] Cancer Sci. 2003 Nov;94(11):965-73 [14611673.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3819-25 [12839979.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2388-92 [12750256.001]
  • [Cites] Mod Pathol. 2003 Apr;16(4):347-58 [12692200.001]
  • [Cites] Carcinogenesis. 2003 Mar;24(3):353-62 [12663492.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):762-77 [12612914.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] Scand J Gastroenterol Suppl. 2002;(236):48-53 [12408504.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):1051-60 [12213734.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Oct;17(10):1078-83 [12201867.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:101-28 [12142355.001]
  • [Cites] Nutr Cancer. 2008;60 Suppl 1:70-80 [19003583.001]
  • [Cites] Nutr Cancer. 2008;60(5):675-84 [18791932.001]
  • [Cites] Carcinogenesis. 2008 May;29(5):1057-63 [18375960.001]
  • [Cites] Eur J Cancer. 2008 Jul;44(10):1345-89 [18280139.001]
  • [Cites] J Cell Mol Med. 2008 Jan-Feb;12(1):67-96 [18053092.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Future Oncol. 2008 Feb;4(1):93-102 [18241004.001]
  • [Cites] World J Gastroenterol. 2008 Jan 21;14(3):378-89 [18200660.001]
  • [Cites] Acta Pharmacol Sin. 2008 Jan;29(1):1-20 [18158862.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9568-76 [17909068.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1659-64 [17557291.001]
  • [Cites] Cancer Biomark. 2007;3(3):135-40 [17611304.001]
  • [Cites] BMC Cancer. 2007;7:84 [17506908.001]
  • [Cites] Subcell Biochem. 2007;42:213-25 [17612053.001]
  • [Cites] Adv Exp Med Biol. 2007;595:213-26 [17569213.001]
  • [Cites] Cancer Cell Int. 2007;7:2 [17362521.001]
  • [Cites] Environ Health Perspect. 2007 Jan;115(1):165-71 [17366838.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]
  • [Cites] Nature. 2002 May 23;417(6887):443-7 [11986622.001]
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):55-67 [11900252.001]
  • (PMID = 19332896.001).
  • [ISSN] 1477-3163
  • [Journal-full-title] Journal of carcinogenesis
  • [ISO-abbreviation] J Carcinog
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2678864
  •  go-up   go-down


37. Gordon PV, Paxton JB, Fox NS: A methodology for distinguishing divergent cell fates within a common progenitor population: adenoma- and neuroendocrine-like cells are confounders of rat ileal epithelial cell (IEC-18) culture. BMC Cell Biol; 2005;6(1):2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A methodology for distinguishing divergent cell fates within a common progenitor population: adenoma- and neuroendocrine-like cells are confounders of rat ileal epithelial cell (IEC-18) culture.
  • BACKGROUND: IEC-18 cells are a non-transformed, immortal cell line derived from juvenile rat ileal crypt cells.
  • We then confirmed the cell-specific phenotype by immunolocalization of proteins corresponding to those genes.
  • The majority of IEC-18 cells in SFM alone had a loss in expression of the adenomatous polyposis coli (APC) gene at the mRNA and protein levels, consistent with adenoma-like transformation.
  • The most common fate switch that we were able to detect correlates with a down regulation of the APC gene and transformation into an adenoma-like phenotype.
  • [MeSH-minor] Adenoma / pathology. Animals. Carcinoma, Neuroendocrine / pathology. Gene Expression Profiling. Gene Expression Regulation. Genes, APC. Methods. Phenotype. Rats

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol. 1999 Nov;277(5 Pt 1):G1027-40 [10564109.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4368-74 [12907606.001]
  • [Cites] J Biol Chem. 2001 Aug 31;276(35):32419-22 [11445558.001]
  • [Cites] Brain Res Mol Brain Res. 2002 Jan 31;98(1-2):81-92 [11834298.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 May;282(5):G877-93 [11960784.001]
  • [Cites] Nat Genet. 2002 Dec;32 Suppl:469-73 [12454640.001]
  • [Cites] Nat Genet. 2002 Dec;32 Suppl:490-5 [12454643.001]
  • [Cites] Bioinformatics. 2004 Jan 1;20(1):105-14 [14693816.001]
  • [Cites] Neurosci Lett. 2004 Jan 23;355(1-2):89-92 [14729242.001]
  • [Cites] Am J Pathol. 2004 Apr;164(4):1369-77 [15039224.001]
  • [Cites] Dis Colon Rectum. 2004 Feb;47(2):219-26 [15043293.001]
  • [Cites] Arch Biochem Biophys. 2004 Sep 1;429(1):100-5 [15288813.001]
  • [Cites] Oncogene. 2004 Sep 16;23(42):7144-8 [15273719.001]
  • [Cites] Proc Natl Acad Sci U S A. 1978 Nov;75(11):5548-52 [103096.001]
  • [Cites] J Natl Cancer Inst. 1981 Dec;67(6):1353-62 [6273638.001]
  • [Cites] FEBS Lett. 1989 Sep 25;255(2):423-6 [2792386.001]
  • [Cites] J Lab Clin Med. 1992 Aug;120(2):329-41 [1500831.001]
  • [Cites] J Clin Invest. 1995 Oct;96(4):1759-67 [7560067.001]
  • [Cites] Genomics. 1998 Jul 1;51(1):27-34 [9693030.001]
  • [Cites] Aliment Pharmacol Ther. 1999 May;13 Suppl 2:15-30 [10429737.001]
  • [Cites] J Gastroenterol. 2000;35(8):575-82 [10955595.001]
  • (PMID = 15656904.001).
  • [ISSN] 1471-2121
  • [Journal-full-title] BMC cell biology
  • [ISO-abbreviation] BMC Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC547914
  •  go-up   go-down


38. Meza R, Jeon J, Renehan AG, Luebeck EG: Colorectal cancer incidence trends in the United States and United kingdom: evidence of right- to left-sided biological gradients with implications for screening. Cancer Res; 2010 Jul 1;70(13):5419-29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using the Surveillance Epidemiology and End Results (SEER) and the Office for National Statistics (ONS) registries (both 1973-2006), we derived stochastic multistage clonal expansion (MSCE) models for right-sided (proximal colon) and left-sided (distal colon and rectal) tumors.
  • The MSCE concept is based on the initiation-promotion-progression paradigm of carcinogenesis and provides a quantitative description of natural tumor development from the initiation of an adenoma (via biallelic tumor suppressor gene inactivation) to the clinical detection of CRC.
  • From 1,228,036 (SEER: 340,582; ONS: 887,454) cases, parameter estimates for models adjusted for calendar-year and birth-cohort effects showed that adenoma initiation rates were higher for right-sided tumors, whereas, paradoxically, adenoma growth rates were higher for left-sided tumors.
  • The net effect was a higher cancer risk in the right colon only after age 70 years.
  • Consistent with this finding, simulations of adenoma development predicted that the relative prevalence for right- versus left-sided tumors increases with increasing age, a differential effect most striking in women.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • [Cites] Gastroenterology. 2000 May;118(5):829-34 [10784581.001]
  • [Cites] N Engl J Med. 2006 Nov 2;355(18):1863-72 [17079760.001]
  • [Cites] J Theor Biol. 2000 Nov 21;207(2):129-43 [11034825.001]
  • [Cites] N Engl J Med. 2002 Jun 6;346(23):1781-5 [12050337.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):403-8 [12216066.001]
  • [Cites] World J Gastroenterol. 2002 Oct;8(5):847-52 [12378628.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15095-100 [12415112.001]
  • [Cites] Am J Gastroenterol. 2003 Jun;98(6):1400-9 [12818288.001]
  • [Cites] N Engl J Med. 2004 Mar 4;350(10):991-1004 [14999111.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jan;2(1):72-7 [15017635.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1215-22 [15247133.001]
  • [Cites] Nature. 1987 Aug 13-19;328(6131):614-6 [3039373.001]
  • [Cites] Am J Gastroenterol. 1990 Aug;85(8):969-74 [2375325.001]
  • [Cites] Cancer. 1991 Jul 1;68(1):84-7 [2049758.001]
  • [Cites] Am J Gastroenterol. 1991 Aug;86(8):941-5 [1858757.001]
  • [Cites] Am J Gastroenterol. 1991 Aug;86(8):946-51 [1858758.001]
  • [Cites] Science. 1991 Aug 9;253(5020):661-5 [1651562.001]
  • [Cites] Int J Cancer. 2007 Feb 1;120(3):664-71 [17096321.001]
  • [Cites] JAMA. 2006 Dec 20;296(23):2815-22 [17179458.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Histopathology. 2007 Jan;50(1):113-30 [17204026.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):96-102 [17241863.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 18;105(11):4283-8 [18337506.001]
  • [Cites] Math Biosci. 2008 May;213(1):56-70 [18374369.001]
  • [Cites] J Clin Oncol. 2008 Jun 10;26(17):2828-38 [18539961.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1360-7 [18539928.001]
  • [Cites] Br J Cancer. 2008 Aug 5;99(3):532-5 [18628760.001]
  • [Cites] JAMA. 2008 Sep 24;300(12):1417-22 [18812532.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16284-9 [18936480.001]
  • [Cites] JAMA. 2008 Dec 17;300(23):2765-78 [19088354.001]
  • [Cites] Ann Intern Med. 2009 Jan 6;150(1):1-8 [19075198.001]
  • [Cites] Ann Intern Med. 2009 Jan 6;150(1):50-2 [19075200.001]
  • [Cites] Nature. 2009 Jan 29;457(7229):608-11 [19092804.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4828-33 [19261858.001]
  • [Cites] Cancer. 2009 Jun 1;115(11):2410-9 [19288570.001]
  • [Cites] Colorectal Dis. 2009 Jul;11(6):547-63 [19207714.001]
  • [Cites] Eur J Cancer. 2009 Jul;45(11):2027-33 [19289271.001]
  • [Cites] Clin Gastroenterol Hepatol. 2009 Jul;7(7):770-5; quiz 711 [19268269.001]
  • [Cites] Colorectal Dis. 2009 Sep;11(7):689-701 [19207713.001]
  • [Cites] Gut. 1992 Jan;33(1):71-8 [1740282.001]
  • [Cites] Surg Radiol Anat. 1992;14(3):251-7 [1440190.001]
  • [Cites] N Engl J Med. 1993 May 13;328(19):1365-71 [8474513.001]
  • [Cites] Am J Gastroenterol. 1993 Jun;88(6):825-31 [8503374.001]
  • [Cites] Arch Intern Med. 1995 Sep 11;155(16):1741-8 [7654107.001]
  • [Cites] Math Biosci. 2005 Oct;197(2):188-210 [16087198.001]
  • [Cites] Cancer. 2006 Sep 1;107(5 Suppl):1142-52 [16835912.001]
  • [Cites] Gastrointest Endosc. 2000 Jul;52(1):1-8 [10882954.001]
  • (PMID = 20530677.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA107028-04; United States / NCI NIH HHS / CA / R01 CA107028; United States / NCI NIH HHS / CA / R01 CA107028-04; United States / NCI NIH HHS / CA / R01 CA107028-05A1; United States / NCI NIH HHS / CA / CA107028-05A1; United States / NCI NIH HHS / CA / R01 CA119224
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS205243; NLM/ PMC2914859
  •  go-up   go-down


39. Landau D, Garrett C, Chodkiewicz C: A case of primary squamous cell colon cancer. J Oncol Pharm Pract; 2007 Mar;13(1):47-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary squamous cell colon cancer.
  • Carcinomas of the colon are a common cancer seen in both inpatient and outpatient settings with approximately 145,000 new cases being diagnosed every year in the USA.
  • Despite the frequency of these cancers being seen, it continues to be a rarity to see a primary squamous cell cancer of the colon.
  • While the exact aetiology of this rare tumour is currently still not completely understood, various aetiologies include chronic irritation leading to squamous differentiation, embryonic migration of ectodermal cells to the colon, or adenomas undergoing squamous transformation.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Colonic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17621567.001).
  • [ISSN] 1078-1552
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


40. Ono S, Fujishiro M, Goto O, Kodashima S, Omata M: Submerging endoscopic submucosal dissection leads to successful en bloc resection of colonic laterally spreading tumor with submucosal fat. Gut Liver; 2008 Dec;2(3):209-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Submerging endoscopic submucosal dissection leads to successful en bloc resection of colonic laterally spreading tumor with submucosal fat.
  • A 72-year-old female with a colonic laterally spreading tumor (LST) was referred to our department.
  • A total colonoscopy revealed a large nongranular LST, 30 mm in diameter, in the ascending colon.
  • The lesion was successfully resected en bloc without complications.
  • The pathological examination indicated the curative resection of a tubulovillous adenoma.
  • We propose that a submerged ESD could also be an effective procedure for colonic neoplasms with submucosal fat by avoiding blurring of the endoscopic view.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Gastroenterol Hepatol. 2007 Jun;5(6):678-83; quiz 645 [17466600.001]
  • [Cites] AJR Am J Roentgenol. 2003 Sep;181(3):781-4 [12933481.001]
  • [Cites] Endoscopy. 1998 May;30(4):351-5 [9689507.001]
  • [Cites] Gastrointest Endosc. 2006 Jan;63(1):178-83 [16377346.001]
  • (PMID = 20485649.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2871645
  • [Keywords] NOTNLM ; Adipose tissue / Colonic neoplasms / Colonoscopy / Resection / Submucosa
  •  go-up   go-down


41. Hoffman A, Kagel C, Goetz M, Tresch A, Mudter J, Biesterfeld S, Galle PR, Neurath MF, Kiesslich R: Recognition and characterization of small colonic neoplasia with high-definition colonoscopy using i-Scan is as precise as chromoendoscopy. Dig Liver Dis; 2010 Jan;42(1):45-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recognition and characterization of small colonic neoplasia with high-definition colonoscopy using i-Scan is as precise as chromoendoscopy.
  • METHODS: The last 30 cm of the colon in a screening population were inspected with HD+ alone, in combination with i-Scan (2:1 randomisation) and subsequently with chromoendoscopy.
  • [MeSH-major] Adenoma / pathology. Colonic Polyps / pathology. Colonoscopy / methods. Colorectal Neoplasms / pathology. Image Interpretation, Computer-Assisted / methods

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. METHYLENE BLUE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
  • [CommentIn] Dig Liver Dis. 2010 Jan;42(1):18-9 [19955024.001]
  • (PMID = 19473893.001).
  • [ISSN] 1878-3562
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] T42P99266K / Methylene Blue
  •  go-up   go-down


42. Carneiro FP, Ramalho LN, Britto-Garcia S, Ribeiro-Silva A, Zucoloto S: Immunohistochemical expression of p16, p53, and p63 in colorectal adenomas and adenocarcinomas. Dis Colon Rectum; 2006 May;49(5):588-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of p16, p53, and p63 in colorectal adenomas and adenocarcinomas.
  • PURPOSE: The aim of this study was to investigate the immunohistochemical expression of p16, p53, and p63 proteins according to some pathologic parameters related to colorectal adenomas and adenocarcinomas such as grade of dysplasia and histologic type.
  • METHODS: Immunohistochemistry with the antibodies p16, p53, and p63 was performed in tubular, tubular-villous, and villous adenomas (n = 30) and in well, moderately, and poorly differentiated adenocarcinomas (n = 30).
  • RESULTS: The p16 and p53 labelings were observed in some adenomas and adenocarcinomas but without any association with p63 expression, histologic type, or grade of differentiation of the neoplasm.
  • P63 expression was found mainly in the villous adenomas and in the poorly differentiated adenocarcinomas.
  • However, p63 expression was closely associated with villous adenomas and poorly differentiated adenocarcinomas.
  • [MeSH-minor] Adenocarcinoma. Adenoma. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. DNA-Binding Proteins. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Keratins / metabolism. Transcription Factors. Tumor Suppressor Proteins

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575619.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


43. Petersen M, Evert M, Schneider-Stock R, Pross M, Rüschoff J, Roessner A, Lippert H, Meyer F: Serous oligocystic adenoma (SOIA) of the pancreas--first reported case of a genetically fixed association in a patient with hereditary non-polyposis colorectal cancer (HNPCC). Pathol Res Pract; 2009;205(11):801-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous oligocystic adenoma (SOIA) of the pancreas--first reported case of a genetically fixed association in a patient with hereditary non-polyposis colorectal cancer (HNPCC).
  • One of these classified cystic neoplasms of the pancreas is serous oligocystic adenoma (SOIA), a rare and benign tumor lesion.
  • He had a medical history significant for subtotal colectomy because of a synchronous double colonic carcinoma.
  • Both tumor tissue specimens had been characterized for a high level of microsatellite instability (MSI) and loss of hMLH1, as well as for a corresponding germ line mutation in hMLH1 gene, leading to the diagnosis of hereditary non-polyposis associated colon cancer (HNPCC).


44. Sacher-Huvelin S, Coron E, Gaudric M, Planche L, Benamouzig R, Maunoury V, Filoche B, Frédéric M, Saurin JC, Subtil C, Lecleire S, Cellier C, Coumaros D, Heresbach D, Galmiche JP: Colon capsule endoscopy vs. colonoscopy in patients at average or increased risk of colorectal cancer. Aliment Pharmacol Ther; 2010 Nov;32(9):1145-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon capsule endoscopy vs. colonoscopy in patients at average or increased risk of colorectal cancer.
  • BACKGROUND: Colon capsule endoscopy (CCE) is a new, non-invasive technology.
  • Colon cleanliness was excellent or good in 52% of cases at CCE.
  • CCE accuracy for the detection of polyps ≥ 6 mm was 39% (95% CI 30-48) for sensitivity, 88% (95% CI 85-91) for specificity, 47% (95% CI 37-57) for positive predictive value and 85% (95% CI 82-88) for negative predictive value.
  • CCE accuracy was better for the detection of advanced adenoma, in patients with good or excellent cleanliness and after re-interpretation of the CCE videos by an independent expert panel.
  • Further studies should pay attention to colonic preparation (Clinicaltrial.gov number NCT00436514).

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 21039676.001).
  • [ISSN] 1365-2036
  • [Journal-full-title] Alimentary pharmacology & therapeutics
  • [ISO-abbreviation] Aliment. Pharmacol. Ther.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00436514
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


45. Bouzourene H, Sandmeier D: [Sessile serrated adenoma: an underdiagnosed colonic polyp]. Rev Med Suisse; 2007 Jul 4;3(118):1702-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sessile serrated adenoma: an underdiagnosed colonic polyp].
  • [Transliterated title] L'adénome dentelé sessile, un polype colique à ne pas méconnaître.
  • Serrated polyps of the colon represent a large morphological spectrum of lesions.
  • They comprise the hyperplastic polyp considered as an innocuous lesion for many years, the traditional serrated adenoma presenting a potential of cancerisation and the recently described the sessile serrated adenoma which seems to be a potential precursor of colonic cancer with microsatellite instability and which probably uses an alternate polyp-neoplasia pathway in addition to the classical adenoma-carcinoma sequence.
  • The aims of this article intend to inform of new concept of colonic carcinogenesis, to be aware of a serrated colonic polyp entity recently described and to use a same nomenclature to facilitate the dialogue between pathologists and clinicians.
  • [MeSH-major] Adenoma / pathology. Colonic Neoplasms / pathology. Colonic Polyps / pathology

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17726906.001).
  • [ISSN] 1660-9379
  • [Journal-full-title] Revue médicale suisse
  • [ISO-abbreviation] Rev Med Suisse
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 10
  •  go-up   go-down


46. Lee EJ, Choi C, Park CK, Maeng L, Lee J, Lee A, Kim KM: Tracing origin of serrated adenomas with BRAF and KRAS mutations. Virchows Arch; 2005 Sep;447(3):597-602
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tracing origin of serrated adenomas with BRAF and KRAS mutations.
  • To characterize serrated neoplasia pathway, we investigated BRAF and KRAS mutations in 35 traditional serrated adenomas.
  • BRAF V599E mutation was found in 27 serrated adenomas (77.1%), and KRAS mutations were found in 3 (8.6%) of 35 traditional serrated adenomas.
  • In 13 cases, mixed polyps composed of traditional serrated adenomas and hyperplastic (serrated) polyps were observed, and seven of them showed the same BRAF mutations in both components.
  • These findings suggest that BRAF mutations are early and a critical event in the serrated adenomas, and most serrated adenomas in both sides of colon may progress from microvesicular hyperplastic polyps via BRAF mutations, and some left-sided serrated adenomas develop via KRAS mutations.
  • [MeSH-major] Adenoma / genetics. Colorectal Neoplasms / genetics. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins B-raf / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):327-32 [12626907.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1452-9 [15489648.001]
  • [Cites] J Pathol. 2001 Mar;193(3):283-5 [11241405.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):65-81 [12502929.001]
  • [Cites] Mod Pathol. 2003 May;16(5):417-23 [12748247.001]
  • [Cites] Oncogene. 2003 Sep 25;22(41):6455-7 [14508525.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):170-8 [15389252.001]
  • [Cites] J Pathol. 1999 Apr;187(5):499-502 [10398112.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4878-81 [12941809.001]
  • [Cites] Int J Cancer. 2004 Jan 10;108(2):237-42 [14639609.001]
  • [Cites] Oncogene. 2004 Jan 15;23 (2):554-8 [14724583.001]
  • [Cites] J Pathol. 2004 Mar;202(3):336-40 [14991899.001]
  • [Cites] Gut. 1997 May;40(5):660-3 [9203947.001]
  • [Cites] Gut. 2004 Aug;53(8):1137-44 [15247181.001]
  • [Cites] Oncogene. 2003 Dec 11;22(57):9192-6 [14668801.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):423-34 [15087661.001]
  • [Cites] Pathology. 2002 Dec;34(6):493 [12555986.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):323-32 [10930367.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17 ):5209-12 [14500346.001]
  • [Cites] Pathology. 2002 Dec;34(6):548-55 [12555993.001]
  • [Cites] J Pathol. 2004 Jun;203(2):617-9 [15141374.001]
  • [Cites] Gut. 1998 May;42(5):680-4 [9659164.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6451-5 [12438234.001]
  • [Cites] Histopathology. 2000 Oct;37(4):295-301 [11012735.001]
  • [Cites] J Clin Pathol. 1999 Jan;52(1):5-9 [10343605.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):484-6 [12644542.001]
  • (PMID = 15991007.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


47. Hai S, Yamamoto S, Tanaka H, Takemura S, Ichikawa T, Kodai S, Shinkawa H, Yamamoto T, Kubo S: Adenomyoma of the common hepatic duct mimicking bile duct cancer: report of a case. Surg Today; 2007;37(7):608-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenoma / diagnosis. Bile Duct Neoplasms / diagnosis. Cholangiocarcinoma / diagnosis. Hepatic Duct, Common

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 1978 May-Jun;21(4):255-60 [657934.001]
  • [Cites] Hepatology. 1990 Oct;12(4 Pt 1):747-52 [2210678.001]
  • [Cites] Arch Surg. 1990 Apr;125(4):543 [2322122.001]
  • [Cites] Arch Pathol (Chic). 1950 Jul;50(1):84-97 [15426507.001]
  • [Cites] Can Assoc Radiol J. 1997 Apr;48(2):101-4 [9146466.001]
  • [Cites] Ann Surg. 1996 Jan;223(1):26-36 [8554415.001]
  • [Cites] Arch Surg. 1962 Sep;85:503-13 [13887615.001]
  • [Cites] J Gastroenterol. 1995 Aug;30(4):547-50 [7550871.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1627-30 [10430308.001]
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):636-8 [10919002.001]
  • [Cites] Dig Dis Sci. 1998 Jun;43(6):1200-4 [9635608.001]
  • [Cites] Hepatogastroenterology. 2000 Jan-Feb;47(31):132-4 [10690595.001]
  • [Cites] Br J Surg. 2001 Jan;88(1):48-51 [11136309.001]
  • [Cites] Am J Gastroenterol. 1988 Apr;83(4):432-4 [3348195.001]
  • [Cites] Radiology. 2005 Jul;236(1):178-83 [15955859.001]
  • [Cites] J Am Coll Surg. 2005 Dec;201(6):862-9 [16310689.001]
  • [Cites] Am Surg. 1971 Mar;37(3):161-6 [5548431.001]
  • (PMID = 17593484.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


48. Celestino C, Harz C, Decaestecker J, Sáenz R: Endoscopic treatment of an iatrogenic perforation of the colon by using endoloop. Gastrointest Endosc; 2006 Oct;64(4):653-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic treatment of an iatrogenic perforation of the colon by using endoloop.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Carcinoma in Situ / surgery. Colonic Neoplasms / surgery. Colonoscopes. Iatrogenic Disease. Intestinal Perforation / surgery. Postoperative Complications / surgery. Suture Techniques / instrumentation

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16996368.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Terhaar sive Droste JS, van Wanrooij RL, Morsink LM, van der Hulst RW, Craanen ME, Bartelsman JW, Meijer GA, Mulder CJ: [Diagnosis of colorectal tumours in daily clinical practice: comparison of colonoscopy and sigmoidoscopy]. Ned Tijdschr Geneeskd; 2009;153:A731
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Diagnostiek van colorectale tumoren in de dagelijkse praktijk. Vergelijking van coloscopie en sigmoïdoscopie.
  • The locations and the histological features of all colonic neoplasia and the indications for endoscopy were recorded.
  • Advanced neoplasm was defined as adenoma >or=10 mm in size, an adenoma with any villous features, or high-grade dysplasia or adenocarcinoma.
  • Of the advanced neoplasia found on colonoscopy, 67% were located in the distal colon and 33% in the proximal colon.
  • Of the patients with advanced neoplasia in the proximal colon (n = 228), 51% had no abnormalities in the distal colon.
  • The percentage of advanced neoplasia in the proximal colon varied from 23% in patients younger than 50 years to 41% in patients aged 80 years and older.
  • Depending on the indication for endoscopy, the prevalence of advanced neoplasia in the proximal colon varied from 11-57%.
  • CONCLUSION: Of the advanced colorectal neoplasms 33% were located in the proximal colon.
  • With increasing age, a shift in tumour localization occurs from distal to proximal in the colon.

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20003556.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Netherlands
  •  go-up   go-down


50. Galamb O: [mRNA expression analysis and classification of colonic biopsy samples using oligonucleotide and cDNA microarray techniques]. Orv Hetil; 2008 Jul 20;149(29):1373-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [mRNA expression analysis and classification of colonic biopsy samples using oligonucleotide and cDNA microarray techniques].
  • We have shown that the sequential overexpression of osteopontin and osteonectin mRNAs and proteins significantly correlates with the progression of the colorectal adenoma-dysplasia-carcinoma sequence.
  • We have identified and validated ten novel markers with continuously increasing mRNA expression in line with the adenoma-dysplasia-carcinoma transition.
  • We have identified the top 27, 13 and 10 genes associated with adenoma, colorectal cancer, and inflammatory bowel diseases.
  • [MeSH-major] Biopsy. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Colon / metabolism. Oligonucleotide Array Sequence Analysis. Osteonectin / metabolism. Osteopontin / metabolism. RNA, Messenger / metabolism
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Carcinoma / genetics. Carcinoma / metabolism. Colorectal Neoplasms / genetics. Colorectal Neoplasms / metabolism. Gene Expression. Humans. Inflammatory Bowel Diseases / genetics. Inflammatory Bowel Diseases / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sequence Analysis, DNA. Up-Regulation

  • MedlinePlus Health Information. consumer health - Biopsy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18617470.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Osteonectin; 0 / RNA, Messenger; 106441-73-0 / Osteopontin
  •  go-up   go-down


51. Robertson DJ, Sandler RS, Haile R, Tosteson TD, Greenberg ER, Grau M, Baron JA: Fat, fiber, meat and the risk of colorectal adenomas. Am J Gastroenterol; 2005 Dec;100(12):2789-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fat, fiber, meat and the risk of colorectal adenomas.
  • OBJECTIVE: The aim of this study was to determine the relationship between fat, fiber, and meat intake, and risk of colorectal adenoma recurrence.
  • METHODS: We determined adenoma recurrence and dietary intake for 1,520 participants in two randomized trials: The Antioxidant Polyp Prevention Study and Calcium Polyp Prevention Study.
  • Subjects underwent baseline colonoscopy with removal of all adenomas, and dietary intake was estimated with a validated semiquantitative food frequency questionnaire.
  • Pooled risk ratios for adenoma recurrence were obtained by generalized linear regression, with adjustment for age, sex, clinical center, treatment category, study, and duration of observation.
  • RESULTS: In the total colorectum, fiber intake was weakly and nonsignificantly associated with a risk for all adenomas (RR quartile 4 vs quartile 1=0.85, 95% CI 0.69-1.05) and advanced adenomas (RR=0.88, 95% CI 0.54-1.44).
  • Associations were stronger for adenomas in the proximal colon (RR=0.73, 95% CI 0.56-0.97) and some fiber subtypes (fruit and vegetable, grain).
  • There was no association between fat or total red meat intake and risk of adenoma or advanced adenoma recurrence.
  • However, when considering other meats, risk (quartile 4 vs quartile 1) for advanced adenoma was increased for processed meat (RR=1.75, 95% CI 1.02-2.99) and decreased for chicken (RR=0.61, 95% CI 0.38-0.98).
  • CONCLUSION: The inverse associations between fiber intake and risk of adenoma recurrence we observed are weak, and not statistically significant.
  • Our data indicate that intake of specific meats may have different effects on risk.
  • [MeSH-major] Adenoma / therapy. Colorectal Neoplasms / therapy. Diet. Dietary Fats / adverse effects. Dietary Fiber / administration & dosage. Neoplasm Recurrence, Local / prevention & control

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • MedlinePlus Health Information. consumer health - Dietary Fiber.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16393237.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA23108; United States / NCI NIH HHS / CA / CA46927
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats
  •  go-up   go-down


52. Ravizza D, Fiori G, Trovato C, Maisonneuve P, Bocciolone L, Crosta C: Is colonoscopy a suitable investigation in the preoperative staging of ovarian cancer patients? Dig Liver Dis; 2005 Jan;37(1):57-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: The aim of this study was to evaluate the utility of preoperative colonoscopy in ovarian cancer patients and the prevalence of adenomas in this population.
  • All the polyps observed were removed.
  • Thirty-six adenomas were removed in 26 (20%) women.
  • An increased prevalence of adenomas was not observed in this population.
  • [MeSH-major] Colonic Neoplasms / secondary. Colonoscopy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenoma / pathology. Adenoma / surgery. Adult. Aged. Aged, 80 and over. Colon / pathology. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15702861.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


53. García Sánchez Mdel V, González R, Iglesias Flores E, Gómez Camacho F, Casais Juanena L, Cerezo Ruiz A, Montero Pérez-Barquero M, Muntané J, de Dios Vega JF: [Diagnostic value of fecal calprotectin in predicting an abnormal colonoscopy]. Med Clin (Barc); 2006 Jun 10;127(2):41-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Precisión diagnóstica de la calprotectina fecal para predecir una colonoscopia patológica.
  • The colonoscopy is the gold standard method of detecting an organic pathology in the colon.
  • Fecal calprotectin (FCP) is a marker that may detect organic pathologies of the colon.
  • People were divided in: normal colonoscopy: 117 people, and 28 colon adenomas, 20 colorectal cancer (CRC) and 25 IBD.
  • 217 mg/kg was the best cut-off for discriminating patients with organic colon disorders.
  • The measurement of FCP is a non-invasive, inexpensive, reliable and easily measured test.
  • [MeSH-major] Colonic Diseases / diagnosis. Colonic Neoplasms / diagnosis. Colonoscopy. Feces / chemistry. Inflammatory Bowel Diseases / diagnosis. Leukocyte L1 Antigen Complex / analysis

  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16801001.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Leukocyte L1 Antigen Complex
  •  go-up   go-down


54. Galamb O, Spisák S, Sipos F, Tóth K, Solymosi N, Wichmann B, Krenács T, Valcz G, Tulassay Z, Molnár B: Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor. Br J Cancer; 2010 Feb 16;102(4):765-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor.
  • BACKGROUND AND AIMS: Treatment of colorectal adenomas with selective cyclooxygenase-2 inhibitors can contribute to the chemoprevention of colorectal cancer (CRC), but the molecular background of their effect is not fully understood.
  • METHODS: HT29 colon adenocarcinoma cells were treated with NS398, and global mRNA expression was analysed on HGU133Plus2.0 microarrays.
  • Discriminatory transcripts between normal and adenoma and between adenoma and CRC biopsy samples were identified using HGU133Plus2.0 microarrays.
  • RESULTS: Between normal and adenoma samples, 20 classifiers were identified, including overexpressed cadherin 3, KIAA1199, and downregulated peptide YY, glucagon, claudin 8.
  • CONCLUSION: NS398 has a reversal effect on the expression of several genes that altered in colorectal adenoma-carcinoma sequence.
  • NS398 more efficiently inverted the expression changes seen in the normal-adenoma than in the normal-carcinoma transition.
  • [MeSH-major] Adenoma / genetics. Colon / metabolism. Colorectal Neoplasms / genetics. Cyclooxygenase 2 Inhibitors / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. Nitrobenzenes / pharmacology. Sulfonamides / pharmacology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4756-60 [14581346.001]
  • [Cites] Br J Surg. 2002 Jul;89(7):845-60 [12081733.001]
  • [Cites] Nat Rev Genet. 2004 Mar;5(3):229-37 [14970825.001]
  • [Cites] J Am Coll Surg. 2004 Sep;199(3):428-35 [15325613.001]
  • [Cites] Oncogene. 2004 Sep 23;23(44):7366-77 [15326482.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1183-8 [7926468.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8465-71 [15623626.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2840-55 [15837998.001]
  • [Cites] J Biomed Sci. 2005;12(1):229-41 [15864753.001]
  • [Cites] Mol Pharmacol. 2005 Aug;68(2):317-29 [15883203.001]
  • [Cites] Diabetologia. 2006 Mar;49(3):562-70 [16447059.001]
  • [Cites] J Natl Cancer Inst. 2006 Jun 7;98(11):736-47 [16757698.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(5):1797-815 [10669755.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] Mol Pharmacol. 2000 Dec;58(6):1398-403 [11093779.001]
  • [Cites] Gut. 2001 May;48(5):660-6 [11302965.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):1010-6 [11309352.001]
  • [Cites] Oncogene. 2001 Jul 27;20(33):4450-6 [11494140.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2001 Oct;15(5):821-33 [11566043.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] J Cardiovasc Pharmacol. 2006;47 Suppl 1:S76-81 [16785835.001]
  • [Cites] Cancer Lett. 2006 Aug 8;239(2):263-70 [16243430.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):873-84 [16943400.001]
  • [Cites] N Engl J Med. 2006 Aug 31;355(9):885-95 [16943401.001]
  • [Cites] Lab Invest. 2006 Nov;86(11):1149-60 [16983329.001]
  • [Cites] Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):147-54 [17164142.001]
  • [Cites] Gastroenterology. 2006 Dec;131(6):1674-82 [17087947.001]
  • [Cites] Dig Dis Sci. 2007 Jul;52(7):1713-21 [17393325.001]
  • [Cites] Cell Prolif. 2007 Oct;40(5):768-79 [17877615.001]
  • [Cites] Dis Colon Rectum. 2008 Mar;51(3):342-7 [18228100.001]
  • [Cites] Dis Markers. 2008;25(1):1-16 [18776587.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2835-45 [18843029.001]
  • [Cites] Cell Oncol. 2009;31(1):19-29 [19096147.001]
  • [Cites] Mol Cancer Ther. 2009 Jan;8(1):261-73 [19139136.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2009;28(1):39-46 [19392653.001]
  • [Cites] Biochem Pharmacol. 2009 Jun 15;77(12):1787-94 [19428334.001]
  • [Cites] Cancer Genomics Proteomics. 2009 Mar-Apr;6(2):93-9 [19451093.001]
  • [Cites] Gastroenterology. 2009 Oct;137(4):1358-66.e1-3 [19549529.001]
  • [Cites] Hepatology. 2002 May;35(5):1117-24 [11981761.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]
  • [Cites] Br J Cancer. 2004 Feb 9;90(3):712-9 [14760389.001]
  • (PMID = 20087348.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Nitrobenzenes; 0 / Sulfonamides; 123653-11-2 / N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
  • [Other-IDs] NLM/ PMC2837560
  •  go-up   go-down


55. Yuan B, Jin X, Zhu R, Zhang X, Liu J, Wan H, Lu H, Shen Y, Wang F: Cronkhite-Canada syndrome associated with rib fractures: a case report. BMC Gastroenterol; 2010;10:121
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Esophagogastroduodenoscopy, video capsule endoscopy and colonoscopy revealed various sizes of generalized gastrointestinal polyps.
  • Histological examination of the biopsy specimens obtained from the stomach and the colon showed adenomatous polyp and inflammatory polyp respectively.

  • MedlinePlus Health Information. consumer health - Chest Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Osteoporosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2001 Sep;54(3):388-91 [11522989.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Mar;16(3):333-42 [11876685.001]
  • [Cites] Expert Opin Pharmacother. 2003 Mar;4(3):385-9 [12614190.001]
  • [Cites] Am J Gastroenterol. 2003 Jun;98(6):1444-6 [12818298.001]
  • [Cites] Gastrointest Endosc. 2008 Mar;67(3):570-2 [18294523.001]
  • [Cites] Medicine (Baltimore). 1982 Sep;61(5):293-309 [7109958.001]
  • [Cites] Gastrointest Endosc. 1997 Dec;46(6):537-41 [9434222.001]
  • [Cites] N Engl J Med. 1955 Jun 16;252(24):1011-5 [14383952.001]
  • [Cites] Digestion. 2007;75(2-3):96-7 [17510553.001]
  • [Cites] Digestion. 2004;69(1):57-62 [14755154.001]
  • (PMID = 20955587.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2972238
  •  go-up   go-down


56. Guz J, Foksinski M, Siomek A, Gackowski D, Rozalski R, Dziaman T, Szpila A, Olinski R: The relationship between 8-oxo-7,8-dihydro-2'-deoxyguanosine level and extent of cytosine methylation in leukocytes DNA of healthy subjects and in patients with colon adenomas and carcinomas. Mutat Res; 2008 Apr 2;640(1-2):170-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship between 8-oxo-7,8-dihydro-2'-deoxyguanosine level and extent of cytosine methylation in leukocytes DNA of healthy subjects and in patients with colon adenomas and carcinomas.
  • Therefore, the aim of the present study was to assess a possible link between 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) background level and 5-methylcytosine content in DNA from human leukocytes of healthy subjects (n=105) as well as in patients with colon adenomas (n=39) and carcinomas (n=50).
  • The mean content of 5-methylcytosine was significantly lower, while 8-oxodG level was significantly higher in leukocytes DNA of patients with colon adenomas and carcinomas in comparison with healthy subjects.
  • The mean values for 5-methylcytosine were: 3.59+/-0.173% (healthy subjects), 3.38+/-0.128% (patients with adenomas), 3.40+/-0.208% (colon cancer patients).
  • DNA from affected tissue (colon) suffered from significant, about 10% reduction in cytosine methylation in comparison with leukocytes of the paired subjects.
  • [MeSH-major] 5-Methylcytosine / metabolism. Adenoma / metabolism. Carcinoma / metabolism. Colonic Neoplasms / metabolism. Deoxyguanosine / analogs & derivatives

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281064.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 6R795CQT4H / 5-Methylcytosine; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; 8J337D1HZY / Cytosine; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


57. Gunter MJ, Hayes RB, Chatterjee N, Yeager M, Welch R, Schoen RE, Yakochi L, Schatzkin A, Peters U: Insulin resistance-related genes and advanced left-sided colorectal adenoma. Cancer Epidemiol Biomarkers Prev; 2007 Apr;16(4):703-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin resistance-related genes and advanced left-sided colorectal adenoma.
  • METHODS: We investigated whether single nucleotide polymorphisms (SNP) in the INS, INSR, IRS1, and IRS2 genes are associated with risk of advanced left-sided colorectal adenoma, a cancer precursor.
  • We analyzed 20 SNPs in a largely Caucasian study population comprising 766 cases with advanced adenomas of the distal colon and 771 controls, all of whom had undergone flexible sigmoidoscopy as part of the screening arm of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
  • RESULTS: Overall, we found limited evidence for a role of gene variants of the insulin signaling pathway and prevalence of advanced colorectal adenoma.
  • We observed a statistically significant interaction between INSR genotypes and body mass index (BMI) with colorectal adenoma prevalence (P value for global test = 0.003) and suggestion of an interaction between INSR genotypes and glycemic load (P value for global test = 0.06); however, exploration of the interaction of BMI and glycemic load with the individual SNPs in INSR did not suggest a single SNP that may explain the significance of these global tests of interaction and did not yield any consistent patterns.
  • CONCLUSION: These findings do not provide strong evidence for associations between polymorphic variation in genes of the insulin signaling pathway and advanced left-sided colorectal adenoma.
  • Evidence for interaction between INSR variants and BMI and glycemic load for risk of advanced left-sided colorectal adenoma requires independent confirmation, and genotyping of INSR across a broader region and at greater density may be necessary to fully elucidate the nature of these interactions.
  • [MeSH-major] Adenomatous Polyps / genetics. Colorectal Neoplasms / genetics. Insulin Resistance / genetics. Receptor, Insulin / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17416760.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Insulin
  •  go-up   go-down


58. Fre S, Pallavi SK, Huyghe M, Laé M, Janssen KP, Robine S, Artavanis-Tsakonas S, Louvard D: Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the intestine. Proc Natl Acad Sci U S A; 2009 Apr 14;106(15):6309-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We also demonstrate a striking synergy between Notch and Wnt signals that results in inducing the formation of intestinal adenomas, particularly in the colon, a region rarely affected in available mouse tumor models, but the primary target organ in human patients.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • FlyBase. FlyBase .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2004 Jun 15;18(12):1385-90 [15198980.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):207 [14981522.001]
  • [Cites] Genesis. 2004 Jul;39(3):186-93 [15282745.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Cell. 1991 Aug 9;66(3):589-600 [1651174.001]
  • [Cites] Science. 1991 Aug 9;253(5020):665-9 [1651563.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Nature. 1993 Oct 7;365(6446):555-7 [8413612.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8969-73 [8090754.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6414-8 [7604005.001]
  • [Cites] Science. 1995 Nov 10;270(5238):983-5 [7481802.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10887-90 [8855277.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1784-7 [9065401.001]
  • [Cites] Cell. 1997 Mar 21;88(6):789-99 [9118222.001]
  • [Cites] Oncogene. 1997 Apr 24;14(16):1883-90 [9150355.001]
  • [Cites] Development. 1997 Jun;124(11):2255-66 [9187151.001]
  • [Cites] Mol Cell Biol. 1997 Nov;17(11):6265-73 [9343387.001]
  • [Cites] Development. 1998 Jun;125(11):2031-40 [9570768.001]
  • [Cites] Science. 1998 May 15;280(5366):1036-7 [9616081.001]
  • [Cites] Int J Dev Biol. 1998;42(3):325-33 [9654016.001]
  • [Cites] Nat Genet. 1998 Aug;19(4):379-83 [9697701.001]
  • [Cites] Development. 2005 Mar;132(6):1443-51 [15716339.001]
  • [Cites] Dev Cell. 2005 Apr;8(4):529-39 [15809035.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):959-63 [15959515.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):964-8 [15959516.001]
  • [Cites] Nat Rev Genet. 2006 May;7(5):349-59 [16619050.001]
  • [Cites] Curr Opin Cell Biol. 2007 Apr;19(2):166-75 [17317139.001]
  • [Cites] Cancer Sci. 2007 Jan;98(1):6-10 [17052257.001]
  • [Cites] J Gastroenterol. 2007 Sep;42(9):705-10 [17876539.001]
  • [Cites] Methods. 2001 May;24(1):71-80 [11327805.001]
  • [Cites] EMBO J. 2000 Jul 3;19(13):3337-48 [10880446.001]
  • [Cites] Nat Protoc. 2008;3(6):1101-8 [18546601.001]
  • [Cites] Virology. 2001 Jul 20;286(1):23-30 [11448155.001]
  • [Cites] N Engl J Med. 2003 Mar 6;348(10):919-32 [12621137.001]
  • [Cites] Genes Dev. 2003 Jul 15;17(14):1709-13 [12865297.001]
  • [Cites] Methods Enzymol. 2003;364:379-408 [14631857.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14920-5 [14657333.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):266-71 [14695885.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):283-7 [14981521.001]
  • [Cites] Am J Pathol. 2004 Aug;165(2):695-705 [15277242.001]
  • (PMID = 19251639.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA098402; United States / NINDS NIH HHS / NS / R37 NS026084; United States / NINDS NIH HHS / NS / R01 NS026084; United States / NCI NIH HHS / CA / R01 CA098402; United States / NINDS NIH HHS / NS / NS26084
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / Drosophila Proteins; 0 / Nerve Tissue Proteins; 0 / Receptors, Notch; 0 / TCF Transcription Factors; 0 / Tcf4 protein, mouse; 0 / Wnt Proteins; 0 / Wnt1 Protein; 0 / wg protein, Drosophila
  • [Other-IDs] NLM/ PMC2649205
  •  go-up   go-down


59. Scott RH, Mansour S, Pritchard-Jones K, Kumar D, MacSweeney F, Rahman N: Medulloblastoma, acute myelocytic leukemia and colonic carcinomas in a child with biallelic MSH6 mutations. Nat Clin Pract Oncol; 2007 Feb;4(2):130-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medulloblastoma, acute myelocytic leukemia and colonic carcinomas in a child with biallelic MSH6 mutations.
  • Background A 13-year-old girl presented with rectal bleeding and was found to have two colonic carcinomas (stage Dukes' C) and multiple colonic polyps.
  • A three-generation family history identified no relatives with colonic carcinomas or polyposis.
  • Investigations Immunohistochemical analysis was performed on a sample of colonic adenoma.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Colonic Neoplasms / genetics. DNA-Binding Proteins / genetics. Leukemia, Myeloid, Acute / genetics. Medulloblastoma / genetics


60. Lenhard K, Bommer GT, Asutay S, Schauer R, Brabletz T, Göke B, Lamerz R, Kolligs FT: Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol; 2005 Feb;3(2):142-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We explored the potential of a single epigenetic marker in comparison with fecal occult blood testing (FOBT) for the discrimination of patients with CRCs and adenomas from those without.
  • METHODS: Methylation-specific polymerase chain reaction (PCR) was performed to analyze hypermethylated in cancer 1 (HIC1) promoter methylation status in a blinded fashion in stool samples from 26 patients with CRC, 13 with adenoma > or =1 cm, 9 with hyperplastic polyps, 9 with chronic inflammatory bowel disease, and 32 with endoscopically normal colon.
  • Forty-two percent of the samples from patients with CRC and 31% of the samples from patients with colorectal adenoma > or =1 cm were positive for HIC1 promoter methylation.
  • No methylated HIC1 promoter DNA was detected in the fecal DNA from patients with endoscopically normal colon or hyperplastic polyps.
  • We postulate that a panel of merely a few genetic and epigenetic markers will be required for the highly sensitive and specific detection of CRCs and adenomas in fecal samples from affected patients.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15704048.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


61. Yuri M, Sasahira T, Nakai K, Ishimaru S, Ohmori H, Kuniyasu H: Reversal of expression of 15-lipoxygenase-1 to cyclooxygenase-2 is associated with development of colonic cancer. Histopathology; 2007 Oct;51(4):520-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversal of expression of 15-lipoxygenase-1 to cyclooxygenase-2 is associated with development of colonic cancer.
  • AIMS: Two different pathways of linoleic acid (LA) metabolism have opposite effects on the development of colonic cancer: a protumoral prostaglandin cascade metabolized by cyclooxygenase (COX)-2, and an antitumoral peroxisome proliferator-activated receptor (PPAR)-gamma ligands metabolized by 15-lipooxygenase (LOX)-1.
  • The aim was to examine the switching of the two LA metabolic pathways in colonic adenomas and carcinomas.
  • MATERIALS AND METHODS: The expression of 15LOX-1 mRNA and COX-2 protein was examined in 54 adenomas, 21 pTis carcinoma-in-adenoma lesions and 36 pT3/p Stage II carcinomas of the colon by in-situ hybridization and immunohistochemistry, respectively.
  • RESULTS: 15LOX-1 expression was found in 89% (48 of 54) of adenomas, 43% (nine of 21) of adenomas and 10% (two of 21) of carcinomas in carcinoma-in-adenoma lesions, but not in pT3 carcinomas (P < 0.0001).
  • In contrast, COX-2 production was found in 11% (six of 54) of adenomas, 52% (11 of 21) of adenomas and 71% (15 of 21) of carcinomas in carcinoma-in-adenoma lesions, and 92% (33 of 36) of pT3 carcinomas (P < 0.0001).
  • Concurrence of 15LOX-1 down-regulation and COX-2 up-regulation was found in 6% (three of 54) of adenomas, 33% (seven of 21) of adenomas and 71% (15 of 21) of carcinomas in carcinoma-in-adenoma lesions, and 92% (33 of 36) of pT3 carcinomas (P < 0.0001).
  • CONCLUSIONS: These results suggest that switching of LA metabolism by reversal of the expression of 15LOX-1 and COX-2 is associated with acquisition of malignant potential in colonic neoplasia.
  • [MeSH-major] Adenoma / metabolism. Arachidonate 15-Lipoxygenase / metabolism. Carcinoma / metabolism. Colonic Neoplasms / metabolism. Cyclooxygenase 2 / metabolism

  • Hazardous Substances Data Bank. LINOLEIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17711445.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 9KJL21T0QJ / Linoleic Acid; EC 1.13.11.33 / Arachidonate 15-Lipoxygenase; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


62. Tomita T: Immunocytochemical localization of lymphatic and venous vessels in colonic polyps and adenomas. Dig Dis Sci; 2008 Jul;53(7):1880-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunocytochemical localization of lymphatic and venous vessels in colonic polyps and adenomas.
  • Using lymphatic vessels endothelial hyaluronan receptor-1 (LYVE-1) immunocytochemical staining, hyperplastic polyps, tubular adenomas to villous adenomas, were investigated for lymphatic vessels compared with immunostained blood vessels using factor-8.
  • Four cases each of hyperplastic polyps, tubular adenomas to villous adenomas, were routinely fixed in formalin and embedded in paraffin and were immunostained using goat anti-LYVE-1 for lymphatic vessels and rabbit anti-factor-8 for blood vessels.
  • In normal colon and hyperplastic polyps, slender lymphatic vessels were noted in muscularis mucosa, which spread into the base of colonic crypt, whereas round venous vessels, they extend into lamina propria.
  • In tubular adenomas, small lymphatic and venous vessels were noted in broad fibrous stalks.
  • In villous adenomas, smaller lymphatic and venous vessels were noted in fine intervillous stroma.
  • In normal colon and hyperplastic polyps, slender, irregularly shaped lymphatic vessels were present in muscularis mucosa, spreading into the base of the colonic crypt.
  • In tubular adenomas, small lymphatic and venous vessels were noted in fibrous stalks.
  • In villous adenomas, smaller lymphatic and venous vessels were noted in intervillous stroma.
  • There are no increased lymphatic and venous vessels in intermucosal stroma and stalks of adenomas compared with normal colon.
  • [MeSH-major] Adenoma / blood supply. Colonic Neoplasms / blood supply. Colonic Polyps. Immunohistochemistry / methods. Lymphatic Vessels. Veins

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1599-604 [9563467.001]
  • [Cites] Clin Exp Med. 2006 Jun;6(2):65-71 [16820993.001]
  • [Cites] Lymphology. 1995 Mar;28(1):4-20 [7791375.001]
  • [Cites] Cancer. 1998 Sep 1;83(5):825-9 [9731879.001]
  • [Cites] Cell Tissue Res. 2007 May;328(2):317-28 [17265066.001]
  • [Cites] Int J Oncol. 2003 Aug;23(2):533-9 [12851706.001]
  • [Cites] Cell. 1999 Sep 17;98(6):769-78 [10499794.001]
  • [Cites] Lymphology. 2003 Jun;36(2):52-61 [12926829.001]
  • [Cites] Am J Pathol. 2006 Mar;168(3):1045-53 [16507917.001]
  • [Cites] Int J Mol Med. 2004 Feb;13(2):211-4 [14719125.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):202-6 [15677543.001]
  • [Cites] Oncol Rep. 2004 Jan;11(1):47-50 [14654901.001]
  • [Cites] Dig Dis Sci. 1995 May;40(5):996-1004 [7729290.001]
  • [Cites] Am J Pathol. 2004 Oct;165(4):1187-97 [15466385.001]
  • [Cites] Pancreas. 2007 Nov;35(4):e18-22 [18090227.001]
  • (PMID = 17990106.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / LYVE1 protein, human; 0 / Vesicular Transport Proteins
  •  go-up   go-down


63. Wang TD, Friedland S, Sahbaie P, Soetikno R, Hsiung PL, Liu JT, Crawford JM, Contag CH: Functional imaging of colonic mucosa with a fibered confocal microscope for real-time in vivo pathology. Clin Gastroenterol Hepatol; 2007 Nov;5(11):1300-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional imaging of colonic mucosa with a fibered confocal microscope for real-time in vivo pathology.
  • The aim of this study was to show the use of functional optical imaging of viable mucosa for quantitative evaluation of colonic neoplasia in real time.
  • RESULTS: Normal mucosa showed circular crypts with uniform size, hyperplasia revealed proliferative glands with serrated lumens, and adenomas displayed distorted elongated glands.
  • Passage of fluorescein through adenomatous mucosa was delayed substantially.
  • For t greater than 5 seconds, high sensitivity, specificity, and accuracy was achieved using a discriminant function to evaluate the contrast ratio to distinguish normal from lesional mucosa (91%, 87%, and 89%, respectively; P < .001), hyperplasia from adenoma (97%, 96%, and 96%, respectively; P < .001), and tubular from villous adenoma (100%, 92%, and 93%, respectively; P < .001).

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUORESCEIN .
  • Hazardous Substances Data Bank. D&C Yellow No. 8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Pharmacol. 2002 Jan 1;63(1):81-8 [11754877.001]
  • [Cites] Endoscopy. 2007 Feb;39 Suppl 1:E145 [17611888.001]
  • [Cites] Appl Opt. 2002 Jan 1;41(1):182-92 [11900434.001]
  • [Cites] Br J Nutr. 2003 May;89(5):639-47 [12720584.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6247-51 [15342411.001]
  • [Cites] Gastroenterology. 2004 Sep;127(3):706-13 [15362025.001]
  • [Cites] Hum Pathol. 1983 Nov;14(11):931-68 [6629368.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Appl Opt. 2004 Nov 1;43(31):5763-71 [15540433.001]
  • [Cites] J Vasc Res. 2004 Sep-Oct;41(5):400-11 [15467299.001]
  • [Cites] Gastroenterology. 2005 Jun;128(7):2119-23 [15940642.001]
  • [Cites] Gastrointest Endosc. 2005 Nov;62(5):686-95 [16246680.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jan;55(1):47-55 [15868166.001]
  • [Cites] Radiology. 2006 Feb;238(2):405-22 [16436809.001]
  • [Cites] J Pharm Sci. 2006 Jun;95(6):1393-401 [16625653.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 May;4(5):566-72 [16630761.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 18;103(29):11003-8 [16835297.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Aug;4(8):979-87 [16843068.001]
  • [Cites] Biochem Pharmacol. 2006 Sep 14;72(6):729-38 [16844096.001]
  • [Cites] Endoscopy. 2006 Sep;38(9):886-90 [16981104.001]
  • [Cites] Nature. 2006 Oct 19;443(7113):765 [17051200.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Nov;4(11):1309-13 [17110299.001]
  • [Cites] Endoscopy. 2006 Nov;38(11):1110-4 [17111332.001]
  • [Cites] Neurosci Lett. 2007 Jan 3;411(1):1-5 [17110033.001]
  • [Cites] Am J Respir Crit Care Med. 2007 Jan 1;175(1):22-31 [17023733.001]
  • [Cites] Cell Tissue Res. 2007 Apr;328(1):77-84 [17165089.001]
  • [Cites] Gastrointest Endosc. 2007 Aug;66(2):398-99, discussion 400 [17521648.001]
  • [CommentIn] Clin Gastroenterol Hepatol. 2007 Nov;5(11):1259-60 [17936080.001]
  • (PMID = 17936692.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / K08 DK067618-04; United States / NIDDK NIH HHS / DK / K08 DK067618; United States / NCI NIH HHS / CA / U54 CA105296; United States / NIDDK NIH HHS / DK / K08 DK067618-05; United States / NIDDK NIH HHS / DK / DK067618-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; TPY09G7XIR / Fluorescein
  • [Other-IDs] NLM/ NIHMS34014; NLM/ PMC2104519
  •  go-up   go-down


64. Fujimori S, Kishida T, Kobayashi T, Sekita Y, Seo T, Nagata K, Tatsuguchi A, Gudis K, Yokoi K, Tanaka N, Yamashita K, Tajiri T, Ohaki Y, Sakamoto C: Helicobacter pylori infection increases the risk of colorectal adenoma and adenocarcinoma, especially in women. J Gastroenterol; 2005 Sep;40(9):887-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Helicobacter pylori infection increases the risk of colorectal adenoma and adenocarcinoma, especially in women.
  • The purpose of this study was to assess the association between H. pylori infection and the risk of colorectal adenoma and adenocarcinoma, and to evaluate any differences on the basis of sex.
  • The odds ratios (ORs) for H. pylori-positive patients with colorectal adenoma and adenocarcinoma, and for tumor patients with either adenoma or adenocarcinoma were calculated.
  • RESULTS: Among the H. pylori-negative patients, there were 52 patients without tumor, 63 with adenoma, 27 with adenocarcinoma, and 90 with tumor.
  • Pooling all subjects, those infected with H. pylori had a significantly increased OR for adenoma, adenocarcinoma, or tumor, compared to H. pylori-free patients (OR, 1.60, 1.80, and 1.66, respectively).
  • CONCLUSIONS: The results therefore suggest that, in patients aged 40-80 years, H. pylori infection increased the risk of colorectal adenoma and adenocarcinoma, with significantly higher risks for female patients.
  • [MeSH-major] Adenocarcinoma / etiology. Adenoma / etiology. Colorectal Neoplasms / etiology. Helicobacter Infections / complications

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Gastroenterol. 2005 Sep;40(9):919-20 [16211355.001]
  • [Cites] Carcinogenesis. 1997 Dec;18(12):2353-9 [9450481.001]
  • [Cites] Gut. 1993 Jun;34(6):752-6 [8314506.001]
  • [Cites] Dis Colon Rectum. 2002 Sep;45(9):1249-54 [12352244.001]
  • [Cites] Dig Dis Sci. 1989 Feb;34(2):171-4 [2914535.001]
  • [Cites] Am J Gastroenterol. 2001 Jan;96(1):84-8 [11197293.001]
  • [Cites] Helicobacter. 2003 Feb;8(1):29-35 [12603614.001]
  • [Cites] Mol Microbiol. 1999 May;32(3):459-70 [10320570.001]
  • [Cites] J Clin Gastroenterol. 1997 Dec;25(4):605-7 [9451672.001]
  • [Cites] Isr Med Assoc J. 2000 Jan;2(1):6-9 [10892362.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2691-4 [8194007.001]
  • [Cites] J Natl Cancer Inst. 1995 May 17;87(10):762-3 [7563155.001]
  • [Cites] Cancer. 1998 Mar 15;82(6):1197-207 [9506368.001]
  • [Cites] Carcinogenesis. 1997 Aug;18(8):1535-9 [9276627.001]
  • [Cites] Gynecol Endocrinol. 1993 Dec;7(4):251-8 [8147234.001]
  • [Cites] Biomed Pharmacother. 1994;48(3-4):157-66 [7993980.001]
  • [Cites] Gut. 1997 Sep;41(3):330-2 [9378387.001]
  • [Cites] N Engl J Med. 2004 Mar 4;350(10):991-1004 [14999111.001]
  • [Cites] Am J Physiol. 1986 Nov;251(5 Pt 1):G597-601 [3777167.001]
  • [Cites] Am J Gastroenterol. 1993 Dec;88(12):2038-43 [8249971.001]
  • [Cites] Cancer Res. 1988 Jun 1;48(11):3035-9 [3365693.001]
  • [Cites] J Gastroenterol Hepatol. 2000 Mar;15(3):277-83 [10764028.001]
  • [Cites] Digestion. 1999;60(3):210-5 [10343134.001]
  • [Cites] JAMA. 1999 Dec 15;282(23):2240-5 [10605976.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):536-40 [7951326.001]
  • [Cites] Lancet. 1992 Nov 14;340(8829):1194-5 [1359263.001]
  • [Cites] Lancet. 1994 Jun 25;343(8913):1636-7 [7911939.001]
  • [Cites] Gut. 1993 Jul;34(7):888-92 [8344574.001]
  • [Cites] Br J Cancer. 2002 Aug 27;87(5):567-73 [12189558.001]
  • [Cites] Gut. 2000 Dec;47(6):820-4 [11076881.001]
  • [Cites] Gut. 1993 Aug;34(8):1032-7 [8174948.001]
  • [Cites] World J Gastroenterol. 2002 Dec;8(6):1103-7 [12439934.001]
  • [Cites] Am J Gastroenterol. 1999 Apr;94(4):1121-2 [10201512.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] J Clin Microbiol. 2004 Jun;42(6):2508-17 [15184428.001]
  • [Cites] Biochim Biophys Acta. 2003 Dec 5;1624(1-3):88-97 [14642818.001]
  • [Cites] Lancet. 1993 May 22;341(8856):1348 [8098476.001]
  • (PMID = 16211345.001).
  • [ISSN] 0944-1174
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


65. Fujimoto T, Yoshimatsu K, Watanabe K, Yokomizo H, Otani T, Matsumoto A, Osawa G, Onda M, Ogawa K: Overexpression of human X-box binding protein 1 (XBP-1) in colorectal adenomas and adenocarcinomas. Anticancer Res; 2007 Jan-Feb;27(1A):127-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of human X-box binding protein 1 (XBP-1) in colorectal adenomas and adenocarcinomas.
  • Recently, overexpression of XBP-1 has been reported in breast cancer including non-invasive carcinomas, and was suggested to play an important role in breast carcinogenesis.
  • To investigate the involvement of XBP-1 in colorectal tumorigenecity, the expression of XBP-1 was examined in four colon cancer cell lines, six colorectal polyps and five colorectal carcinomas.
  • MATERIALS AND METHODS: The study population consisted of eleven patients who had undergone resection for colorectal cancer or adenoma from 2000 to 2002.
  • Four colon cancer cell lines, DLD1, SW480, HCT15 and WiDr, were also analyzed for expression of XBP-1.
  • Reverse transcription-polymerase chain reaction was performed using eleven primary colon tumors.
  • RESULTS: The XBP-1 gene was overexpressed in four cases out of five primary colorectal carcinomas and in four cases out of six colorectal adenomas.
  • Immunohistochemical staining demonstrated that XBP-1 protein was strongly stained in the cytoplasms of cancer cells, whereas it was unreactive in the normal colon epithelial cells and stromal cells.
  • CONCLUSION: These data indicate that increased expression of XBP-1 gene may play some role in human colon carcinogenesis through impairment of cell differentiation regulation.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Colorectal Neoplasms / metabolism. DNA-Binding Proteins / biosynthesis. Nuclear Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352224.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / regulatory factor X transcription factors
  •  go-up   go-down


66. Noguera Aguilar JF, Amengual Antich I, Morón Canis JM, Plaza Martínez A, Martínez Córcoles JA, Tortajada Collado C, Pujol Tugores JJ: Effect of rofecoxib on colon chemical carcinogenesis at colonic anastomotic area in the rat. Rev Esp Enferm Dig; 2005 Jun;97(6):405-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of rofecoxib on colon chemical carcinogenesis at colonic anastomotic area in the rat.
  • AIM: To investigate the effect of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib on the incidence of perianastomotic colonic tumors in a model of chemical carcinogenesis in the rat.
  • EXPERIMENTAL DESIGN: Experimental study with 45 male Sprague-Dawley rats randomly assigned to one of three groups: control (n = 15) with colocolic anastomosis and chemical carcinogenesis with 1-2 dimethylhydrazine (1-2 DMH); rofecoxib 0.0027% (n = 15) with colonic anastomosis, chemical carcinogenesis and the addition of dietary rofecoxib at doses of 27 parts per million (ppm), and rofecoxib 0.0058% (n = 15) with colonic anastomosis, chemical carcinogenesis and the addition of dietary rofecoxib at doses of 58 ppm.
  • Carcinogenic induction was performed with 1-2 DMH at a weekly dose of 25 mg/kg of weight for 18 weeks, and colonic tumors induced were analyzed in postoperative week 20.
  • The main parameter evaluated was the percentage of colonic neoplastic tissue, which relates tumor surface area to the colon's surface area.
  • RESULTS: Rofecoxib at doses of 2.5 mg/kg or 0.0058 ppm significantly reduced chemical colon carcinogenesis in rats, both in the perianastomotic area and the rest of the colon (p < 0.01).
  • CONCLUSIONS: Rofecoxib causes a reduction in chemical colon carcinogenesis in rats.
  • [MeSH-major] Adenocarcinoma / prevention & control. Adenoma / prevention & control. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Colorectal Neoplasms / prevention & control. Cyclooxygenase Inhibitors / therapeutic use. Lactones / therapeutic use. Sulfones / therapeutic use

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16011415.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng; spa
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Carcinogens; 0 / Cyclooxygenase Inhibitors; 0 / Lactones; 0 / Sulfones; 0QTW8Z7MCR / rofecoxib
  •  go-up   go-down


67. Ashktorab H, Brim H, Al-Riyami M, Date A, Al-Mawaly K, Kashoub M, Al-Mjeni R, Smoot DT, Al-Moundhri M, Al-Hashemi S, Ganguly SS, Raeburn S: Sporadic colon cancer: mismatch repair immunohistochemistry and microsatellite instability in Omani subjects. Dig Dis Sci; 2008 Oct;53(10):2723-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sporadic colon cancer: mismatch repair immunohistochemistry and microsatellite instability in Omani subjects.
  • We assessed colonic cancers in an attempt to identify tumors with DNA MMR deficiency and microsatellite instability (MSI).
  • Colon cancer tissue was assayed using immunohistochemistry for expression of hMLH1 and hMSH2, and a panel of five pairs of microsatellite primers (NR21, NR22, NR24, BAT25, and BAT26) for MSI-H analysis and additional dinucleotide markers (D17S250, D5S346, and D2S123) used for MSI-L.
  • The methylation status of the p16 promoter was determined by methylation-specific polymerase chain reaction (PCR).
  • The information currently available indicates that there is an incidence of 4.7% colon cancer (49/1036) and 12.1% (126/1290) colon adenoma among the cases who underwent colonoscopy at these centers.
  • [MeSH-major] Adenoma / genetics. Colonic Neoplasms / genetics. Colorectal Neoplasms / genetics. DNA Mismatch Repair. Microsatellite Instability

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2001 Jun;48(6):821-9 [11358903.001]
  • [Cites] Eur J Cancer Prev. 1993 Mar;2(2):105-15 [8461861.001]
  • [Cites] Am J Hum Genet. 2004 Mar;74(3):532-44 [14973781.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5410-6 [16061855.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3455-60 [9699680.001]
  • [Cites] Am J Pathol. 1994 Jul;145(1):148-56 [8030745.001]
  • [Cites] CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47 [11814064.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10 (1 Pt 1):191-5 [14734469.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):66-73 [12794758.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1090-5 [10070967.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):779-85 [10091754.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5635-43 [16110022.001]
  • [Cites] Gastroenterology. 2005 Sep;129(3):837-45 [16143123.001]
  • [Cites] Science. 1993 May 7;260(5109):812-6 [8484121.001]
  • [Cites] Histopathology. 2007 Jan;50(1):113-30 [17204026.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):808-11 [9041175.001]
  • [Cites] Gastroenterology. 1999 Jul;117(1):123-31 [10381918.001]
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1713-8 [9563488.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4749-56 [9354436.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5470-4 [8968103.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):386-95 [3422035.001]
  • [Cites] Gastroenterology. 2002 Dec;123(6):1804-11 [12454837.001]
  • [Cites] Surgery. 2001 Jul;130(1):17-20 [11436007.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1670-6 [10223559.001]
  • [Cites] Int J Cancer. 2005 Oct 10;116(6):914-9 [15856472.001]
  • [Cites] Cancer. 2005 Sep 1;104(5):952-61 [16015629.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5849-52 [8261392.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):394-401 [14762775.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):6991-5 [11585722.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4584-94 [15542810.001]
  • [Cites] N Engl J Med. 1998 May 21;338(21):1481-7 [9593786.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1112-7 [12631615.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1043-8 [11844828.001]
  • [Cites] Clin Chem Lab Med. 2001 Feb;39(2):121-8 [11341745.001]
  • [Cites] Int J Cancer. 1997 Dec 19;74(6):664-9 [9421366.001]
  • [Cites] Isr Med Assoc J. 2005 Aug;7(8):520-4 [16106779.001]
  • (PMID = 18299982.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA102681
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / MLH1 protein, human; 0 / Mucins; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutL Protein Homolog 1; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


68. Varker KA, Campbell J, Shah MH: Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. Cancer Chemother Pharmacol; 2008 Apr;61(4):661-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of the patients had gastrointestinal primaries (small bowel, 8; pancreas, 5; colon, 1).
  • [MeSH-major] Adenoma, Islet Cell / drug therapy. Angiogenesis Inhibitors / therapeutic use. Carcinoid Tumor / drug therapy. Carcinoid Tumor / secondary. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / secondary. Thalidomide / therapeutic use

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17589846.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Biomarkers, Tumor; 0 / Pancreatic Hormones; 106477-83-2 / pancreastatin; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


69. Crispin A, Birkner B, Munte A, Nusko G, Mansmann U: Process quality and incidence of acute complications in a series of more than 230,000 outpatient colonoscopies. Endoscopy; 2009 Dec;41(12):1018-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Colon preparation resulted in clear bowels in 76.31 % of patients, liquid residues in 22.22 %, and dirty bowels in 1.47 %.
  • [MeSH-minor] Acute Disease. Adenoma / diagnosis. Aged. Colon / injuries. Colonic Neoplasms / diagnosis. Colonic Polyps / surgery. Female. Heart Diseases / etiology. Hemorrhage / etiology. Humans. Intestinal Perforation / etiology. Male. Middle Aged. Respiration Disorders / etiology. Risk Factors

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart New York.
  • (PMID = 19856246.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


70. Takahashi T, Nosho K, Yamamoto H, Mikami M, Taniguchi H, Miyamoto N, Adachi Y, Itoh F, Imai K, Shinomura Y: Flat-type colorectal advanced adenomas (laterally spreading tumors) have different genetic and epigenetic alterations from protruded-type advanced adenomas. Mod Pathol; 2007 Jan;20(1):139-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flat-type colorectal advanced adenomas (laterally spreading tumors) have different genetic and epigenetic alterations from protruded-type advanced adenomas.
  • Morphologically, colorectal adenomas can be divided into two groups, protruded-type and flat-type.
  • However, the accurate frequencies of genetic and epigenetic alterations in flat-type colorectal advanced adenomas (laterally spreading tumors) have remained largely unknown.
  • In the current study, we investigated genetic and epigenetic alterations in 101 flat-type colorectal advanced adenomas and 68 protruded-type colorectal advanced adenomas by using direct DNA sequencing and quantitative real-time PCR (MethyLight), respectively.
  • KRAS mutation was detected in a significantly higher percentage of flat-type adenomas (35%) than in protruded-type adenomas (13%).
  • When the samples were limited to the tumors in the distal colon, the difference of KRAS mutation was still significant.
  • KRAS mutation in G-to-A transitions at codons 12 and 13 was detected in a significantly higher percentage of flat-type adenomas (26%) than in protruded-type adenomas (9%).
  • BRAF and beta-catenin mutations were detected in 3 and 8% of the 101 flat-type adenomas, respectively.
  • No significant difference was found between frequencies of those mutations in flat-type adenomas and protruded-type adenomas.
  • Methylations of MGMT, CDKN2A (p16) and MLH1 were detected in 28, 33 and 9% of the 101 flat-type adenomas, respectively.
  • CDKN2A methylation was detected in a significantly lower percentage of flat-type adenomas than in protruded-type adenomas (63%).
  • Methylation of at least one gene was detected in a significantly lower percentage of flat-type adenomas (54%) than in protruded-type adenomas (78%).
  • In conclusion, KRAS mutation was frequently detected in flat-type advanced adenomas and the mutational patterns in most of them with KRAS mutations were a transition from G-to-A.
  • Therefore, these genetic alterations seem to play an important role in the development of flat-type advanced adenomas, especially in the distal colon.
  • Epigenetic alterations infrequently occurred in flat-type advanced adenomas, suggesting that they have different genetic and epigenetic alterations from those of protruded-type advanced adenomas.
  • [MeSH-major] Adenoma / genetics. Adenoma / pathology. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. DNA Methylation. Epigenesis, Genetic. Gene Expression Regulation, Neoplastic

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. GUANINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17143260.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / CTNNB1 protein, human; 0 / Carrier Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Proteins; 0 / beta Catenin; 5Z93L87A1R / Guanine; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins; EC 6.5.1.- / DNA Repair Enzymes; JAC85A2161 / Adenine
  •  go-up   go-down


71. Nusko G, Hahn EG, Mansmann U: Characteristics of metachronous colorectal adenomas found during long-term follow-up: analysis of four subsequent generations of adenoma recurrence. Scand J Gastroenterol; 2009;44(6):736-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics of metachronous colorectal adenomas found during long-term follow-up: analysis of four subsequent generations of adenoma recurrence.
  • OBJECTIVE: Because of the high recurrence rates of colorectal adenomas, regular surveillance by colonoscopy has been recommended, but there is still a dearth of information on the long-term results of follow-up colonoscopy after polypectomy.
  • The aims of this study were to determine the differences between initial adenomas and metachronous lesions, to evaluate the effect of long-term surveillance and to describe the hypothetical origin of the colorectal adenoma-carcinoma sequence.
  • MATERIAL AND METHODS: Between 1978 and 2003 a total of 1091 patients undergoing periodic surveillance examinations were prospectively documented at the Erlangen Registry of Colorectal Polyps.
  • Statistical analysis using chi(2) testing of adenoma characteristics found in four subsequent recurrence periods was carried out, and the relative risk (RR) for the development of metachronous adenomas of advanced pathology was calculated.
  • RESULTS: In comparison with the initial findings, metachronous adenomas are generally significantly smaller lesions (p<0.00001), usually tubular in shape (p<0.00001) and bearing high-grade dysplasia less often (p<0.00001) and are usually located in the right colon (p<0.00001).
  • These differences are found between the initial and four subsequent generations of metachronous adenomas.
  • The number of synchronous adenomas is reduced only in the first recurrence (p<0.001); in the further generations equal proportions of multiplicity are found, as in the baseline examination.
  • Patients with adenomas of advanced pathology, i.e. large, tubulovillous or villous adenomas at baseline, have a significantly higher risk for large (RR 2.73; 95% CI 1.77-4.20), tubulovillous or villous (RR 1.55; 95% CI 1.06-2.25) or multiple (RR 2.45; 95% CI 1.83-3.29) metachronous adenomas at the first recurrence.
  • CONCLUSIONS: Metachronous adenomas show the uniform characteristics of being small tubular lesions rarely bearing high-grade dysplasia, usually located in the right colon.
  • [MeSH-major] Adenoma / pathology. Colorectal Neoplasms / pathology. Neoplasms, Second Primary

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19277927.001).
  • [ISSN] 1502-7708
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


72. Yoshida I, Suzuki A, Vallée M, Matano Y, Masunaga T, Zenda T, Shinozaki K, Okada T: Serum insulin levels and the prevalence of adenomatous and hyperplastic polyps in the proximal colon. Clin Gastroenterol Hepatol; 2006 Oct;4(10):1225-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum insulin levels and the prevalence of adenomatous and hyperplastic polyps in the proximal colon.
  • BACKGROUND & AIMS: Obesity and diabetes mellitus are associated with an increased incidence of proximal colon cancer.
  • Colonic adenoma that has been reported to be associated with elevated serum insulin levels and subsets of hyperplastic polyps might serve as a precursor of colon cancer.
  • In this study, we sought to determine segment-specific associations between serum insulin levels and the prevalence of adenoma and hyperplastic polyps in the proximal and distal colon.
  • We performed multinomial logistic regression models by using the outcome categories of none (reference), proximal-only, distal-only, and both-segment lesions for the presence of adenoma/hyperplastic polyp with serum insulin, age, gender, lifestyle characteristics, and the presence of other types of lesions as predictors.
  • RESULTS: Overall, serum insulin levels were significantly associated with adenoma (OR, 1.5; 95% CI, 1.1-2.0; P = .005) and borderline associated with hyperplastic polyps (OR, 1.3; 95% CI, 1.0-1.7; P = .075).
  • In multinomial logistic regression models, elevated serum insulin levels were significantly associated with proximal-only adenoma (OR, 1.8; 95% CI, 1.2-2.5; P = .002), both-side hyperplastic polyp (OR, 1.7; 95% CI, 1.1-2.5; P = .015), and proximal-only hyperplastic polyp (OR, 1.5; 95% CI, 1.0-2.1; P = .048) and borderline associated with distal-only adenoma (OR, 1.5; 95% CI, 1.0-2.1; P =.059) but not with distal-only hyperplastic polyp.
  • CONCLUSIONS: Serum insulin levels directly correlate with the presence of adenoma and hyperplastic polyps in the proximal colon and might also less strongly correlate with the presence of distal adenoma.
  • [MeSH-major] Adenomatous Polyposis Coli / blood. Biomarkers, Tumor / blood. Colonic Polyps / blood. Colonic Polyps / epidemiology. Insulin / blood

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Gastroenterol Hepatol. 2007 Jan;5(1):137
  • (PMID = 16979948.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Insulin
  •  go-up   go-down


73. Ivanov D, Toyonaga T: The first case of endoscopic submucosal dissection of cecal adenoma in Serbia. Med Pregl; 2009 Jan-Feb;62(1-2):27-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The first case of endoscopic submucosal dissection of cecal adenoma in Serbia.
  • In 2006, we performed a colonic ESD in Serbia.
  • The adenoma was removed en bloc and prepared for further histopathological examination.
  • Histopathological examination showed that the tumor was a "flat adenoma" of the colon mucosa with a low grade dysplasia.
  • [MeSH-major] Adenoma / surgery. Cecal Neoplasms / surgery. Colonoscopy

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19514597.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] eng; srp
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


74. Phelps RA, Broadbent TJ, Stafforini DM, Jones DA: New perspectives on APC control of cell fate and proliferation in colorectal cancer. Cell Cycle; 2009 Aug 15;8(16):2549-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aberrant Wnt/beta-catenin signaling following loss of the tumor suppressor adenomatous polyposis coli (APC) is thought to initiate colon adenoma formation.
  • However, examination of tumors from familial adenomatous polyposis coli (FAP) patients has failed to confirm the presence of nuclear beta-catenin in early lesions following APC loss despite robust staining in later lesions.
  • This observation presents the possibility that colon adenomas arise through a beta-catenin-independent function of APC.
  • Though there are currently contrasting models to explain colon tumorigenesis, our goal is to begin to reconcile data from multiple different model systems and provide a functional view into the initiation and progression of colon cancer.
  • [MeSH-major] Adenomatous Polyposis Coli / pathology. Cell Differentiation / physiology. Colorectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19597346.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 94
  •  go-up   go-down


75. Goodlad RA, Ryan AJ, Wedge SR, Pyrah IT, Alferez D, Poulsom R, Smith NR, Mandir N, Watkins AJ, Wilkinson RW: Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer. Carcinogenesis; 2006 Oct;27(10):2133-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We used AZD2171, an oral, highly potent and selective vascular endothelial growth factor (VEGF) signaling inhibitor, to investigate the role of VEGF receptor-2 (VEGFR-2) signaling in adenoma development and growth in Apc(Min/+) mice.
  • In the early-intervention study, AZD2171 reduced the number of macroscopic polyps in the small bowel and colon.
  • Macropolyp diameter was lower in the small bowel, but remained unchanged in the colon.
  • Microscopic analysis revealed that AZD2171 significantly reduced the number of larger micropolyps in the small bowel, with no large micropolyps present in the colon.
  • AZD2171 treatment had no effect on microvessel density or localization of beta-catenin staining in adenomas or non-tumor intestinal tissue, but significantly reduced the number of cells expressing VEGFR-2 mRNA.
  • In conclusion, the effects of AZD2171 in the small intestine of Apc(Min/+) mice are consistent with an antiangiogenic mechanism of action, limiting growth of adenomas to < or =1 mm.
  • These data also suggest that an early step in adenoma development may depend on VEGFR-2 signaling.
  • Together, these results indicate that VEGFR-2 signaling may play key roles in the development and progression of intestinal adenomas.
  • [MeSH-major] Adenoma / prevention & control. Genes, APC / physiology. Intestinal Neoplasms / prevention & control. Intestinal Polyps / drug therapy. Quinazolines / therapeutic use. Signal Transduction / drug effects. Vascular Endothelial Growth Factor Receptor-2 / antagonists & inhibitors

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16782971.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Quinazolines; 0 / RNA, Messenger; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; NQU9IPY4K9 / cediranib
  •  go-up   go-down


76. Shelton DN, Sandoval IT, Eisinger A, Chidester S, Ratnayake A, Ireland CM, Jones DA: Up-regulation of CYP26A1 in adenomatous polyposis coli-deficient vertebrates via a WNT-dependent mechanism: implications for intestinal cell differentiation and colon tumor development. Cancer Res; 2006 Aug 1;66(15):7571-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation of CYP26A1 in adenomatous polyposis coli-deficient vertebrates via a WNT-dependent mechanism: implications for intestinal cell differentiation and colon tumor development.
  • Mutations in the adenomatous polyposis coli (APC) tumor suppressor gene seem to underlie the initiation of many colorectal carcinomas.
  • Paradoxically, however, previous studies found that dietary supplementation of Apc(MIN) mice with retinoic acid failed to abrogate adenoma formation.
  • While investigating the above finding, we found that expression of CYP26A1, a major retinoic acid catabolic enzyme, was up-regulated in Apc(MIN) mouse adenomas, human FAP adenomas, human sporadic colon carcinomas, and in the intestine of apc(mcr) mutant zebrafish embryos.
  • [MeSH-major] Adenomatous Polyposis Coli Protein / deficiency. Colonic Neoplasms / metabolism. Cytochrome P-450 Enzyme System / biosynthesis. Intestines / pathology. Wnt Proteins / metabolism

  • Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • ZFIN. ZFIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885356.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Cytochrome P-450 Enzyme Inhibitors; 0 / Morpholines; 0 / Oligonucleotides; 0 / Wnt Proteins; 5688UTC01R / Tretinoin; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / retinoic acid 4-hydroxylase
  •  go-up   go-down


77. Obtulowicz T, Swoboda M, Speina E, Gackowski D, Rozalski R, Siomek A, Janik J, Janowska B, Ciesla JM, Jawien A, Banaszkiewicz Z, Guz J, Dziaman T, Szpila A, Olinski R, Tudek B: Oxidative stress and 8-oxoguanine repair are enhanced in colon adenoma and carcinoma patients. Mutagenesis; 2010 Sep;25(5):463-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxidative stress and 8-oxoguanine repair are enhanced in colon adenoma and carcinoma patients.
  • Oxidative stress is involved in the pathogenesis of colon cancer.
  • In the examined groups of patients with colorectal cancer (CRC, n = 89), benign adenoma (AD, n = 77) and healthy volunteers (controls, n = 99), we measured: vitamins A, C and E in blood plasma, 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) and 8-oxo-7,8-dihydroguanine (8-oxoGua) in leukocytes and urine, leukocyte 8-oxoGua excision activity, mRNA levels of APE1, OGG1, 8-oxo-7,8-dihydrodeoxyguanosine 5'-triphosphate pyrophosphohydrolase (MTH1) and OGG1 polymorphism.
  • The vitamin levels decreased gradually in AD and CRC patients.
  • 8-OxodG increased in leukocytes and urine of CRC and AD patients.
  • 8-OxoGua excision was higher in CRC patients than in controls, in spite of higher frequency of the OGG1 Cys326Cys genotype, encoding a glycosylase with decreased activity. mRNA levels of OGG1 and APE1 increased in CRC and AD patients, which could explain increased 8-oxoGua excision rate in CRC patients.
  • The results suggest that oxidative stress occurs in CRC and AD individuals.
  • [MeSH-major] Adenoma / metabolism. Carcinoma / metabolism. Colonic Neoplasms / metabolism. DNA Repair / genetics. Deoxyguanosine / analogs & derivatives. Oxidative Stress / genetics
  • [MeSH-minor] Adenomatous Polyps / blood. Adenomatous Polyps / metabolism. Adult. Aged. Aging / genetics. Antioxidants / metabolism. Case-Control Studies. DNA Glycosylases / genetics. DNA Glycosylases / metabolism. DNA Repair Enzymes / genetics. DNA Repair Enzymes / metabolism. DNA, Neoplasm / metabolism. DNA-(Apurinic or Apyrimidinic Site) Lyase / genetics. DNA-(Apurinic or Apyrimidinic Site) Lyase / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Staging. Phosphoric Monoester Hydrolases / genetics. Phosphoric Monoester Hydrolases / metabolism. Polymorphism, Single Nucleotide / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Sex Characteristics. Smoking / adverse effects. Smoking / genetics

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534734.001).
  • [ISSN] 1464-3804
  • [Journal-full-title] Mutagenesis
  • [ISO-abbreviation] Mutagenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / DNA, Neoplasm; 0 / RNA, Messenger; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.6.- / 8-oxodGTPase; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human; EC 4.2.99.18 / APEX1 protein, human; EC 4.2.99.18 / DNA-(Apurinic or Apyrimidinic Site) Lyase; EC 6.5.1.- / DNA Repair Enzymes; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


78. Miyoshi N, Ohue M, Noura S, Yano M, Sasaki Y, Kishi K, Yamada T, Miyashiro I, Ohigashi H, Iishi H, Ishikawa O, Imaoka S: Surgical usefulness of indocyanine green as an alternative to India ink for endoscopic marking. Surg Endosc; 2009 Feb;23(2):347-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: India ink has been commonly used for preoperative colonic tattooing, but various complications have been reported.
  • [MeSH-major] Adenoma / surgery. Carcinoma / surgery. Colonoscopy. Colorectal Neoplasms / surgery. Coloring Agents. Indocyanine Green

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. INDOCYANINE GREEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Sci. 1961 Aug;21:43-57 [13689739.001]
  • [Cites] J Clin Gastroenterol. 2000 Oct;31(3):233-6 [11034004.001]
  • [Cites] Am J Surg Pathol. 1996 Oct;20(10):1266-70 [8827034.001]
  • [Cites] Arch Surg. 2005 Mar;140(3):285-8 [15781794.001]
  • [Cites] Am J Ophthalmol. 2006 Nov;142(5):765-70 [17056360.001]
  • [Cites] Gastrointest Endosc. 1991 Jan-Feb;37(1):56-8 [1706283.001]
  • [Cites] Gastrointest Endosc. 1975 Aug;22(1):42-3 [1205106.001]
  • [Cites] Surgery. 2001 Mar;129(3):335-40 [11231462.001]
  • [Cites] Endoscopy. 2006 Feb;38(2):190-2 [16479428.001]
  • [Cites] Surg Endosc. 2003 Mar;17(3):521 [12488998.001]
  • [Cites] Gastrointest Endosc. 2005 Jan;61(1):186-7 [15672088.001]
  • [Cites] Endoscopy. 2001 Aug;33(8):687-91 [11490385.001]
  • [Cites] Gastrointest Endosc. 1991 Jan-Feb;37(1):65-8 [1706285.001]
  • [Cites] Am J Surg. 2003 Jan;185(1):88-9 [12531454.001]
  • [Cites] Gastrointest Endosc. 2000 Apr;51(4 Pt 1):438-42 [10744816.001]
  • [Cites] Am Surg. 1993 Mar;59(3):205-10 [8476162.001]
  • [Cites] Endoscopy. 1999 Mar;31(3):271-3 [10344435.001]
  • [Cites] Gastrointest Endosc. 2003 May;57(6):735-7 [12709711.001]
  • [Cites] Ophthalmology. 1994 Mar;101(3):529-33 [8127574.001]
  • [Cites] Gastrointest Endosc. 1991 Jan-Feb;37(1):68-71 [1706286.001]
  • [Cites] Gastrointest Endosc. 2002 Sep;56(3):339-42 [12196769.001]
  • [Cites] Am Surg. 1989 Jul;55(7):457-61 [2472762.001]
  • [Cites] Dis Colon Rectum. 2003 Jul;46(7):987 [12847379.001]
  • [Cites] Surg Endosc. 1999 Apr;13(4):397-400 [10094755.001]
  • (PMID = 18443867.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Coloring Agents; IX6J1063HV / Indocyanine Green
  •  go-up   go-down


79. Ok KS, Kim YS, Kim HH, Ryu SH, Lee JH, Moon JS, Kang YK: [The difference of clinicopathologic features according to leptin expression in colorectal adenoma]. Korean J Gastroenterol; 2010 Jul;56(1):20-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The difference of clinicopathologic features according to leptin expression in colorectal adenoma].
  • BACKGROUND/AIMS: Colorectal adenoma and cancer are known to be associated with obesity.
  • Leptin, an adipocyte-derived hormone that plays a crucial role in obesity has been suggested as a growth factor in colon cancer.
  • However, the association between adenoma and leptin remains controversial.
  • We evaluated the leptin expression in human colorectal adenoma and its correlation to clinicopathologic factors.
  • METHODS: Leptin expression was assessed by immunohistochemistry in 91 samples of colorectal adenoma larger than 5 mm, which were removed by endoscopic polypectomy.
  • In leptin positive group, the correlation of leptin expression with adenoma size and histological showed positive tendency without statistical significance.
  • CONCLUSIONS: Leptin expression of colorectal adenoma was associated with BMI.
  • The question of whether leptin contributes to colorectal adenoma development is unresolved and will require additional studies.
  • [MeSH-major] Adenoma / pathology. Colorectal Neoplasms / pathology. Leptin / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20664314.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Leptin
  •  go-up   go-down


80. Weng SW, Liu JW, Chen WJ, Wang PW: Recurrent Klebsiella pneumoniae liver abscess in a diabetic patient followed by Streptococcus bovis endocarditis--occult colon tumor plays an important role. Jpn J Infect Dis; 2005 Apr;58(2):70-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent Klebsiella pneumoniae liver abscess in a diabetic patient followed by Streptococcus bovis endocarditis--occult colon tumor plays an important role.
  • The patient later developed Streptococcus bovis bacteremia originating from a colon tumor with complications of endocarditis, osteomyelitis, and silent splenic abscess.
  • Occult colon tumor may have played an important role in our case, with recurrent infection arising from colonizers of the gastrointestinal tract.
  • As our case shows, the possible association between occult colon tumor and K. pneumoniae liver abscess in diabetic patients should be surveyed.
  • [MeSH-major] Colonic Neoplasms / complications. Endocarditis, Bacterial / microbiology. Klebsiella Infections / etiology. Liver Abscess / microbiology. Streptococcal Infections / etiology
  • [MeSH-minor] Adenoma, Villous / complications. Aged. Anti-Bacterial Agents / therapeutic use. Diabetes Mellitus, Type 2 / complications. Humans. Klebsiella pneumoniae / isolation & purification. Male. Streptococcus bovis / isolation & purification

  • Genetic Alliance. consumer health - Endocarditis.
  • Genetic Alliance. consumer health - Klebsiella.
  • MedlinePlus Health Information. consumer health - Streptococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858282.001).
  • [ISSN] 1344-6304
  • [Journal-full-title] Japanese journal of infectious diseases
  • [ISO-abbreviation] Jpn. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


81. Fichera A, Little N, Jagadeeswaran S, Dougherty U, Sehdev A, Mustafi R, Cerda S, Yuan W, Khare S, Tretiakova M, Gong C, Tallerico M, Cohen G, Joseph L, Hart J, Turner JR, Bissonnette M: Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. Cancer Res; 2007 Jan 15;67(2):827-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis.
  • Colonic carcinogenesis involves the progressive dysregulation of homeostatic mechanisms that control growth.
  • The epidermal growth factor (EGF) receptor (EGFR) regulates colonocyte growth and differentiation and is overexpressed in many human colon cancers.
  • A requirement for EGFR in colonic premalignancy, however, has not been shown.
  • In the current study, we used a specific EGFR antagonist, gefitinib, to investigate this role of the receptor in azoxymethane colonic premalignancy.
  • The azoxymethane model shares many clinical, histologic, and molecular features of human colon cancer.
  • Gefitinib also significantly reduced the number of large aberrant crypt foci and decreased the incidence of colonic microadenomas from 75% to 33% (P<0.05).
  • Gefitinib concomitantly decreased cell cycle-regulating cyclin D1 and prostanoid biosynthetic enzyme cyclooxygenase-2 in microadenomas, suggesting that these regulators are key targets of EGFR in colonic carcinogenesis.
  • These results show for the first time that EGFR signaling is required for early stages of colonic carcinogenesis.
  • Our findings suggest, moreover, that inhibitors of EGFR might be useful in chemopreventive strategies in individuals at increased risk for colonic malignancies.

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2006 Jul 21;281(29):20474-82 [16699180.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1521-6 [11818567.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5749-54 [12384534.001]
  • [Cites] Int J Oncol. 2003 Jan;22(1):145-50 [12469197.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1653-62 [12496057.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):307-15 [12584182.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):762-77 [12612914.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):293-7 [10667579.001]
  • [Cites] J Cell Biochem Suppl. 2000;34:52-60 [10762015.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):2053-63 [10815932.001]
  • [Cites] EMBO J. 2000 Jul 3;19(13):3159-67 [10880430.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4602-9 [10969813.001]
  • [Cites] Endocr Relat Cancer. 2001 Mar;8(1):11-31 [11350724.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):802-8 [11533659.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7184-8 [11585753.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3517-23 [12839936.001]
  • [Cites] Int J Cancer. 2004 Feb 10;108(4):540-8 [14696118.001]
  • [Cites] Oncogene. 2004 May 6;23(21):3813-21 [15021908.001]
  • [Cites] Cancer Sci. 2004 Jun;95(6):475-80 [15182426.001]
  • [Cites] Cancer J. 2004 May-Jun;10(3):145-52 [15285921.001]
  • [Cites] Nat Med. 2004 Aug;10(8):789-99 [15286780.001]
  • [Cites] Lab Anim. 1981 Jan;15(1):57-9 [7022018.001]
  • [Cites] Int J Cancer. 1984 Jul 15;34(1):49-56 [6746117.001]
  • [Cites] Cancer Res. 1988 Jan 1;48(1):137-41 [2446740.001]
  • [Cites] J Clin Invest. 1990 Jul;86(1):356-62 [2365825.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7792-6 [1715580.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5270-4 [1913650.001]
  • [Cites] Cell. 1993 Apr 23;73(2):263-78 [8477445.001]
  • [Cites] Carcinogenesis. 1994 Jul;15(7):1317-23 [8033306.001]
  • [Cites] Carcinogenesis. 1995 Mar;16(3):451-6 [7697797.001]
  • [Cites] Cancer Lett. 1995 Jun 29;93(1):55-71 [7600544.001]
  • [Cites] Trends Biochem Sci. 1995 May;20(5):187-90 [7610482.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):4743-6 [7585496.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):669-74 [8608874.001]
  • [Cites] Gastroenterology. 1996 Apr;110(4):1259-62 [8613017.001]
  • [Cites] Gut. 1996 Aug;39(2):262-6 [8977341.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):657-62 [9012840.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] Gastroenterology. 1997 Apr;112(4):1103-13 [9097992.001]
  • [Cites] Cancer Res. 1997 Sep 1;57(17):3717-22 [9288778.001]
  • [Cites] J Biol Chem. 1997 Sep 12;272(37):23247-54 [9287333.001]
  • [Cites] J Biol Chem. 1997 Dec 26;272(52):33181-90 [9407106.001]
  • [Cites] Hum Pathol. 1998 Aug;29(8):771-7 [9712416.001]
  • [Cites] N Engl J Med. 1998 Oct 29;339(18):1277-84 [9791143.001]
  • [Cites] J Biol Chem. 1998 Nov 6;273(45):29864-72 [9792703.001]
  • [Cites] Clin Cancer Res. 1995 Jan;1(1):19-31 [9815883.001]
  • [Cites] Carcinogenesis. 1998 Nov;19(11):2001-6 [9855016.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5522-7 [10318916.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7547-54 [15569985.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2265-71 [15788676.001]
  • [Cites] Am J Clin Oncol. 2005 Aug;28(4):340-4 [16062074.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):209-14 [16003751.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5656-64 [16740703.001]
  • (PMID = 17234795.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30DK42086; United States / NIDDK NIH HHS / DK / P30 DK042086; United States / NIDDK NIH HHS / DK / R01 DK061931-08; United States / NIDDK NIH HHS / DK / R01 DK068271-04; United States / NCI NIH HHS / CA / CA097540; United States / NCI NIH HHS / CA / R01 CA036745; United States / NCI NIH HHS / CA / CA036745; United States / NIDDK NIH HHS / DK / DK068271-04; United States / NIDDK NIH HHS / DK / R01 DK061931; United States / NIDDK NIH HHS / DK / R01 DK068271; United States / NIDDK NIH HHS / DK / DK061931-08; United States / NCI NIH HHS / CA / R37 CA036745
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Cyclooxygenase 2 Inhibitors; 0 / Quinazolines; 0 / beta Catenin; 136601-57-5 / Cyclin D1; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; MO0N1J0SEN / Azoxymethane; S65743JHBS / gefitinib
  • [Other-IDs] NLM/ NIHMS109727; NLM/ PMC2705749
  •  go-up   go-down


82. Tonelli F, Garcea A, Batignani G: Different role of the colonic pouch for low anterior resection and coloanal anastomosis. Tech Coloproctol; 2005 Apr;9(1):15-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Different role of the colonic pouch for low anterior resection and coloanal anastomosis.
  • BACKGROUND: Functional outcome after sphincter-saving operations can be improved by colonic pouch compared to the straight procedure.
  • However, it is not clear whether the colonic pouch has a different behavior in patients treated by low anterior resection with colorectal (LAR) or coloanal anastomosis (CAA).
  • METHODS: We evaluated the 1-year results of 75 patients who underwent a sphincter-saving operation for rectal carcinoma or villous tumor of the middle or lower third of the rectum: 18 patients underwent coloanal anastomosis (CAA), in 13 patients we performed a coloanal anastomosis with a colonic pouch (PCAA), 20 patients had low anterior resection (LAR) and 24 had LAR with pouch construction (PLAR).
  • CONCLUSIONS: Colonic J-pouch provides an advantage over straight anastomosis in sphincter-saving operations by reducing the daily number of defecations, and the frequencies of fecal soiling and urgency.
  • [MeSH-major] Anal Canal / surgery. Colon / surgery. Colonic Pouches
  • [MeSH-minor] Adenoma, Villous / surgery. Adult. Aged. Aged, 80 and over. Anastomosis, Surgical. Carcinoma / surgery. Female. Humans. Male. Manometry. Middle Aged. Rectal Neoplasms / surgery. Rectum / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868493.001).
  • [ISSN] 1123-6337
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


83. Moxon D, Raza M, Kenney R, Ewing R, Arozullah A, Mason JB, Carroll RE: Relationship of aging and tobacco use with the development of aberrant crypt foci in a predominantly African-American population. Clin Gastroenterol Hepatol; 2005 Mar;3(3):271-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Additionally, alcohol and tobacco use are associated with an increased risk for colon cancer, but the early pathologic events by which these agents promote neoplastic transformation are not well understood.
  • Aberrant crypt foci (ACF) are potential precursors of adenoma and cancer, and can be visualized by magnification endoscopy.
  • Decreased colonic folate level was associated with increased homocysteine levels and lower dietary folate intake but did not correlate with ACF number.
  • CONCLUSIONS: Increasing age and tobacco use were linked independently to the presence of colonic ACF in this predominantly African-American population.
  • [MeSH-major] Colonic Neoplasms / etiology. Precancerous Conditions / etiology
  • [MeSH-minor] African Americans. Aged. Aging / physiology. Colonoscopy. Female. Folic Acid Deficiency / complications. Humans. Intestinal Mucosa / pathology. Male. Smoking / adverse effects. Tobacco Use Disorder / complications. Urban Population

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15765447.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-80360
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


84. Chakravarti B, Dwivedi SK, Mithal A, Chattopadhyay N: Calcium-sensing receptor in cancer: good cop or bad cop? Endocrine; 2009 Jun;35(3):271-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One situation is loss of CaR expression, resulting in loss of growth suppressing effects of elevated extracellular Ca(2+) by CaR, reported in parathyroid adenoma and in colon carcinoma.
  • CaR signaling and effects have been studied in several cancers including ovarian cancers, gastrinomas, and gliomas in addition to comparatively detailed studies in breast, prostate, and colon cancers.
  • Pharmacological agonists and antagonists of CaR hold therapeutic promise depending on whether activation of CaR is required such as in case of colon cancer or inactivating the receptor is required as in the case of breast- and prostate tumors.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem J. 2003 Jun 15;372(Pt 3):787-97 [12628005.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10330-4 [9294210.001]
  • [Cites] Am J Obstet Gynecol. 1998 Feb;178(2):305-13 [9500491.001]
  • [Cites] J Clin Invest. 2004 Feb;113(4):598-608 [14966569.001]
  • [Cites] N Engl J Med. 1985 Feb 21;312(8):474-83 [3881673.001]
  • [Cites] J Biol Chem. 2000 Mar 17;275(11):7553-7 [10713061.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1293-4; author reply 1295 [15026815.001]
  • [Cites] Cancer. 2003 Feb 1;97(3 Suppl):779-84 [12548575.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2001 Dec;281(6):E1267-74 [11701443.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1588-94 [9362426.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Cancer Res. 1993 Apr 15;53(8):1724-6 [8467485.001]
  • [Cites] Endocrinology. 2003 Dec;144(12):5188-93 [12970167.001]
  • [Cites] Hum Pathol. 1996 Dec;27(12):1319-23 [8958305.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):698-714 [8969974.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Sep;88(9):4455-64 [12970324.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):67-71 [12517779.001]
  • [Cites] Bone. 2004 Sep;35(3):664-72 [15336602.001]
  • [Cites] Breast. 2004 Dec;13 Suppl 1:S19-28 [15585379.001]
  • [Cites] Acta Neuropathol. 1986;70(1):17-21 [3727931.001]
  • [Cites] Neurol Med Chir (Tokyo). 1995 Sep;35(9):631-8 [7566395.001]
  • [Cites] Metabolism. 1984 Jan;33(1):50-3 [6690886.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):2057-66 [10595935.001]
  • [Cites] Rev Endocr Metab Disord. 2000 Nov;1(4):253-63 [11706739.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1784-7 [9065401.001]
  • [Cites] AJR Am J Roentgenol. 1990 Sep;155(3):587-93 [2167004.001]
  • [Cites] Cancer Metastasis Rev. 1998 Mar;17(1):107-18 [9544426.001]
  • [Cites] Nat Med. 2002 Jan;8(1):35-40 [11786904.001]
  • [Cites] Arq Bras Endocrinol Metabol. 2006 Aug;50(4):685-93 [17117294.001]
  • [Cites] Curr Osteoporos Rep. 2007 Sep;5(3):120-7 [17925193.001]
  • [Cites] Oncogene. 2006 Dec 4;25(57):7531-7 [17143297.001]
  • [Cites] Int J Oncol. 2003 Apr;22(4):779-86 [12632068.001]
  • [Cites] Cell Calcium. 2004 Mar;35(3):217-28 [15200145.001]
  • [Cites] N Engl J Med. 1997 Nov 20;337(21):1506-10 [9366582.001]
  • [Cites] Br J Cancer. 1999 Oct;81(3):496-502 [10507776.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Dec;85(12):4789-94 [11134144.001]
  • [Cites] J Bone Miner Res. 2001 Nov;16(11):2092-102 [11697806.001]
  • [Cites] Carcinogenesis. 2000 Jun;21(6):1149-55 [10837003.001]
  • [Cites] Tidsskr Nor Laegeforen. 1992 Aug 10;112(18):2346-8 [1329263.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34871-9 [11390379.001]
  • [Cites] Cell Biochem Biophys. 2000;33(1):63-95 [11322513.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1389-94 [9769374.001]
  • [Cites] J Cell Biol. 2002 Jul 22;158(2):221-6 [12119356.001]
  • [Cites] Exp Cell Res. 2005 Aug 15;308(2):439-45 [15950968.001]
  • [Cites] J Bone Miner Res. 2002 Nov;17 Suppl 2:N141-5 [12412791.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Apr;10(2):169-80 [16025223.001]
  • [Cites] J Urol. 1996 Nov;156(5):1691-5 [8863572.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2003 Feb;284(2):E435-42 [12388158.001]
  • [Cites] Curr Opin Nephrol Hypertens. 1996 Jul;5(4):307-15 [8823527.001]
  • [Cites] J Biol Chem. 1998 Jan 9;273(2):1114-20 [9422777.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Mar;45(3):220-30 [16281261.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1130-4 [9515795.001]
  • [Cites] Ann N Y Acad Sci. 1999;889:120-7 [10668488.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Mar;56(3):243-54 [9056538.001]
  • [Cites] Hum Pathol. 1982 May;13(5):454-8 [6281168.001]
  • [Cites] Int J Oncol. 2004 May;24(5):1111-9 [15067332.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6213s-6216s [17062703.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Nov 2;264(3):615-8 [10543980.001]
  • [Cites] Prostate. 1997 May 15;31(3):168-74 [9167768.001]
  • [Cites] Endocr Pathol. 2003 Spring;14(1):61-70 [12746564.001]
  • [Cites] J Physiol. 1998 Dec 1;513 ( Pt 2):411-24 [9806992.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Jul;85(13):4857-60 [3387442.001]
  • [Cites] J Lab Clin Med. 1994 Apr;123(4):547-55 [8145003.001]
  • [Cites] Oncogene. 2005 Mar 24;24(13):2144-54 [15735754.001]
  • [Cites] Semin Oncol. 1998 Jun;25(3):281-304 [9633841.001]
  • [Cites] Endocrinology. 2002 Feb;143(2):596-606 [11796515.001]
  • [Cites] J Musculoskelet Neuronal Interact. 2004 Sep;4(3):308-18 [15615499.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Apr;88(4):1603-9 [12679445.001]
  • [Cites] J Comp Neurol. 1986 May 15;247(3):275-96 [3522658.001]
  • [Cites] Nature. 1999 Dec 23-30;402(6764):884-8 [10622253.001]
  • [Cites] Eur J Oncol Nurs. 2007;11 Suppl 2:S32-7 [17804294.001]
  • [Cites] Lancet Oncol. 2001 Mar;2(3):149-56 [11902565.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13566-71 [15347804.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3812-8 [12097294.001]
  • [Cites] In Vitro Cell Dev Biol. 1989 Jul;25(7):643-9 [2753852.001]
  • [Cites] Glia. 1996 May;17(1):39-51 [8723841.001]
  • [Cites] J Cell Biol. 2004 Mar 1;164(5):769-79 [14993236.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Apr;81(4):1312-7 [8636323.001]
  • [Cites] Am J Physiol Renal Physiol. 2001 Feb;280(2):F291-302 [11208605.001]
  • [Cites] Annu Rev Cell Dev Biol. 2004;20:781-810 [15473860.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2006 May;290(5):E761-70 [16603723.001]
  • [Cites] Ther Apher Dial. 2005 Aug;9 Suppl 1:S27-34 [16109139.001]
  • [Cites] Am J Hum Genet. 1998 Dec;63(6):1588-93 [9837810.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5031-6 [11016624.001]
  • [Cites] Glia. 1999 Mar;26(1):64-72 [10088673.001]
  • [Cites] Gan To Kagaku Ryoho. 2007 Jan;34(1):1-10 [17220661.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):148-58 [14699496.001]
  • [Cites] Int J Clin Oncol. 2008 Feb;13(1):18-23 [18307015.001]
  • [Cites] J Cell Biochem. 1991 Jul;46(3):250-4 [1774225.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36865-75 [15215241.001]
  • [Cites] Semin Oncol. 1991 Jun;18(3):177-85 [2042059.001]
  • [Cites] Lab Invest. 1994 Oct;71(4):510-8 [7967506.001]
  • [Cites] Science. 1986 Oct 10;234(4773):161-6 [3018928.001]
  • [Cites] Hum Mutat. 2000 Oct;16(4):281-96 [11013439.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6258s-6263s [17062710.001]
  • [Cites] J Bone Miner Res. 2005 Feb;20(2):318-29 [15647826.001]
  • [Cites] Mol Genet Metab. 1999 Oct;68(2):328-31 [10527684.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Apr;81(4):1598-606 [8636374.001]
  • [Cites] Oncogene. 2004 Jan 29;23(4):991-9 [14647423.001]
  • [Cites] J Biol Chem. 1991 Aug 25;266(24):15771-81 [1874734.001]
  • [Cites] Nat Genet. 1995 Dec;11(4):389-94 [7493018.001]
  • [Cites] Cancer Metastasis Rev. 1989 Aug;8(2):98-101 [2673568.001]
  • [Cites] N Engl J Med. 1986 Apr 24;314(17):1094-101 [2870434.001]
  • [Cites] Curr Opin Cell Biol. 1999 Apr;11(2):177-83 [10209148.001]
  • [Cites] J Clin Endocrinol Metab. 1983 Mar;56(3):572-81 [6822654.001]
  • [Cites] Endocrinology. 1991 Jun;128(6):2999-3004 [2036974.001]
  • [Cites] Am J Physiol Cell Physiol. 2000 Sep;279(3):C691-9 [10942719.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):867-74 [11158059.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Dec 13;299(4):532-8 [12459170.001]
  • [Cites] J Endocrinol. 1989 Jul;122(1):219-27 [2788697.001]
  • [Cites] EMBO J. 2006 Jul 12;25(13):2978-88 [16763551.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9065-73 [16982748.001]
  • [Cites] Clin Calcium. 2008 Jan;18(1):32-6 [18175869.001]
  • [Cites] Cytometry. 1996 May 1;24(1):64-73 [8723904.001]
  • [Cites] Cancer Res. 1980 Nov;40(11):3982-7 [6162540.001]
  • [Cites] J Comput Assist Tomogr. 1992 Nov-Dec;16(6):856-9 [1385498.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2482-9 [15059902.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] J Neurosci Res. 1997 Apr 15;48(2):122-7 [9130140.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2003 Aug;285(2):E329-37 [12700162.001]
  • [Cites] Biochem Soc Trans. 2003 Dec;31(Pt 6):1203-8 [14641026.001]
  • [Cites] Eur J Endocrinol. 2003 Apr;148(4):403-11 [12656660.001]
  • [Cites] Growth Factors. 2005 Jun;23(2):117-23 [16019433.001]
  • [Cites] Prostate. 2001 May 15;47(3):212-21 [11351351.001]
  • [Cites] Biochem J. 2000 Dec 1;352 Pt 2:353-61 [11085928.001]
  • [Cites] Int J Cancer. 2007 Oct 1;121(7):1455-62 [17557293.001]
  • [Cites] Am J Respir Cell Mol Biol. 1994 Dec;11(6):701-6 [7946399.001]
  • [Cites] Diabetes. 2000 Mar;49(3):409-17 [10868962.001]
  • [Cites] J Biol Chem. 1995 May 26;270(21):12919-25 [7759551.001]
  • [Cites] J Bone Miner Res. 1999 Jun;14(6):878-82 [10352095.001]
  • [Cites] Endocrinology. 1986 Nov;119(5):2284-9 [3464413.001]
  • [Cites] Endocrinology. 2000 May;141(5):1882-92 [10803599.001]
  • [Cites] J Biol Chem. 1998 Aug 14;273(33):21267-75 [9694886.001]
  • [Cites] Biochem J. 1986 Sep 15;238(3):905-12 [2432886.001]
  • [Cites] Acta Diabetol Lat. 1979 Jan-Mar;16(1):9-18 [377879.001]
  • [Cites] Cancer Treat Rev. 2003 Jun;29(3):189-98 [12787713.001]
  • [Cites] News Physiol Sci. 2002 Apr;17:62-7 [11909994.001]
  • [Cites] J Histochem Cytochem. 2000 May;48(5):595-602 [10769043.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Mar;52(3):339-48 [10718832.001]
  • [Cites] Physiol Rev. 2002 Jan;82(1):245-89 [11773614.001]
  • [Cites] J Biol Chem. 2002 Jul 5;277(27):24571-8 [11964407.001]
  • [Cites] Endocrinology. 2005 Apr;146(4):1727-36 [15637291.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):409-16 [11809689.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):279-88 [12086864.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Oct;82(10):3481-6 [9329389.001]
  • [Cites] J Cell Biochem. 2004 Mar 1;91(4):718-29 [14991763.001]
  • [Cites] Eur J Endocrinol. 2000 May;142(5):500-5 [10802529.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Jun;288(6):E1206-13 [15657090.001]
  • [Cites] Histol Histopathol. 2003 Jan;18(1):245-51 [12507303.001]
  • [Cites] Annu Rev Cell Dev Biol. 2004;20:695-723 [15473857.001]
  • [Cites] Oncologist. 2007 Sep;12(9):1035-43 [17914073.001]
  • [Cites] J Cell Biol. 2003 Sep 1;162(5):899-908 [12952940.001]
  • [Cites] Curr Opin Genet Dev. 2007 Feb;17(1):40-4 [17188489.001]
  • [Cites] Brain Res. 1999 Dec 18;851(1-2):116-24 [10642834.001]
  • [Cites] J Clin Endocrinol Metab. 1977 Jul;45(1):105-13 [874057.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 23;320(2):455-60 [15219850.001]
  • [Cites] Bone. 2004 Aug;35(2):479-88 [15268900.001]
  • [Cites] CA Cancer J Clin. 1997 Jan-Feb;47(1):5-27 [8996076.001]
  • [Cites] Acta Neurochir (Wien). 1994;127(1-2):48-54 [7942181.001]
  • [Cites] Physiol Rev. 2001 Jan;81(1):239-297 [11152759.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10439-48 [17079465.001]
  • [Cites] Breast Cancer. 1999 Oct 25;6(4):292-297 [11091732.001]
  • [Cites] Eur J Surg Oncol. 2006 Jun;32(5):511-5 [16564154.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Jul;293(1):G403-11 [17463182.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):703-7 [9467597.001]
  • [Cites] J Biol Chem. 1999 Apr 9;274(15):10173-83 [10187801.001]
  • [Cites] Clin Breast Cancer. 2005 Feb;5 Suppl(2):S46-53 [15807924.001]
  • [Cites] Support Care Cancer. 2007 Nov;15(11):1243-9 [17393190.001]
  • [Cites] J Biol Chem. 1997 Jan 31;272(5):2620-8 [9006895.001]
  • [Cites] Exp Cell Res. 2000 Jul 10;258(1):1-11 [10912782.001]
  • [Cites] Endocrinology. 1999 Jun;140(6):2908-16 [10342884.001]
  • [Cites] Front Biosci. 2003 May 01;8:s377-90 [12700051.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Mar 16;269(2):427-32 [10708570.001]
  • [Cites] Oncogene. 2002 Nov 7;21(51):7839-49 [12420221.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1753-60 [10749150.001]
  • [Cites] J Bone Miner Res. 1989 Dec;4(6):839-44 [2610020.001]
  • [Cites] J Clin Invest. 1997 Jan 1;99(1):88-96 [9011580.001]
  • [Cites] Endocrinology. 2000 Dec;141(12):4357-64 [11108243.001]
  • [Cites] Annu Rev Nutr. 1999;19:545-86 [10448536.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Mar 6;232(1):80-3 [9125156.001]
  • [Cites] Neuroepidemiology. 1990;9(1):2-16 [2330068.001]
  • [Cites] Endocrinology. 1995 Dec;136(12):5416-22 [7588290.001]
  • [Cites] J Natl Med Assoc. 2007 Jan;99(1):35-45 [17304967.001]
  • [Cites] Endocrinology. 2004 Mar;145(3):1211-7 [14645111.001]
  • [Cites] Nihon Rinsho. 1998 Jun;56(6):1419-24 [9648458.001]
  • [Cites] Br J Urol. 1996 Jan;77(1):102-6 [8653278.001]
  • [Cites] In Vitro. 1984 Aug;20(8):652-62 [6500605.001]
  • [Cites] Endocrinology. 1993 Apr;132(4):1658-64 [8462465.001]
  • [Cites] Virchows Arch. 2001 Dec;439(6):725-51 [11787845.001]
  • [Cites] J Bone Miner Res. 2002 Jul;17(7):1164-70 [12096830.001]
  • [Cites] Biochem Biophys Res Commun. 1975 Nov 17;67(2):525-9 [812497.001]
  • [Cites] Subcell Biochem. 2007;45:405-27 [18193646.001]
  • [Cites] Ann Oncol. 2007 Jun;18 Suppl 6:vi164-7 [17591815.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):355-60 [15225800.001]
  • [Cites] J Biol Chem. 2001 Sep 14;276(37):34880-7 [11390380.001]
  • [Cites] Hosp Pract (Off Ed). 1992 Nov 15;27(11):51-8 [1331139.001]
  • [Cites] J Cell Physiol. 2007 Dec;213(3):589-602 [17786953.001]
  • [Cites] Cell Calcium. 2004 Mar;35(3):229-37 [15200146.001]
  • [Cites] J Bone Miner Res. 2003 Dec;18(12):2200-5 [14672355.001]
  • (PMID = 19011996.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Calcium-Sensing
  • [Number-of-references] 203
  •  go-up   go-down


85. Zhang YJ, Dai Q, Sun DF, Xiong H, Tian XQ, Gao FH, Xu MH, Chen GQ, Han ZG, Fang JY: mTOR signaling pathway is a target for the treatment of colorectal cancer. Ann Surg Oncol; 2009 Sep;16(9):2617-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Herein, the purpose of this study was to analyze the distribution pattern of mTOR signaling components in CRC and adenoma and to determine whether targeted inhibition of mTOR could be a potential therapeutic strategy for CRC.
  • METHODS: Immunohistochemical analysis was performed on human CRC and adenoma for mTOR signaling components, including mTOR, p70s6 K, and 4EBP1.
  • RESULTS: mTOR signaling components, including mTOR, p70s6 K, and 4EBP1, were highly activated in glandular elements of CRC and colorectal adenomas with high-grade intraepithelial neoplasia (HIN), with a correlation between staining intensity and depth of infiltration in CRC.
  • Inhibition of mTOR expression using a specific mTOR siRNA resulted in considerably decreased in vitro and in vivo cell growth.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / metabolism. Adenoma / therapy. Colorectal Neoplasms / therapy. Phosphoproteins / metabolism. Protein Kinases / metabolism. Ribosomal Protein S6 Kinases, 70-kDa / metabolism. Signal Transduction
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Apoptosis. Cell Cycle. Cell Proliferation. Colon / metabolism. Female. Humans. Lymphatic Metastasis. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Middle Aged. RNA, Small Interfering / administration & dosage. Rectum / metabolism. TOR Serine-Threonine Kinases. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19517193.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / EIF4EBP1 protein, human; 0 / Phosphoproteins; 0 / RNA, Small Interfering; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.1.1 / mTOR protein, mouse; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa
  •  go-up   go-down


86. He JJ: [Meta analysis of 2025 cases with multiple primary colorectal carcinoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2006 May;9(3):225-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 30.9% of the lesions were located in the rectum, 19.9% in the sigmoid, 9.0% in the descending colon, 5.2% the in splenic flexure, 9.1% in the transverse colon, 6.1% in the hepatic flexure, 11.8% in the ascending colon,and 8.1% in the caecum.
  • 37.6% of the cases were complicated with extra- intestinal lesions,and 43.7% adenoma or polyps.
  • Histological type was the same in 60.6% of the cases,and adenocarcinoma accounted for 89.2% and cancerization of adenoma 8.4%.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16721683.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Meta-Analysis
  • [Publication-country] China
  •  go-up   go-down


87. Kita H, Hikichi Y, Hikami K, Tsuneyama K, Cui ZG, Osawa H, Ohnishi H, Mutoh H, Hoshino H, Bowlus CL, Yamamoto H, Sugano K: Differential gene expression between flat adenoma and normal mucosa in the colon in a microarray analysis. J Gastroenterol; 2006 Nov;41(11):1053-63